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Summary 
Asthma is a chronic inflammatory condition of the airways characterised by reversible 
airflow obstruction, airway hyper-responsiveness and inflammatory infiltrates in the 
airway walls containing eosinophils, T lymphocytes and mast cells. T helper (Th) 
lymphocyte subsets, defined by the cytokines they secrete, are thought to play a key 
role in the in the initiation and perpetuation of chronic airway inflammation. Th2 cells, 
producing interleukin (IL)-4, IL-5, IL-9 and IL-13, are thought to be of particular 
importance. In contrast, Thl cells producing interferon (IFN)-y may counteract the 
development of Th2 responses and so down-regulate the asthmatic response. 
The prevalence of asthma is increasing but the reasons for this are not fully 
understood. In addition, some patients do not respond adequately to treatment with 
corticosteroids, currently the most effective anti-inflammatory agents used routinely in 
human asthma. There is therefore continual interest in developing new therapeutic 
agents for asthma. A greater understanding of the regulation of inflammatory 
responses in asthma will assist in the identification of potential targets for therapeutic 
intervention. 
The aims of this thesis were (i) to assess the role of the cytokine IL-18 in allergic 
airway inflammation by determining IL-18 levels in induced sputum in asthmatic 
subjects in comparison to normal subjects, and by studies in a murine model of 
allergic asthma using IL-18 gene deficient mice and (ii) to assess the potential anti-
inflammatory actions of simvastatin and thymosin beta 4 sulfoxide in the murine 
asthma model. 
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IL-18 is a pro-inflammatory cytokine which can promote IFN-y secretion and, in 
association with IL-12, enhance the development of Thl responses. However, in some 
circumstances it may also stimulate Th2 responses. IL-18 therefore has the potential to 
suppress or exacerbate allergic airway inflammation. The role of IL-18 in both clinical 
and experimental asthma remains unclear. 
Statins are inhibitors of the rate-limiting enzyme, 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) reductase, in cholesterol biosynthesis. As such they have been widely 
used as cholesterol lowering agents in clinical practice. They have previously been 
shown to have anti-inflammatory properties independent of their cholesterol-lowering 
ability in clinical studies of atherosclerotic disease and in animal models of Thl-
mediated inflammation. 
Thymosin beta 4 sulfoxide (T~4S0) is a 5 kDa peptide. Intracellularly its principal 
activity is to regulate actin polymerization. Corticosteroid treatment of monocytes in 
vitro induces the release of T~4S0 extracellularly, where it can inhibit neutrophil 
chemotaxis. Exogenous administration of T~4S0 has been shown to reduce 
neutrophilic inflammation in animal models. 
In this study it is shown that IL-18 is detectable in induced sputum fluid and IL-18 
mRNA is expressed in induced sputum cells from asthmatic and nOlmal subjects. IL-
18 protein levels in induced sputum, and IL-18 mRNA expression in induced sputum 
cells were not significantly different between these groups. IL-18 production was 
localised to sputum macrophages. However, cigarette smoking significantly reduced 
IL-18 levels in induced sputum fluid in both asthmatic and normal subjects. In 
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asthmatics, but not normal subjects, the reduction in IL-18 levels in sputum fluid was 
associated with reduced IL-18 mRNA expression in induced sputum cells. 
A murine model of allergic asthma, using BALB/C mice sensitised and challenged 
with ovalbumin (OVA), was used to examine the role of IL-18 in allergic responses in 
vivo. IL-18 gene knockout (ko) had significantly reduced bronchoalveolar lavage 
(BAL) total cell count and eosinophilia compared to wild-type (WT) mice. IL-18 ko 
mice had reduced IL-4 expression in thoracic lymph nodes, as assessed by quantitative 
peR, and significantly reduced OVA-specific IL-4 secretion from thoracic lymph 
node cultures assessed by ELISA. Serum OVA-specific IgG 1, IgG2a and IgE and total 
IgE levels were not significantly different between IL-18 ko and WT mice. 
The murine model of allergic asthma was also used to examine the anti-inflammatory 
activities of simvastatin and T~4S0 in a Th2-mediated, eosinophilic condition. 
Simvastatin treatment, either orally or intraperitoneally, and T~4S0 intraperitoneally 
reduced the total inflammatory cell infiltrate and eosinophilia in BAL fluid in response 
to inhaled OV A challenge. At higher doses of simvastatin intraperitoneally, a 
histological reduction in inflammatory infiltrates in the lungs was observed. Treatment 
with simvastatin intraperitoneally, but not orally, and T~4S0 were also associated 
with a reduction in IL-4 and IL-5 levels in BAL fluid. OVA-induced IL-4 and IL-5 
secretion was reduced in thoracic lymph node cultures from both simvastatin-treated 
and T~4S0-treated mice. Neither simvastatin nor T~4S0 treatment altered serum total 
IgE or OVA-specific IgG 1 and IgG2a levels. 
IV 
The results described show that IL-18 can be detected in the induced sputum fluid of 
asthmatic and normal subjects and that cigarette smoking significantly reduces its 
levels. Studies in a murine model of allergic asthma suggest that IL-18 has a pro-
inflammatory role in allergic airway inflammation, at least in part through its ability 
to induce IL-4 secretion. Both simvastatin and thymosin beta 4 sulfoxide had 
convincing anti-inflammatory properties in the murine model of asthma used, and 
these agents, or related compounds, may have therapeutic potential in human asthma. 
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1.1 Asthma 
1.1.1 Introduction 
Asthma is a chronic inflammatory condition of the airways characterised by reversible 
airflow obstruction, airway hyper-responsiveness (AHR) and inflammatory infiltrates in 
the airway walls containing eosinophils, T lymphocytes and mast cells. Atopic asthma 
is associated with raised serum IgE levels. T helper (Th) lymphocyte subsets, defined by 
the cytokines they secrete are thought to play a key role in the in the initiation and 
perpetuation of this inflammation. In particular, Th2 cells, producing the cytokines 
interleukin (IL)-4, IL-5 and IL-13, are thought to be of particular importance. However 
a complex network of cell types and inflammatory mediators (reviewed by Barnes et aI., 
1998 and Larche et aI., 2003) contribute to the development of the inflammatory 
response (Figure 1.1). 
The functions of the major cell types involved in the development of airway 
inflammation in asthma are discussed below. The actions of specific cytokines which 
have a significant role in the control of allergic responses are also highlighted. 
1.1.2 Cellular inflammation in asthma 
1.1.2.1 T helper (Th) lymphocytes 
After antigen is presented to naive CD4+ T cells via peptide presentation in the groove 
of the class II major histocompatibilty complex (MHC-II) on antigen presenting cells, 
2 
such T helper lymphocytes can develop into either Thl cells, secreting IFN-y or Th2 
cells which produce IL-4, IL-5, IL-9 and IL-13 (Abbas et aI., 1996). In the presence of 
IL-12, which signals intracellularly through STAT-4-dependent pathways, the 
differentiation of Th1 cells is induced. Th1 cells specifically express the transcription 
factor T -bet (Szabo et aI., 2000). In contrast, the development of Th2 cells is reliant on 
the presence of IL-4 and STAT -6-dependent signalling pathways which induce the 
activity of the Th2-specific transcription factor GATA-3 (Zhang et aI., 1997). 
Th1 lymphocytes selectively express the IL-18 receptor alpha (IL-18Ra) chain on their 
cell surface (Xu et aI., 1998a) while Th2 cells express the orphan receptor T1/ST2 
(Lohning et aI., 1998, Xu et aI., 1998b). Both these molecules are required for the 
production of effective Th1 or Th2 responses, since mice deficient in IL-18Ra have 
impaired Thl responses (Hoshino et aI., 1999a), and T1/ST2 deficient mice have 
reduced Th2 effector functions (Townsend et aI., 2000). 
As stated above, asthma is characterised by a predominance of Th2 lymphocytes and 
their pattern of cytokine secretion (Robinson et aI., 1992). Bronchial biopsies from 
atopic and non-atopic asthmatics show elevated levels of IL-4, IL-5 and IL-13 (Humbert 
et aI., 1996) and increased expression ofGATA-3 and STAT-6 have also been observed 
(Christodoulopoulos et aI., 2001). Murine models of asthma have confirmed the 
importance of these cytokines in the development of allergic lung inflammation; mice 
deficient in IL-4 have reduced airway inflammation (Hogan et aI., 1997) whereas 
transgenic mice over-expressing IL-5 (Lee et aI., 1997) or IL-13 (Zhu et aI., 1999) have 
enhanced inflammatory responses. 
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Figure 1.1. Cell types involved in the pathogenesis of asthma. 
Th1 cell 
Key cell types involved in the development of airway inflammation in asthma. Th2 
lymphocytes play an important role. (Adapted from Lewis, 2002). 
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Th1 lymphocyte responses were originally proposed to be protective in asthma since 
immunotherapy for specific allergies resulted in skewing of the immune response 
towards a Th1 profile (McHugh et al., 1995). In addition, antigen-induced IFN-y 
production was reduced in peripheral blood monocytes (PBMC) from chronic 
asthmatics when compared to normal controls (Smart et al., 2002) and the presence of 
IFN-y was shown to be necessary for the inhibition of the development of airway 
eosinophilia by Th1 cells in a murine model of asthma (Cohn et al., 1999). However, 
IFN-y is produced by bronchoalveolar lavage lymphocytes from asthmatics (Krug et al., 
1996) and may enhance some aspects of airway inflammation (Ford et al., 2001). In a 
murine model of asthma, the transfer of Th1 cells into mice did not reduce airway 
inflammation, but enhanced it (Hansen et al., 1999, Randolph et al., 1999a, Randolph et 
al., 1999b). Therefore, although Th2 responses are more important in the development 
of asthmatic airway inflammation, Th1 responses may also contribute. 
The specific effects of the cytokines discussed above, and additional cytokines 
important in allergic responses, are summarised in Table 1.1. 
1.1.2.2 Regulatory T cells 
Since the ThllTh2 paradigm cannot fully explain the regulation of the activity of T 
lymphocytes in asthma it is now thought that regulatory T cells, which actively control 
or suppress the function of other cells, might be involved. Four types of these cells have 
now be identified - CD4+CD25+ lymphocytes, TR cells, Th3 cells and natural killer T 
(NKT) cells. The properties of each of these cell types are discussed in this section. 
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Cy to kine 
IL-3 
IL-4 
IL-5 
IL-9 
IL-I0 
IL-13 
GM-CSF 
IFN-y 
IL-12 
Actions 
Differentiation and activation of eosinophils, 
mast cells basophils and neutrophils 
B-cell switch to IgE synthesis 
Enhances Th2 development 
Mast cell development 
Eosinophil and basophil activation 
Mucus hypersecretion 
Eosinophil and basophil differentiation, 
maturation and activation 
Mast cell and eosinophil development, 
AHR, mucus secretion 
Suppresses ThllTh2 activation 
Favours regulatory T cell production 
Mast cell development 
B-cell switch to IgE, AHR 
Eosinophilia, mucus hypersecretion 
Differentiation and activation of esoinophils 
and mast cells 
Inhibits IgE synthesis and Th2 induction 
Activates eosinophils and macrophages 
Favours Thl development 
Inhibits IgE synthesis 
Table 1.1. Cytokines involved in the regulation of the asthmatic response. 
The cytokines shown have important regulatory roles in asthma. This list has been 
chosen to highlight cytokines which will be discussed with regard to the actions of IL-
18. GM-CSF - granulocyte-macrophage colony stimulating factor. 
(Adapted from Larche et aI., 2003). 
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CD4+CD2S+ cells comprise 10% of all CD4+ cells. They specifically express the cell 
surface marker glucocorticoid-induced TNF receptor (GITR) (Shimizu et al., 2002) and 
the transcription factor Foxp3 (Hori et al., 2003). They are thought to suppress immune 
responses by the secretion of transforming growth factor (TGF)-~ and through cell-cell 
contact mechanisms involving cell-surface bound TGF-~ and the interaction of 
cytotoxic T lymphocyte antigen 4 (CTLA-4) with its ligand (Nakamura et al., 2001). In 
murine models of asthma, they have been shown to suppress the development of airway 
inflammation (Suto et al., 2001) but do not suppress AHR (Hadeiba and Locksley, 
2003). CD4+CD2S+ cells from atopic donors have suppressive activity on antigen-
induced Th2 cytokine production in vitro (Bellinghausen et al., 2003a, Bellinghausen et 
al., 2003b), but the suppressive activity of such cells is less than that from non-atopic 
donors (Ling et al., 2004), implying that disordered activity of this subset of regulatory 
T cells may allow the development of allergic responses. 
Th3 cells produce TGF-~ and have been shown to suppress the development of 
experimental autoimmune encephalitis (Chen et al., 1996). TR1 are CD4+ cells which 
secrete high levels of IL-1 0, and can suppress experimental colitis (Groux et al., 1997) 
and Th2 responses in vitro (Cottrez et al., 2000). Although no direct role for these cells 
has been demonstrated in asthma, since T cells engineered to produce TGF-~ (Hansen et 
al., 2000) or IL-10 (Oh et al., 2002) have a suppressive role in experimental models, it is 
possible that these cells are involved in the down-regulation of the asthmatic response. 
In contrast NKT cells can enhance Th2 responses. These cells are either CD4+ or CD4-
CDS- cells which have an invariant Va14 T cell receptor chain and recognise glycolipid 
antigens in association with CD1d, an MHC class I-like protein. They have been shown 
to have a regulatory role in autoimmune disease (reviewed by Wilson and Delovitch, 
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2003). They are dependent on IL-15 for survival (Matsuda et ai., 2002). When activated, 
these cells can produce IL-4, IL-13 and IFN-y. Although NKT cells are not essential for 
the development of Th2 responses (Brown et ai., 1996), they are required for the 
development of AHR and allergen-induced airway inflammation (Akbari et ai., 2003, 
Lisbonne et ai., 2003) in murine models of asthma. NKT cells may therefore have pro-
inflammatory activity in human asthma. 
1.1.2.3 Dendritic cells 
Dendritic cells are the principal antigen presenting cell in the airway wall, and as such, 
they are able to influence the development of both Th2 lymphocytes and regulatory T 
cells. Dendritic cells from the respiratory mucosal wall preferentially induce Th2 
cytokine responses (Stumbles et ai., 1998) and have been shown to be required for the 
development of eosinophilia and AHR in a murine model of asthma (Lambrecht et ai., 
1998). The exact mechanisms by which dendritic cells induce Th2 responses remain 
unclear. When exposed to allergens in vitro, dendritic cells from atopic donors secrete 
IL-13 which will enhance Th2 responses (Bellinghausen et ai., 2003a). In addition, the 
Th2-promoting activity of dendritic cells may involve the actions of specific co-
stimulatory molecules such as inducible costimulator (leOS), which has been 
implicated in the development of Th2-mediated inflammatory responses (Tesciuba, et 
ai. 2001). Pulmonary dendritic cells producing IL-10 have been implicated in the 
induction of tolerance to inhaled allergen a murine asthma model (Akbari et ai., 2001). 
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1.1.2.4 Eosinophils 
While Th2 lymphocytes and regulatory T cells are modulators of the inflammatory 
response in asthma, eosinophils, mast cells and basophils are often considered as 
effector cells in the allergic response because of the inflammatory mediators they 
produce. 
Elevated levels of eosinophils are present in the airways of both atopic (Bentley et aI., 
1993) and non-atopic asthmatics (Gaga et aI., 2000). They are impOliant in the 
development of bronchoconstriction in the late asthmatic response (De Monchy, et aI. 
1985). Eosinophil numbers in the BAL fluid of asthmatics correlate with the severity of 
human asthma (Louis R, et aI.1997). IL-5 is essential for the maturation of eosinophils 
and their migration to the lungs. Mice deficient in IL-5 do not develop airway 
eosinophilia and AHR after antigen challenge (Pope et aI., 2001). Granulocyte-
macrophage colony stimulating factor (GM-CSF) is also important in eosinophil 
maturation and survival (Esnault and Malter, 2001). Chemokines are important in 
trafficking of eosinophils to the lungs, and blocking the chemokine receptor CCR3, 
which binds several chemokines including eotaxin, with a monoclonal antibody, has 
been shown to specifically inhibit pulmonary eosinophilia and AHR in a murine model 
of asthma (Justice et aI., 2003). 
Eosinophils express surface receptors for IgE (Rajakulasingam et aI., 1998) and this 
may enhance eosinophil migration to the lungs during allergic inflammation (Coyle et 
aI., 1996). The binding of IgE to its cell surface receptors, induces degranulation of 
eosinophils. Other molecules including the complement component C3b and cytokines, 
such as IL-5 and GM-CSF, also enhance degranulation (Carlson, et aI.1993). 
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Eosinophil granules contain many inflammatory mediators which promote the influx of 
other inflammatory cells into the airways. These include eosinophil cationic protein 
(ECP), myelin basic protein (MBP), eosinophil peroxidase and reactive oxygen species 
such as H20 2. Lipid mediators such as the prostaglandin (PG)E2 and the leukotriene 
(LT)C4 are also produced (reviewed by Lacy and Moqbel, 2001). 
In addition to their role as effector cells in asthmatic inflammation, eosinophils have the 
potential to modulate T lymphocyte responses. Eosinophils can produce a wide range of 
cyokines including IL-4 (Bandeira-Melo et al., 2002) and IL-13 (Woerly et al., 2002). 
Eosinophils also have the ability to present antigen to T lymphocytes and enhance the 
release of IL-4 and IL-13 from them (Shi et al., 2000). 
1.1.2.5 Mast cells and basophils 
Whereas eosinophils are important in the late asthmatic response, mast cells, and the 
inflammatory mediators they secrete, are responsible for the immediate 
bronchoconstrictor response to inhaled antigen. Both mast cells and basophils are seen 
in bronchial biopsies in asthmatic subjects (Koshino et al., 1996), although mast cells, 
and not basophils, are permanently present in the airways. Both cell types express the 
high affinity IgE (FcERI) receptor on their surface, the presence of which can be up-
regulated on the surface of mast cells by IgE (Yamaguchi et al., 1997). Allergen-
induced cross-linking of these receptors by IgE, causes the release of mediators from 
cell granules resulting in acute bronchoconstriction. Studies in mast cell "knockin" mice 
have shown that mast cells are involved in the development of AHR (Kobayashi et al., 
2000) and also in the development of chronic inflammatory changes in the lung 
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(Williams and Galli, 2000). Both mast cells and basophils release histamine and L TC4 
and also produce chemokines and cytokines, including IL-4, IL-5 and TNF-a (Bradding 
et aI., 1994), so contributing to the influx of inflammatory cells, including lymphocytes 
and eosinophils, in the late-phase of the asthmatic response. Mast cells have also been 
shown to act as antigen presenting cells (Mecheri and David, 1997). 
1.1.2.6 Other cells involved in the asthmatic response 
The cell types described above are thought to be particularly important in the 
development of airway inflammation in asthma. However, many other cells are present 
in the airways which are able to secrete pro-inflammatory molecules. Increasingly, 
airway epithelial cells are now thought to be an impOliant source of inflammatory 
mediators, including the eosinophil-attracting chemokines regulated on activation, 
nOlmal T-cell expressed and secreted (RANTES) (Berkman et aI., 1996) and eotaxin 
(Ying et aI., 1997). Neutrophils are thought to secrete many pro-inflammatory 
molecules and are present in increased amounts in severe asthmatics and in those with 
steroid-resistant disease (Wenzel et aI., 1997). Macrophages can also secrete pro-
inflammatory cytokines such as IL-6 and TNF-a (Gosset et aI., 1991) but they also have 
been shown to have anti-inflammatory actions (Strickland et aI., 1996). These additional 
cell types may all contribute to allergic airway inflammation. 
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1.2 Interleukin-18 
1.2.1 Introduction 
Many cytokines, including IL-4, IL-5 and IL-13, have a well-characterised role in the 
development of allergic inflammation, as described in the previous section. More 
recently discovered cytokines may also be involved in the control of airway 
inflammation in asthma, but their actions are less well established. Interleukin-18 is one 
such cytokine which was originally identified as interferon-gamma-inducing factor, 
with a key role in the development of endotoxic shock in mice pre-treated with 
Propionibacterium acnes and then challenged with LPS. In these initial studies IL-18 
was a potent stimulator of IFN-y secretion from Th1 cells and augmented the cytolytic 
activity ofNK cells.(Okamura et al., 1995). Although IL-18 was first proposed to be a 
promoter of Th1 lymphocyte responses, and hence have a possible anti-inflammatory 
action in asthma, the actions of IL-18 are now thought to be more extensive, including a 
pro-inflammatory role in Th2 responses (reviewed by Nakanshi et al., 2001). 
In this section, the structure of the IL-18 gene and protein will be discussed, as will 
factors regulating their activity. IL-18 acts by binding to a specific cell surface receptor, 
and the characteristics of this receptor are also described below. The role of IL-18 in 
innate and cell mediated immunity, including its ability to promote both Th1 and Th2 
responses, will be discussed in later sections. 
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1.2.2 The interleukin IL-18 gene 
The gene for murine IL-18 is found on chromosome 9. It contains 7 exons, the first two 
of which are non-coding. Two promoters for this gene have been identified both of 
which lack TA TA sequences. IL-18 mRNA lacks destabilising sequences found 
commonly in other cytokine genes. The promoter upstream of Exon 2 is constitutively 
activated while the promoter upstream of exon 1 can be upregulated by LPS (Tone et 
aI., 1997). This latter promoter contains a site for binding of an IFN consensus sequence 
binding protein (ICSBP) which is critical for its activity, whereas the promoter before 
ex on 2 includes an essential PU.1 binding site (Kim et aI., 1999). The activity of these 
transcription factors is increased by IFN-y (Weisz et aI., 1994) and LPS (Shackelford et 
aI., 1995). In murine macrophages, the up-regulation ofIL-18 gene expression by IFN-y 
also involves transcription factor activator protein (AP)-1 (Kim et aI., 2000). A nuclear 
factor (NF)-KB binding-sequence is also present in the promoter region ofIL-18; TNFa 
and hydrogen peroxide have been shown to increase IL-18 mRNA expression via NF-
KB-dependent mechanisms in rat cardiac myocytes (Chandrasekar et aI., 2003). In 
contrast, the transcription factor Bc 16, acts as a repressor of IL-18 expression in murine 
macrophges (Takeda et aI., 2003). 
The human IL-18 gene is found on chromosome 11 and consists of 6 exons and five 
introns. The first 92 bp of the 5' flanking region are essential for the constitutive 
expression ofIL-18 in monocytic cells (Kalina et aI., 2000a). There is 75% homology in 
the 5' flanking regions of the human and murine IL-18 genes, which suggests that there 
is conservation of regulatory mechanisms between the two species (el Kares et aI., 
2000). Polymorphisms at -137bp and -167bp in the promoter regions of the human gene 
have been linked to the susceptibility to post-injury sepsis (Stassen et aI., 2003) and a 
polymorphism at 105 bp in the coding region of the gene has been associated with the 
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pathogenesis of asthma (Higa et aI., 2003a). Additional single nucleotide 
polymorphisms (SNP) at the human IL-18 gene locus have been suggested as markers 
of susceptibility to allergic rhinitis and to the development of specific IgE to common 
allergens (Kruse et aI., 2003). 
IL-18 mRNA was first found in liver macrophages and Kupffer cells (Okamura et aI., 
1995) but has since been detected in a wide range of cell types including T and B 
lymphocytes, dendritic cells, osteoblasts, microglia, astrocytes and keratinocytes 
(Nakanishi et aI., 2001). IL-18 therefore has the potential to be involved in the 
regulation of immune responses in several organs. 
1.2.3 IL-18 protein structure 
Murine IL-18 is initially produced as the 192 amino acid peptide pro-IL-18 with a 
molecular weight of 24kDa peptide (Okamura et aI., 1995). Human pro-IL-18 is 193 
amino acids long and has 65% homology with murine IL-18 (Ushio et aI., 1996). A 
homodimer of human IL-18 has been found in serum (Shida et aI., 2001). Neither 
murine or human pro-IL-18 has a conventional hydrophobic signal peptide at the N-
terminus but both contain an unusual leader sequence in this region. Mature, active IL-
18 is produced by the cleavage of 35 amino acids from the N-terminus of the precursor 
peptide. Interleukin-1 ~ converting enzyme (ICE or caspase-1) is the most impOliant 
enzyme responsible for the conversion of pro-IL-18 into mature IL-18 (Ghayur et aI., 
1997, Gu et aI., 1997). Proteinase-3 can also cleave IL-18 into its active form (Sugawara 
et aI., 2001), whereas caspase-3 cleaves active IL-18 into inactive peptides (Akita et aI., 
1997). It is thought that the processing of IL-18 by these proteases is more important 
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than alterations in gene expression in the control of the biological activity of IL-18, 
since levels of IL-18 mRNA are often relatively stable in many cell types. 
In both its peptide sequence and secondary and tertiary protein structure, IL-18 bears 
similarity to IL-l~. Both these cytokines fold into ~-pleated sheets with a tertiary beta-
trefoil banel configuration (Kato et aI., 2003). Mutational analysis has shown that the 
glutamate and lysine residues, at positions 42 and 89 respectively, are important for the 
binding ofIL-18 to its receptor and its serum binding protein (Kim et aI., 200la). 
In addition to modulation of the activity of IL-18 by intracellular proteolytic processing 
and regulation of gene activity, the extracellular actions of IL-18 can be inhibited by its 
binding to specific serum IL-18 binding proteins (IL-18 BP). Isoforms of IL-18 BP have 
been found in both humans and mice (Aizawa et aI., 1999, Novick et aI., 1999). These 
proteins contain a single extracellular immunoglobulin domain but do not contain a 
transmembrane region. They are not related to the IL-l or IL-18 receptor family but do 
show homology with pox virus proteins, which are able to inhibit the actions of IL-18 in 
vitro (Xiang and Moss, 1999, Calderara et aI., 2001) and in vivo (Born et aI., 2000). The 
expression of IL-18BP is increased by IFN-y in human keratinocytes, colonic carcinoma 
cell lines and renal mesangial cells (Muhl et aI., 2000) and peripheral blood monocyte 
cultures (Veenstra et aI., 2002), so providing a negative-feedback loop for the actions of 
IL-18. Serum levels of IL-18 BP, and IL-18, are elevated in the serum of patients with 
several inflammatory conditions, including rheumatoid arthritis (Bresnihan et aI., 2002), 
where the raised levels of IL-18BP are proposed to counter-regulate the effects of 
increased IL-18 and therefore raised IFN-y levels. Consistent with this proposal, the 
administration of exogeneous IL-18BP has been shown to have anti-inflammatory 
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effects in collagen-induced arthritis in mice, an animal model of rheumatoid arthritis 
(Plater-Zyberk et al., 2001, Banda et al., 2003, Smeets et al., 2003). 
The actions of IL-18 may also be antagonised by the presence of IL-1 H, an IL-1-
receptor agonist (IL-1ra)- related cytokine which is able to bind to the IL-18 receptor 
(Pan et al., 2001). 
1.2.4 The IL-18 receptor and its intracellular signalling 
The interleukin-18 receptor is a heterodimer of two proteins chains, both of which are 
members of the IL-1 receptor (IL-1R) subfamily of the Toll/interleukin-1 receptor (TIR) 
family. These subunits are now termed IL-18 receptor a and p. In common with other 
members of this family the extracellular portions of the IL-18 receptor chains have three 
immunoglobulin (Ig)-like domains while the intracellular regions contain a TIR domain 
which is essential for the initiation of intracellular signalling. A schematic diagram of 
the IL-18 receptor complex and its signalling pathways is shown in Figure 1.2. There is 
significant homology between the human and mouse IL-18Ra and IL-18RP subunits 
(Pamet et aI., 1996). 
IL-18 receptor a (IL-18Ra) was originally identified as IL-1Rrp (Torigoe et aI., 1997). 
It was shown to be required for the actions of IL-18, since splenocytes from mice 
deficient in IL-1Rrp had defective IFN-y production and cytolytic activity and did not 
activate NF-xB in response to IL-18 (Hoshino et aI., 1999a). The human IL-18 receptor 
a gene is found within the IL-1 R gene cluster on chromosome 2q 12 (Dale and Nicklin, 
1999). IL-18 initially binds to the IL-18Ra chain and the ligated receptor is then 
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Figure 1.2. The IL-18 receptor complex and its intracellular signalling pathways. 
IL-18 principally triggers intracellular signalling via the TIR domain, recruiting 
MyD88, lRAKs and TRAF-6. The signalling mechanisms mediated by Tyk2 and 
STAT-3/STAT-4 are less well defined. (Adapted from O'Neill and Dinarello, 2000). 
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recognised by the IL-18R~ chain (originally called IL-IR-accessory protein (AcP)-like 
protein, AcPL) to form a heterodimeric transmembrane receptor. Both receptor chains 
are needed for signal transduction (Debets et aI., 2000). IL-18Ra alone has a relatively 
low affinity for IL-18 (dissociation constant (Kd) ~ 20 nM) but this increases 
significantly on association with the ~ subunit of the receptor (Kd ~ 0.3nM) (Born et al., 
1998). The increased affinity for IL-18 is thought to be due to conformational changes 
which occur in IL-18Ra on binding to IL-18R~ subunit (Wu et aI., 2003). The third of 
the extracellular domain closest to the cell membrane is thought to be important in the 
formation of the complex of IL-18 with both parts of its receptor complex (Azam et aI., 
2003). 
Intracellularly, the TIR domain of the IL-18 receptor initiates intracellular signalling 
through MyD88 and interleukin-l receptor associated kinase (IRAK) in a similar way to 
IL-l, resulting in the activation of p38 mitogen-activated protein (MAP) kinases 
(Thomassen et aI., 1998), NF-K8 and c-Jun N-terminal kinase (JNK) (Azam et al., 
2003). Mice deficient in MyD88 (Adachi et aI., 1998) and IRAK (Kanakaraj et al., 
1999) have decreased NFKB activation, IFN-y production and NK cell cytotoxicity in 
response to IL-18. In addition to IRAK-l and 2, IRAK-4 has been shown to be essential 
for IL-18 induced responses in T helper lymphocytes and NK cells (Suzuki et al., 2003). 
Although the IL-18 receptor signals through IRAKfMyD88 in lymphocytes to produce 
nuclear translocation of NF-KB, in macro phages STAT-4 activation is required to 
induce IFN-y production by IL-12 and IL-18 (Schindler et aI., 2001). IL-18 also 
activates the transcription factors S TAT -3 and the MAP p44 erk-l and p-42 erk-2 in NK 
cell lines (Kalina et aI., 2000b). Absence of the Janus associated kinase (JAK) 
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signalling molecule Tyk2 also resulted in reduced cytolytic activity and IFN-y 
production in NK cells after stimulation with IL-18 (Shimoda et al., 2002). 
As stated above, the IL-18Ra chain has been shown to be selectively expressed on Th1 
lymphocytes, but not Th2 cells (Xu et al., 1998a). IL-12 up-regulates IL-18Ra 
expression on Th1 cells and subsequently signalling through this receptor by IL-18 
maintains IL-12RP expression, an essential process for continuing Th 1 cell 
development (Yoshimoto et al., 1998a). NaiVe murine CD4+ T cells do express low 
levels of IL-18Ra, but this can be down-regulated by the presence of IL-4 after antigen 
stimulation, so helping skew the immune response towards Th1 cell development 
(Smeltz et al., 2001). The suppression of IL-18Ra expression by IL-4 can be inhibited 
by the presence of IFN-y (Smeltz et al., 2002). IFN-a also promotes the expression of 
IL-18Ra and P in NK and T cells (Sareneva et al., 2000) while TNF-a up-regulates IL-
18 Ra expression in myeloid and monocytoid cell lines (Nakamura et al., 2000). 
Non-lymphoid cell types including neutrophils (Leung et al., 2001), eosinophils (Wang 
et al., 2001) and fibroblast-like synoviocytes (Moller et al., 2002a) also express the IL-
18Ra chain. Messenger RNA for the IL-18 receptor is present in several organs, 
including the lung, liver and heart (Parnet et al., 1996). Therefore IL-18 is likely to have 
a broad range of actions, extending beyond its ability to modulate T helper lymphocyte 
responses. These activities will be discussed in the following section. 
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1.3 The role of IL-18 in cellular immunity 
1.3.1 Th1 lymphocyte responses 
IL-18 was initially discovered as a cytokine which induced IFN-y production from Th1 
lymphocytes, both alone and synergistically with IL-12, in both murine (Okamura et aI., 
1995) and human T cells (Micallef et aI., 1996). Similarly, IL-18 also enhanced antigen-
induced IFN-y production in murine Th1 cell lines (Kohno et aI., 1997). Although the 
effect ofIL-18 on IFN-y production is similar to that ofIL-12, these two cytokines may 
use different mechanisms to mediate this response since IL-18 can directly activate the 
human IFN-y promoter in CD4+ cells whereas IL-12 requires additional stimulation 
through T-cell receptor signalling (Barbulescu et aI., 1998). The synergism of IL-18 
with IL-12 on IFN -y production is thought to be, at least in part, due to the ability of IL-
12 to up-regulate expression of the IL-18Ra chain on the surface of T lymphocytes, as 
discussed above. IL-18 will only potentiate development of Th1 cells in the presence of 
IL-12 and is unable to do this alone (Robinson et aI., 1997). In addition to its ability to 
stimulate IFN-y release from Th1 cells, IL-18 enhanced the Fas ligand-mediated 
cytolytic activity of a murine Th1 clone (Dao et aI., 1996). Studies in IL-18 deficient 
mice have shown impaired Th1 responses, and NK cell activity, to Proprionibaeterium 
aenes and BCG (Takeda et aI., 1998). IL-18 deficiency also conferred increased 
susceptibility to Leishmania major infection and increased the severity of septic arthritis 
in a mouse model of this disease (Wei et aI., 1999). IL-18 can directly promote the 
polarisation and migration ofThl cells in vitro (Komai-Koma et aI., 2003). 
Although IL-18 has a direct effect on the development and activity of Th1 lymphocytes 
it may also enhance the development of a Th1 response through the activation of 
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dendritic cells. Monocyte-derived human dendritic cells (DC 1) in vitro express the IL-
18Ra, secrete IFN-y and migrate in response to IL-18 (Gutzmer et ai., 2003). IL-18 is 
released constitutively from such cells. Plasmacytoid-derived dendritic cells (DC2) also 
express the IL-18R and can polarize allogeneic T helper lymphocytes towards a Thl 
response in vitro (Kaser et ai., 2003). 
Through its ability to enhance Thl development and increase IFN-y production, IL-18 
will indirectly augment the innate immune response, through the activation of 
macrophages. However, IL-18 will also directly promote the activity of cells of the 
innate immune system, such as NK cells, macrophages and neutrophils. The actions of 
IL-18 on NK cells were noted at the time of its discovery (Okamura et ai., 1995). 
Subsequently, IL-18 has been shown to stimulate murine bone-marrow derived 
macrophages to produce IFN-y (Munder et ai., 1998) and peritoneal macrophages to 
secrete TNF-a, IL-l~, IL-6 and IL-8 (Netea et aI., 2000). IL-18-induced TNF-a 
secretion and nitric oxide (NO) production is increased from murine macrophages after 
infection with Listeria monocytogenes (Neighbors et ai., 2001) and human CD14+ 
mononuclear cells produce IL-8 and IL-l ~ after stimulation with IL-18 (Puren et aI., 
1998). Neutrophil activity is enhanced by IL-18 (Wyman et ai., 2002) and IL-18 will 
promote neutrophil accumulation at sites of inflammation (Leung et ai., 2001). 
Because of its Th I-promoting properties, IL-18 has been suggested to have a pro-
inflammatory action in several inflammatory conditions. However, the ability of IL-18 
to enhance the innate immune response alongside specific Thl cell mediated immunity 
is likely to be important in host defence against infection and tumour development. 
Since IL-18 is expressed in the respiratory epithelium (Cameron et aI., 1999) and is 
produced by human and murine alveolar macrophages (Shigehara et aI., 2001, Jordan et 
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aI., 2001, respectively), IL-18 has the potential to modulate immune responses in the 
lung. The effects of IL-18 in infectious and inflammatory disease will be discussed 
below, using lung disease to provide examples of specific functions. Table 1.2 
highlights the proposed role of IL-18 in several extra-pulmonary conditions. 
1.3.2 Infectious disease 
1.3.2.1 Bacterial infection 
1.3.2.1.1 Intracellular bacteria 
Mycobacterium tuberculosis (MTB) causes infection characterised by the formation of 
granulomata in the lungs. In human tuberculosis, Th1 responses and IFN-y production 
in the lung are thought to be important in defence against MTB but conversely there 
may be suppressed responses in the periphery, depending on the stage of disease. Levels 
of circulating IL-18 were elevated in patients with severe active tuberculosis (Yamada 
et aI., 2000) and correlated with disease activity in this study. IL-18 levels have been 
shown to be elevated in the bronchoalveolar fluid (Morosini et aI., 2003) and in the 
pleural fluid (Song et aI., 2002) of sufferers of MTB. Monocytes and alveolar 
macrophages exposed to MTB show increased levels of IL-18 secretion when cultured 
with T cells or IFN-y (Vankayalapati et aI., 2000). However, consistent with the 
presence of peripheral anergy in some MTB patients, mycobacterium-stimulated 
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Proposed Role of IL-18 
Pathogenic 
Autoimmune Disease 
Rheumatoid arthritis 
Insulin dependent diabetes 
Multiple sclerosis 
Inflammatory disease 
Crohn's disease 
Atherogenesis 
Graft versus host disease 
Infectious disease 
HIV 
Mycobacterium leprae 
Protective 
Infectious disease 
Mycobacterium leprae 
Salmonella typhinurium 
Shigella jlexneri 
Vaccinia 
Leishmania major 
Trypanosma cruzi 
Plasmodium 
(Gracie et al., 1999) 
(Rothe et al., 1997) 
(Wildbaum et al., 1998) 
(Pizarro et al., 1999) 
(Gerdes et al., 2002) 
(Fujimori et al., 2000) 
(Shapiro et al., 1998) 
(Garcia et al., 1999) 
(Kobayashi et al., 1998) 
(Mastroeni et al., 1999) 
(Sansonetti et al., 2000) 
(Tanaka-Kataoka et al., 1999) 
(Wei et al., 1999) 
(Meyer Zum Buschenfelde et al., 1997) 
(Singh et al., 2002) 
Table 1.2. The role of interleukin in extra-pulmonary disease. 
This highlights specific conditions in which IL-18 is thought to play an important role. 
(After Gracie et al., 2003). 
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PBMC from MTB patients produced less IL-l8 and IFN-y than those from healthy 
volunteers (Vankayalapati et aI., 2003). In animal models of mycobacterial infection, 
IL-l8 knockout mice have increased susceptibility to infection with MTB resulting in 
increased numbers of live bacteria in their lungs and large pulmonary and splenic 
granulomata; in these mice, the administration of exogeneous IL-l8 reduced the severity 
of disease (Sugawara et aI., 1999). Similarly, increased systemic expression of IL-l8, 
produced by the intramuscular injection of a viral vector encoding the IL-l8 gene, 
reduced bacterial load in the lungs of mice infected with Mycobacterium avium (Kim et 
aI., 200lb, Shiratsuchi and Ellner, 2001). In consequence, the production ofIL-l8 in the 
lung was thought to be important in immunity against mycobacterial infection. 
The intracellular pathogen Chlamydia trachomatis, can induce a pneumonitis in mice. 
Although lung inflammation was slightly increased in IL-l8 knockout mice infected 
with this organism, the absence of IL-l8, unlike that of IL-l2, did not affect bacterial 
clearance. In contrast to mycobacterial infection, IL-l8 was therefore not thought to be 
essential for the resolution of this intracellular infection (Lu et aI., 2000). 
1.3.2.1.2 Extracellular bacteria 
Streptococcus pneumoniae is a common pathogen in community acquired pneumonia in 
humans. In mice infected with S. pneumoniae, an increase in IL-l8 gene expression and 
protein levels in the lung was observed. There was an increase in bacterial load in the 
lung and increased incidence of systemic infection in IL-l8 deficient mice, indicating 
that IL-l8 was required for efficient clearance of this bacterial infection. The influence 
of IL-l8 in the immune response to S. pneumoniae was thought to be independent from 
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that of IL-12 (Lauw et al., 2002). Likewise, mice infected with Legionella pneumophilia 
also had increased levels of IL-18 in the lung during infection, but inhibition of the 
activity of IL-18 with a monoclonal antibody, although reducing IFN -y production, did 
not significantly alter the resolution of lung infection. However, inhibition of the 
activity of IL-l2 decreased the clearance of L. pneumophilia from the lung (Brieland et 
al.,2000). 
In contrast to its action in pulmonary infection with S. pneumoniae and L. 
pneumophilia, IL-18 was found to impair the clearance of the gram negative 
extracellular bacteria Pseudomonas aeruginosa from the lungs of infected mice (Schultz 
et al., 2003). This organism is often a cause of hospital acquired pneumonia. Exotoxin 
A from Ps. Aeruginosa has been shown to reduce IL-18 mRNA expression in infected 
murine lungs (Wieland et al., 2002) and impair host defence to this organism (Schultz et 
al., 2001a). Other pro-inflammatory cytokines, such as IFN-y, have also been shown to 
inhibit the clearance of Ps. Aeruginosa (Schultz et al., 2001 b). The inhibitory effect of 
IL-18 on resolution of Pseudomonas infection in the lung is in contrast to its actions in 
other Gram negative infections, such as Salmonella typhimurium, where it contributes to 
resolution of infection (Mastroeni et al., 1999). 
The small extracellular bacterium Mycoplasma pneumoniae can also cause pneumonia 
in humans. Serum levels of IL-18 were raised in patients suffering from M pneumoniae 
and there was a correlation with disease severity (Tanaka et al., 2002). IL-18 levels 
were also elevated in the pleural fluid of children with M pneumoniae with pleural 
effusions (Narita et al., 2000). As yet, there is no information from animal models on 
how IL-18 may influence the course of this infection. 
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1.3.2.2 Yeast and fungal and infection 
In clinical practice, persistent fungal infection usually only occurs in the 
immunocompromised. The yeast-like organism Crypotoccus neoformans can cause 
disseminated disease, including meningio-encephalitis, but initial infection is usually by 
inhalation of the organism. Thl driven cell-mediated immunity is required to prevent 
dissemination of this organism from the lung. In a murine model of this infection, 
clearance of C. neoformans was enhanced, and dissemination of infection prevented, by 
exogeneous administration of IL-18 (Kawakami et aI., 1997). Consistent with this was 
the finding that clearance of C. neoformans was impaired in IL-18 deficient mice, but 
dissemination to the brain was not reduced (Kawakami et aI., 2000a). In the absence of 
IL-12, the ability ofIL-18 to induce IFN -y from NK cells is important in enhancing host 
resistance to infection (Kawakami et aI., 2000b). 
Candida albicans is a yeast which can also cause systemic infection in the 
immunocompromised. Mice deficient in caspase-l, and hence decreased mature IL-18, 
did not have increased susceptibility to primary infection but had impaired Thl 
responses on re-infection with this organism (Mencacci et aI., 2000). Mice deficient in 
IL-18, but not IL-12, had increased mortalility in disseminated candidal infection and 
decreased monocyte infiltration at sites of infection (Netea et aI., 2003). Again, the 
induction of IFN -y by IL-18 was thought to be vital in the development of an effective 
response to infection. 
The fungus Aspergillus fumigatus may colonise the lung and produce invasive disease. 
IL-18 was shown to protect against pulmonary infection in a murine model of this 
infection. Inhalation of A fumigatus resulted in an increase in IL-18, IFN-y, TNFa and 
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IL-12 in BAL fluid. Neutralisation of IL-18 activity, by the use of a monoclonal 
antibody against its receptor, reduced IFN-y secretion while neutralisation of both IL-12 
and IL-18 resulted in increased growth of A fumigatus from lung tissue in vitro 
(Briel and et aI., 2001). 
1.3.2.3 Viral infection 
IL-18 can promote effective innate and adaptive immunity to viral infection by 
enhancing the activity of NK cells and cytotoxic CD8+ T lymphocytes respectively. In 
NK cells, IL-18 can up-regulate both perforin-mediated activity (Hyodo et aI., 1999) 
and FasL-mediated cell cytotoxicity (Tsutsui et aI., 1996) against virally infected cells. 
It can also directly stimulate the development of CD8+ cells in an IL-12-independent 
manner (Okamoto et aI., 1999). The role of IL-18 has been studied in a number of viral 
respiratory tract infections. 
Infection of human macrophages by influenza A induces IL-18 secretion (Sareneva et 
aI., 1998), an effect dependent on proteolytic processing of IL-18 by caspase 1 
(Pit'honen et aI., 1999). Studies in IL-18 deficient mice demonstrated that IL-18 is able 
to augment early pulmonary immune responses to influenza A infection, by enhancing 
IFN-y production and NK cell activity, implying that IL-18 has a protective role in this 
infection (Liu et aI., 2004). Adenoviral infection in humans causes symptoms similar to 
the common cold. IL-l8 and IL-12 levels were increased in the BAL fluid in 
adenovirally-infected mice (Berclaz et aI., 2002). However, mice treated with an anti-
IL-18 antibody had decreased inflammatory lung lymphocytic infiltrates and neither IL-
18 nor IL-12 was absolutely required for the development ofThl lymphocytes during 
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the immune response to adenoviral infection (Xing et ai., 2000). Respiratory syncitial 
virus infection (RSV) is an important cause of bronchiolitis in children. In a murine 
model of this condition a predominantly Thl cytokine response was produced. 
However, the absence of IL-18 did not affect the inflammatory response, unlike the 
absence ofIFN-y (Boelen et ai., 2002). Therefore, although IL-18 may have a protective 
role in Influenza A infection, the importance of its actions in other viral respiratory 
infections, such as RSV and adenovirus, are less clear. 
1.3.3 Interstitial lung disease 
IL-18 has been demonstrated to have a pro-inflammatory role in autoimmune conditions 
such as rheumatoid arthritis (Gracie et ai., 1999). Although such conditions may involve 
the lung, this is a rare occunence and so evidence is lacking for the actions of IL-18 in 
these cases. However, some information is available on the effects of IL-18 in a range 
of inflammatory interstitial lung diseases in which T cell mediated immunity is 
important. In all the conditions described below, IL-18 has been implicated as having a 
pro-inflammatory action. 
Sarcoidosis is a granulomatous disease of unknown aetiology which predominantly 
involves the lung. As such, Thl lymphocyte responses are believed to be impOliant in 
its pathogenesis. Patients with sarcoidosis have been shown to have elevated IL-12 and 
IL-18 levels in BAL fluid. IL-18 has been localised to granulomata in sarcoid lung, 
(Shigehara et ai., 2001) and alveolar macrophages from sarcoid patients secrete 
increased amounts of IL-18 in response to LPS compared to those from healthy controls 
(Ho et ai., 2002). Pulmonary CD4+ lymphocytes from sarcoid subjects, have increased 
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activation of the transcription factors AP-1 and NF-KB; IL-18 has been implicated in 
contributing to the up-regulation of these pro-inflammatory transcription factors in vitro 
(Greene et aI., 2000). A polymorphism (CAlAA) at -607 bp in the IL-18 promoter has 
been linked to the development of sarcoidosis. (Takada et aI., 2002). IL-18 levels have 
also been found to be elevated in the BAL fluid of people with berylliosis, another 
granulomatous lung disease (Barna et aI., 2002). IL-18 mRNA expression has also been 
detected in lymph node cells and lung macrophages from animal models of silicosis, but 
consistent pattern of expression has been established (Garn et aI., 2000, Davis et aI., 
2001). 
The repeated administration of IL-2 and IL-18 to mice induced a fatal interstitial 
lymphocytic pneumonia (Okamoto et aI., 2002). Increased IL-18 mRNA expression has 
been found in patients with lymphoid interstial pneumonia (LIP) (Teruya-Feldstein et 
aI., 2001). Elevated concentrations of IL-18 have been observed the BAL fluid of 
patients with bronchiolitis obliterans organising pneumonia (BOOP), in which a 
lymphocytic alveolitis occurs, and also in the fibrotic lung disease, usual interstitial 
pneumonia (UIP) (Forlani et aI., 2002). 
In animal models of acute lung injury, IL-18 mRNA expression and protein levels were 
increased when lung injury was induced by either immune complex deposition (Jordan 
et aI., 2001) or endotoxaemia (Arndt et aI., 2000). In the latter study, lung haemorrhage 
also induced IL-18 mRNA expression but did not alter IL-18 protein levels. 
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1.3.4 Tumour immunity 
In addition to its effects in the immune reponse to bacterial infection and inflammatory 
conditions, IL-18 has been shown to have anti-tumour activity. This anti-tumour effect 
is partially mediated by the ability of IL-18 to enhance the cytotoxicity of NK cells 
(Osaki et al., 1998) and CD8+ cytotoxic T lymphocytes (Kohyama et al., 1998). 
However, the induction of T helper lymphocytes responses by IL-18 is also contributes 
to its anti-tumour acitivity (Xiang et al., 2001). IL-18 may also inhibit angiogenesis in 
tumours, so preventing their growth (Cao et al., 1999). Local production ofIL-18 could 
be derived from tumour-associated macrophages (Wahl and Kleinman, 1998). Dendritic 
cell vaccines genetically engineered to over-express IL-18 have shown anti-tumour 
effects in experimental models (Tatsumi et al., 2003). Exogeneous administration of IL-
18 prevented the development of metastases in an animal model of lung cancer (Iwasaki 
et al., 2002). In clinical disease, elevated serum levels of IL-18 were observed in 
patients with metastatic cancer (Lissoni et al., 2000). Lymphocytes isolated from 
malignant pleural effusions produced IFN -y in response to IL-18 and IL-12 but this was 
not associated with increased cell cytotoxicity (Yao et al., 2002). 
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1.4. The role of IL-18 in allergic disease and humoral immunity 
1.4.1 Th2 lymphocyte responses 
From the above discussion it is clear that IL-18 has an important role in infectious and 
inflammatory disease associated with its capacity to enhance the development of Th1 
responses and augment IFN-y production from both Th1 lymphocytes and NK cells. 
However, it has become apparent that it also has a role in the development of Th2 
responses. Low levels of IL-18 Ra are found on the surface of naIve T cells allowing 
them to respond to IL-18. Yoshimoto et aI. (2000) found that CD4+ T cells stimulated 
with IL-18 and IL-2 produce low levels of IL-4, and, when subsequently stimulated 
with aCD3 can develop into Th2 cells in an IL-4 dependent manner. However, IL-18 
can also stimulate Th2 cell development after antigen stimulation without the presence 
of IL-4 (Xu et aI., 2000). In the latter study, the ability of IL-18 to induce Th2 
differentiation varied with the strain of mouse from which the T cells were isolated and 
was inhibited by IL-12, indicating that genetic background, and therefore probably other 
cytokines, are important in influencing this effect. Transgenic mice over-expressing IL-
18 had higher levels of both Th2 and Th1 cytokines in their serum and in spleen cell 
cultures (Hoshino et aI., 2001). Thl cells stimulated with antigen, IL-18 and IL-2 in 
vitro have been shown to secrete cytokines conventionally considered to be Th2 
cytokines, such as IL-9, IL-13 and GM-CSF, and Th1 type memory cells also enhanced 
airway inflammation in a murine model of asthma (Sugimoto et aI., 2004). This 
suggests that IL-18 may act directly on Thl cells as well Th2 lymphocytes to promote 
allergic responses. Levels of the IL-18Ra chain have been shown to be increased on 
pulmonary lymphocytes and macrophages after antigen challenge in a murine asthma 
model (Kuribayashi et aI., 2002), implying that IL-18 can act on these cells to regulate 
inflammation in the airways during allergic responses. 
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In association with IL-2, IL-18 can induce the production ofIL-13 and GM-CSF in NK 
cells and T cells (Hoshino et aI., 1999b). NKT cells can also be stimulated to secret IL-
4, IL-9 and IL-13 by combined treatment with IL-18 and IL-2 (Yoshimoto et aI., 2003). 
Basophils and mast cells cultured with IL-3 also express IL-18Ra and secrete IL-13 and 
IL-4 after stimulation with IL-18 and IL-3 (Yoshimoto et aI., 1999). Exogeneous IL-18 
treatment in mice induces the activity of the histamine-producing enzyme, histamine 
decarboxylase, in the lung, liver, spleen and bone (Yamaguchi et aI., 2000). Histamine 
can stimulate IL-18 production in PBMC cultures (Kohka et aI., 2000) and this may 
represent a positive feedback mechanism on IL-18 secretion in allergic responses, where 
large amounts of histamine are released from mast cells. IL-18 may also have a direct 
action on eosinophils; these cells have been found to express the IL-18Ra chain and 
secrete IL-8 in response to IL-18 (Wang et aI., 2001). 
1.4.2 Allergic disease 
Because of its ability to promote Th2 lymphocyte differentiation and stimulate Th2 
cytokine secretion in vitro, there has been interest in the role of IL-18 in allergic 
conditions such as asthma and atopic dermatitis. 
Polymorphisms in the coding and promoter regions of the human IL-18 gene (Higa et 
aI., 2003a) and IL-18Ra gene (Watanabe et aI., 2002) have been associated with asthma. 
Serum IL-18 levels were elevated in patients with acute asthma exacerbations (Tanaka 
et aI., 2001a) and also in stable asthmatics (EI-Mezzein et aI., 2001) and those suffering 
from the related allergic conditions, atopic dermatitis (EI-Mezzein et aI., 2001) and 
allergic rhinitis (Verhaeghe et aI., 2002). In contrast other studies have shown that IL-18 
levels are reduced in bronchoalveolar lavage (BAL) fluid from asthmatics (Ho et aI., 
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2002) and that IL-18 mRNA expression in the airway epithelium of asthmatics was 
decreased (Cameron et at, 1999) compared to normal controls and patients with 
sarcoidosis. 
There is also conflicting evidence for the role of IL-18 in murine models of asthma. At 
the time of antigen challenge IL-18 has anti-allergic properties when administered with 
IL-12 (Hofstra et at, 1998) or when expressed in an adenoviral vector (Walter et aI., 
2001); in the latter case the anti-inflammatory effect of IL-18 was dependent on the 
presence of IL-12 and IFN-y. Similarly, IL-18 given after sensitisation, but before the 
time of antigen challenge, decreased eosinophilic inflammation in an RSV -induced 
mouse asthma model (Zhang et aI., 2003). The use of a neutralising antibody to IL-18 
resulted in an increase in airway inflammation in a murine model of fungal asthma 
(Blease et aI., 2001) and mice deficient in IL-18 had an increased inflammatory 
response in the airways (Kodama et aI., 2000), supporting the hypothesis that IL-18 has 
anti-inflammatory activity in allergic airway inflammation. However, IL-18 can 
increase IL-4 and IL-5 production and airway eosinophilia if given at the time of 
allergic sensitisation (Wild et aI., 2000), and can also enhance eosinophil influx to the 
ailways (Kumano et aI., 1999), at least in part by stimulating eotaxin production 
(Campbell et aI., 2000). 
IL-18 has a clearer pro-inflammatory action in atopic dermatitis. Several studies have 
shown raised levels of IL-18 in the serum of atopic dermatitis patients (including Shida 
et aI., 2001, Tanaka et aI., 2001b, El-Mezzein et aI., 2001). In one study, serum IL-18 
levels correlated with blood eosinophil levels (Y oshizawa et at, 2002). 
In an experimental model of atopic dermatitis in NClNga mice, IL-18 levels were 
increased in the serum (Tanaka et aI., 2001b) and skin (Xu et al., 1998c) of affected 
33 
mIce. In particular, cutaneous Langerhans cells have been identified as an important 
source of IL-18 (Wang et aI., 2002). Transgenic mice over-expressing IL-18 
spontaneously developed dermatitis and elevated levels of Th2 cytokines and histamine 
even in the absence of IgE and STAT-6 (Konishi et aI., 2002); contact hypersensitivity 
in mice was also increased in a similar study (Kawase et aI., 2003). Inhibition of the 
activity of IL-18 by the administration of IL-18 BP reduced skin inflammation in a 
mouse model of allergic contact dermatitis (PIitz et aI., 2003). 
Conversely, administration of an anti-IL-18 antibody failed to inhibit the development 
of cutaneous allergic inflammation in NClNga mice (Higa et aI., 2003b). One clinical 
study has shown that the amount of IL-18mRNA and IL-18 production from the 
monocytes of atopic dermatitis sufferers was lower than that of healthy controls 
(Higashi et aI., 2001). 
1.4.3 The role of IL-18 in IgE production. 
Atopic disease is characterised by increased levels of serum IgE. B cells which have 
been activated with anti-CD40, can be stimulated to produce IFN-y by combined 
treatment with IL-18 and IL-12. This inhibits IL-4-induced production ofIgE and IgG 1 
and enhances IgG2a production (Yoshimoto et aI., 1997). IL-18-secreting macrophages 
were shown to have a role in suppressing IgE production in vivo in SJL mice, which 
characteristically have low serum IgE responses to helminth infections (Yoshimoto et 
aI., 1998b). In a murine model of asthma, when mice were treated with IL-12 and IL-18 
decreassed serum IgE levels accompanied the reduction in airway inflammation 
(Hofstra et aI., 1998). 
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In the absence of IL-12, IL-18 can enhance IgE production. Serum IgE levels were 
increased in transgenic mice over-expressing IL-18 either systemically (Hoshino et ai., 
2001) or cutaneously (Konishi et ai., 2002) and also when IL-18 was given alone at the 
time of antigen sensitisation in a murine model of asthma (Wild et ai., 2000). The 
increase in IgE production in response to IL-18 is augmented by IL-18-induced up-
regulation of CD40L on the surface of CD4+ T cells (Hoshino et ai., 2000). It is 
dependent on IL-4/IL-4Ra signalling, but not IL-13, and requires activation of the 
transcription factor STAT-6 (Yoshimoto et ai., 2000). CD4+ T cells and NKT cells are 
also essential for this response (Yoshimoto et ai., 2003). 
IL-18 was initially proposed to have an anti-inflammatory action in asthma because of 
its action in Th1 lymphocyte development. However, since Th1 responses may enhance 
the development of airway inflammation in asthma, and IL-18 can also directly 
stimulate Th2 responses and cytokine production, altering the actions of IL-18 for 
therapeutic benefit in asthma may be complicated. Further assessment of the role of IL-
18 in allergic inflammation is needed in order to decide if this would be worthwhile. 
Since the direct manipulation of the activity of specific cytokines to produce an anti-
inflammatory response in asthma may be difficult, agents which generally suppress the 
allergic response could be used to treat asthma. At present, corticosteroids are the most 
commonly used drugs for this purpose. However, there is continual interest m 
developing new therapeutic agents. A summary of the actions of corticosteroids m 
asthma will be discussed in the following section, as does a discussion of the properties 
of two potential anti-inflammatory agents simvastatin and thymosin beta 4 sulfoxide. 
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1.5 Anti-inflammatory molecules 
Asthma is now considered to be an inflammatory condition of the airways. Modern 
treatment is therefore aimed at suppressing airway inflammation. COliicosteroids are 
currently the most commonly used drugs for this purpose. New therapeutic strategies 
include the targeting of the activities of specific pro-inflammatory cytokines, but novel 
agents are also being developed. The actions of corticosteroids and those of two 
compounds with potential anti-inflammatory actions in asthma, simvastatin and 
thymosin beta 4 sulfoxide, are discussed below. 
1.5.1 Corticosteroids 
Corticosteroids are the most effective anti-inflammatory agents used in the treatment of 
asthma. Their anti-inflammatory action is principally mediated by binding to cytosolic 
glucocorticoid receptors. These receptors then translocate to the nucleus and dimerise 
before binding to glucocorticoid response elements (GRE) in the DNA to inhibit gene 
activity. Corticosteroids probably mediate most of their effects by suppressing the 
expression of the transcription factors AP-1, NF-KB and nuclear factor of activated T 
cells (NF-AT), and the subsequent down-regulation of the expression of many other 
pro-inflammatory genes (Barnes and Adcock, 2003). However, corticosteroids can also 
destabilise the mRNA of some pro-inflammatory cytokines (Amano et al., 1993) and 
alter protein production by other post transcriptional mechanisms (Mozo et al., 1998), 
although these mechanisms are probably of lesser importance for their anti-
inflammatory actions. 
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In asthma corticosteroid treatment can effectively suppress the expression of IL-4 and 
IL-5 in BAL fluid (Robinson et aI., 1993) and IL-13 expression in bronchial biopsies 
(Naseer et aI., 1997); the reduction in the levels of these Th2 cytokines was 
accompanied by an increase in IFN-y and IL-12 mRNA. Also, increased production of 
the anti-inflammatory cytokine IL-10 was observed from the alveolar macrophages of 
steroid-treated asthmatic patients (John et aI., 1998). In vitro, steroids inhibit the 
allergen-induced production of IL-3, IL-5 and GM-CSF from PBMC cultures from 
asthmatics (Powell et aI., 2001). In a murine model of asthma, the corticosteroid 
dexamethasone reduced airway inflammation and IL-5, IL-13 and eotaxin secretion 
(Eum et aI., 2003). In addition, corticosteroids directly induce the apoptosis of 
lymphocytes (Caron-Leslie et aI., 1991) and eosinophils (Adachi et aI., 1996), and this 
is thought to be relevant to the resolution of airway inflammation after exacerbations of 
asthma (Woolley et aI., 1996). 
Conversely, corticocosteroids have been shown to have Th2 promoting activity in vitro, 
including enhancement ofIL-4-induced IgE production (Jabara et aI., 1991), but in vivo 
these activities are thought to be overridden by their anti-inflammatory properties 
(Barnes, 2001). 
Although corticosteroids are effective treatment for most asthmatics, some patients have 
relatively steroid-resistant disease. The exact mechanisms of steroid resistance are 
unclear, but proposed mechanisms include intrinsic insensitivity of T lymphocytes to 
corticoteroid treatment (Syed et aI., 1998), alterations in the relative levels of expression 
of the glucocorticoid receptor a and ~ isoforms (Sousa et aI., 2000) and increased 
infiltration of neutrophils, which are inherently steroid-insensitive (Green et aI., 2002). 
Cigarette smoking induces a neutrophilia in the airways of asthmatics (Chalmers et aI., 
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2001) and reduces the effectiveness of steroid treatment in asthma, both by inhalation 
(Chalmers et al., 2002) and oral administration (Chaudhuri et al., 2003). This effect may 
at least be partly due to the compounds in cigarette smoke inhibiting the action of the 
enzyme histone deacetylase (Ito et al., 2001), which is thought to be involved in 
mediating the DNA binding activity of the glucocorticoid-glucocorticoid receptor 
complex (Kagoshima et al., 2001). 
Despite being a valuable treatment for the majority of asthmatics, corticosteroids have 
significant side effects at high doses. Because of these side effects, and the occurrence 
of steroid-resistance in some patients, there is interest in the development of new anti-
inflammatory agents for the treatment of asthma. Two potential agents are described 
below. 
1.5.2 Simvastatin 
Statins are inhibitors of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase. A schematic representation of 
cholesterol biosynthesis is shown in Figure 1.3A. Statins are widely used as cholesterol-
lowering agents in clinical practice. Simvastatin, the chemical structure of which is 
illustrated in Figure 1.3B, is a naturally occurring member of this class of drugs. 
Simvastatin treatment is known to decrease morbidity and mortality from coronary 
artery disease (Scandinavian Simvastatin Survival Study (4S), 1994). An additional ant-
inflammatory role for statins, independent of their cholesterol-lowering activity, was 
suggested by clinical studies which demonstrated that statin treatment after cardiac 
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Figure 1.3. The cholesterol biosynthetic pathway and structure of simvastatin. 
(A) A schematic diagram of the cholesterol biosynthetic pathway, indicating the site of 
action of statins. (B) The chemical structure of simvastatin. 
HMG-CoA - 3_hydroxy-3-methylglutaryl-coenzyme A; PP - pyrophosphate 
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transplantation could reduce organ rejection (Kobashigawa et aI., 1995) and coronary 
graft vessel disease (Wenke et aI., 1997). Decreased serum inflammatory markers, such 
as C-reactive protein, were observed in statin-treated atherosclerosis patients (Albert et 
aI., 2001) and ex vivo there was reduced inflammation in atherosclerotic plaques from 
subjects who had received statin treatment (Crisby et aI., 2001). Statins have also been 
shown to have anti-inflammatory and anti-atherosclerotic activity in animal models of 
these conditions (Sparrow et aI., 2001). 
The immunomodulatory effects of statins are thought to be mediated through various 
mechanisms (Takemoto and Liao, 2001). Although these are not yet fully understood, 
they are thought to include suppression of cell migration to sites of inflammation by 
inhibiting the expression of cellular adhesion molecules such as the integrin CD 11 b on 
monocytes (Weber et aI., 1997), lymphocyte function-associated antigen (LF A)-Ion 
leukocytes and intercellular adhesion molecule (ICAM)-1 on the vascular endothelium 
(Niwa et aI., 1996). In addition, statins have been shown to allosterically inhibit the 
interaction between the cellular adhesion molecules LF A-I and intercellular adhesion 
molecule ICAM-l (Weitz-Schmidt et aI., 2001). Stains also reduce IFN-y-induced 
expression of major histocompatibility complex (MHC)-II on antigen presenting cells 
(Kwak et aI., 2000). 
By inhibiting the production of L-mevalonic acid and its metabolites, statins prevent the 
isoprenylation, and hence trafficking to the cell surface membrane of the signalling 
molecules such as Ras and Rho, which are involved in the activation of lymphocytes 
(Czyzyk et aI., 2003, Greenwood et aI., 2003). Statins up-regulate the acivity of the 
nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-y) (Grip et 
aI., 2002) leading to down-regulation of pro-inflammatory molecules, including NF-KB 
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(Zelvyte et aI., 2002). Both these mechanisms may contribute to the inhibition of the 
production of pro-inflammatory cytokines and chemokines. Statins can also inhibit the 
production of cytokines, such as IL-6, and chemokines, including monocyte 
chemotactic protein (MCP)-l and RANTES (Diomede et aI., 2001), so further reducing 
influx of inflammatory cells. In relation to atherogenesis, statins augment the activity of 
the endothelial nitric oxide synthase (eNOS), which is thought to be protective against 
the development of atherosclerosis (Ni et aI., 2001), but decrease activity of pro-
inflammatory inducible nitric oxidse synthase (iNOS) (Wagner et aI., 2002). 
Atherosclerotic plaques contain a predominance of Th1 lymphoctes (Frostegard et aI., 
1999). Since statins inhibit inflammation in plaques, recent studies have focussed on the 
potential ability of statins to modulate Thl-predominant disease, such as rheumatoid 
arthritis (Dolhain et aI., 1996) and multiple sclerosis (Lassmann et aI., 2001). In 
collagen-induced atihritis (CIA), an animal model of rheumatoid arthritis, simvastatin 
treatment reduced the development of arthritis and also decreased the severity of 
established disease (Leung et aI., 2003). Similarly, in experimental allergic encephalitis, 
a model of multiple sclerosis, treatment with atorvastatin prevented the onset and 
reversed the severity of relapsing disease (Youssef et aI., 2002, Aletas et aI., 2003). 
Statins, or related compounds, therefore have the potential to be effective 
immunosuppressive agents in clinical inflammatory disease beyond their established 
role in the treatment of atherosclerosis. Studies in rats have shown that simvastatin is 
taken up and metabolised in the lungs (Nezasa et aI., 2002) and can attenuate the 
development of pulmonary hypeliension when given intraperitoneally (Girgis et aI., 
2003) or orally (Nishimura et aI., 2002). These studies suggest that simvastatin is active 
in the lung and could potentially have anti-inflammatory activity in pulmonary disease. 
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1.5.3 Thymosin beta 4 and its sulfoxide 
Although small molecular pharmacological agents may be used as anti-inflammatory 
agents, peptide molecules with immunomodulatory activity exist which may also have 
therapeutic potential in asthma. 
The beta thymosins are a family of 5 kDa acidic peptides which are highly conserved in 
mammalian cells. Their main intracellular function is to sequester monomeric G-actin 
and prevent its polymerisation into filamentous F-actin (reviewed by Huff et aI, 2001). 
As such they have an important role in the control of actin-based cytoskeletal 
remodelling. 
Thymosin beta 4 (P4) comprises 70-80% of all beta thymosins and is ubiquitously 
expressed in cells. It is a 43 amino acid peptide, the sequence of which is shown in 
Figure 1.4. The peptide is thought to fold into two a-helices, comprising residues 5 to 
19 and 30 to 40, on either side of the G-actin binding region. The gene for murine 
thymosin P4 is found on the X chromosome and has three exons and two introns (Li et 
al., 1996). A splice variant of this gene is present in murine spleen and thymic cells 
(Rudin et al., 1990). Seven genes homologous to rodent thymosin P4 have been 
identified in the human genome, but some of these may be pseudo genes (Clauss et al., 
1991). 
A role for thymosin P4 in modulation of the immune response was initially suggested 
when thymosin P4 was found induce terminal terminal deoxynucleotidyl transferase in 
thymocytes (Low et al., 1981). Subsequently, the expression ofthymosin P4 was shown 
to be down-regulated in a similar way to the class II human leukocyte antigen, Fc 
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receptor, and complement receptor in a myeloma cell line. Increased expression of the 
thymosin p4 gene was also present in increased amounts in mature granulocytes (Gondo 
et ai., 1987). In addition, thymosin P4 mRNA levels were up-regulated by IFN-a in a 
lymphoblastoid cell line (McMahon et ai., 1986). Levels of thymosin P4 expression 
have also been shown to be elevated during the S phase of the cell cycle in thymocytes 
(Schobitz et ai., 1991). 
Although thymosin P4 is present in high concentrations in blood leukocytes (Hannapel 
et aI, 1993), it is only present at low concentrations in plasma since the peptide lacks an 
appropriate signal sequence for secretion from cells. However, thymosin P4 can be 
released extracellularly at sites of tissue damage and inflammation (Frohm et aI, 1996), 
where it can have additional actions beyond its intracellular role. 
Extracellular thymosin P4 is able to promote angiogenesis (Malinda et aI, 1998) and it 
also has anti-inflammatory properties. Thymosin p4 enhances wound healing (Malinda 
et aI, 1999; Philp et al 2003), with an associated decrease in polymorphonuclear cells 
infiltration and inflammatory cytokine expression (Sosne et aI, 2001). Given 
intraperitoneally, thymsosin P4 reduced lethality and down-regulated IL-1a production in 
a rat model of endotoxin-induced septic shock (Badamchian et aI, 2003). 
Thymosin P4 contains a methionine at amino acid position 6 which can be oxidised to 
form a sulfoxide residue, forming the peptide thymosin P4 sulfoxide (TP4S0). This 
oxidation decreases the affinity of thymosin P4 (Heintz et aI, 1994) for G-actin and may 
promote its extracellular release. TP4S0 was identified as the factor reducing fMLP-
induced neutrophil chemotaxis in supernatants derived from steroid-treated monocytes 
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Figure 1.4. The peptide sequence of thymosin beta 4. 
The methionine residue (in red) is oxidised to form thymosin beta 4 sulfoxide. The 
residues in blue are conserved between species. The peptide folds to from two a-helices 
on either side of the G-actin binding sequence. The first four amino acids can be cleaved 
from the N terminus, to form seraspenide (ac-SKDP) which has independent biological 
activity. 
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(Chettibi et aI, 1994; Young et aI, 1999). T~4S0 was shown to promote wound healing 
in an in vitro model at ten times the potency of the equivalent dose of thymosin ~4. 
T~4S0 also decreased footpad swelling in carrageenin-induced inflammation in mice, 
whereas thymosin ~4 did not (Young et aI, 1999). A splice variant of thymosin ~4 
derived from lymphocytes also had anti-inflammatory activity in murine models of the 
T lymphocyte mediated-conditions, irritant contact dermatitis and allergic contact 
dermatitis (Girardi et aI, 2003). 
In addition to the direct anti-inflammatory actions of thymsosin ~4 and T~4S0, 
thymosin ~4 may have an indirect immunosuppressive effect by acting as precursor of 
the peptide acSDKP, also called seraspenide. This peptide, which can be enzymatically 
cleaved from the N-terminus ofthymosin ~4, has been shown to inhibit the proliferation 
ofhaemopoeitic stem cells (Lenfant et al., 1989, Grillon et al., 1990). 
The gene for thymosin ~4 is highly expressed in the lung (Gomez-Marquez et al., 
1989). It is therefore possible that thymosin ~4 may be oxidised to T~4S0 and released 
extracellulary to exert its immunomodulatory effects in inflammatory lung disease. 
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1.6 The aims of the thesis. 
IL-18 is a cytokine with the ability to induce both Thl and Th2 mediated immune 
responses. As such it may have an important immunomodulatory role in asthma. As yet, 
there are conflicting reports of the activity of IL-18 in both human asthma and murine 
models of this disease. Further investigation of the actions of IL-18 is needed to assess 
its potential as therapeutic target for the treatment of clinical asthma. 
This thesis will aim to elucidate further the role of IL-18 in asthma by: 
• Establishing the presence of IL-18 in induced sputum from asthmatic and non-
asthmatic subjects and comparing the levels of IL-18 between these groups, by 
both ELISA and quantitative polymerase chain reaction. 
• Assessing if inhaled steroid therapy and cigarette smoking alter the levels of IL-18 
detected in induced sputum samples. 
• Determining which cell types in induced sputum produce IL-18 by 
immunocytochemistry. 
• Using ovalbumin-sensitised BALB/c mice and IL-18 gene knockout (ko) mice to 
directly define the role of IL-18 in vivo in the development of an asthmatic 
response to a specific antigen. 
Inhaled and oral corticosteroid treatment are the most effective anti-inflammatory 
agents used in the treatment of human asthma. Although most patients respond to this 
therapy, there are some patients who do not. There is therefore continual interest in the 
development of new anti-inflammatory agents for the treatment of this condition. 
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The statins are a group of drugs which are commonly used in clinical practice as 
cholesterol lowering agents. They are now thought to have anti-inflammatory activity 
independent of their lipid lowering activity, both in the development of clinical 
atherosclerosis and in animal models of inflammatory diseases, such as multiple 
sclerosis. Similarly, thymosin beta 4 sulfoxide has been shown to have anti-
inflammatory properties. Neither of these compounds as been shown to have an 
immunomodulatory effects in conditions such as asthma, where eosinophils and Th2 
lymphocytes are important mediators of disease activity. 
An additional aim of this thesis will therefore be: 
• Establishing any potential anti-inflammatory effects of simvastatin and thymosin 
beta 4 sulfoxide in allergic inflammation by the use of an ovalbumin-sensitised 
murine model of asthma. 
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2.1 Reagents and buffers 
The source of reagents either purchased or donated is given in the text or tables. Details 
of preparations of individual buffers and reagents are given within the text. 
2.2 Cell culture 
All culture media and supplements were obtained from Invitrogen, Paisley, UK. 
Dulbecco's modification of Eagle's medium (Dulbecco's MEM) supplemented with 
2mM L-glutamine, 100 Ulml penicillin and 100 /-Lg/ml streptomycin ("complete 
Dulbecco's MEM") was used for sputum cell isolation. Supplements were stored in 5ml 
aliquots (xlOO concentration) at -20°C then thawed and added to the medium prior to 
culture. RPMI 1640 supplemented with glutamine, penicillin and streptomycin 
("complete RPMI") as above was used for murine lymphocyte isolation. Cells were 
cultured in the appropriate complete medium supplemented with 1 0% foetal calf serum 
(FCS) which had been mycoplasma screened by the manufacturer, heat inactivated at 
56°C for 30 minutes in a circulating water bath, then stored in 50 ml aliquots at -20°C. 
Aliquots were thawed immediately prior to addition to the culture medium. Cell culture 
was performed at 37°C in a humidified incubator with 5% C02. Cells were counted 
directly using an improved Neubauer haemocytometer (VWR International, Leicester, 
UK) on a Nikon Labphot microscope. During cell purification and washing, cells were 
centrifuged at 400 x g at 4°C unless otherwise stated. 
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2.3 Ethical considerations 
Sputum and peripheral blood samples from asthmatic patients and normal volunteers 
were collected after informed consent was obtained from all subjects. Approval from 
the Ethical Committee in the West Glasgow Hospitals NHS Trust was given for the 
clinical study (The Role of Interleukin-18 in Asthma, Protocol No. 99/81; Professor 
N.C. Thomson, Gatinavel General Hospital). All animal experimentation was 
performed under project licence following UK Home Office review, Project Licence 
6012217 procedure 11 for the murine model of allergic asthma. 
2.4 Patients and clinical samples 
Induced sputum samples were obtained from asthmatic patients and normal subjects 
attending the Asthma Research Unit, Gartnavel General Hospital, Glasgow. All 
asthmatic subjects met the American Thoracic Society Criteria (1987) for the diagnosis 
of asthma and had had no acute exacerbations of their asthma in the six weeks prior to 
providing a sample. Samples were collected from 20 normal smokers, 20 normal non-
smokers, 35 asthmatic non-smokers (17 treated with ~2-agonist alone and 18 treated 
with ~2-agonist and inhaled corticosteroid) and 31 asthmatic smokers (17 treated with 
~2-agonist alone and 18 treated with ~2-agonist and inhaled corticosteroid). 
2.4.1 Induction of induced sputum samples 
Sputum induction was performed as previously described (Pin et aI., 1992). Briefly, 
volunteers were given salbutamol 200 Ilg by metered-dose inhaler and spirometry 
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checked. Sputum induction was then commenced using hypertonic (3%) saline 
administered via an ultrasonic nebuliser (Sonix 2000, Medix Ltd, Harlow, UK) over a 
period of 20 minutes. The subjects were encouraged to expectorate at any time 
throughout the procedure. In addition, inhalation was stopped every 5 minutes to permit 
expectoration, and to allow for spirometry to be carried out. The sample was collected 
in a sterile container and processed within 2 hours. The protocol dictated that the 
procedure would be discontinued if the forced expiratory volume in one second (FEV 1) 
fell by more than 20%; however, this did not occur in any patients. 
2.4.2 Sputum cell preparation 
All samples were processed without knowledge of the clinical information relating to 
the individual subject. Sputum samples were transferred to a petri dish and the volume 
and macroscopic characteristics of the whole sample recorded. Sputum plugs were 
separated from contaminating saliva using sterile forceps. The plugs were placed in a 
pre-weighed tube and the weight recorded. The sputum was then mixed with 2.5 times 
(w/v) of freshly prepared 0.05% dithiothreitol solution made by mixing dithiothreitol 
powder (Sigma Chemical Co., Poole, UK) with Dulbecco's MEM medium (Invitrogen) 
supplemented with 10% FCS. This was vortexed briefly and incubated at 37DC for 15 
minutes with constant agitation. The suspension was filtered through 'Nytex' 50llm 
monofilament nylon filter cloth (Cadish Precision Meshes Ltd, London, UK) to remove 
mucus and then centrifuged at 300 x g for 10 minutes. The cell pellet was washed four 
times in Dulbecco' s MEM medium before analysis. The supernatants were further 
centrifuged at 600 x g for 10 minutes to remove debris and stored at -70DC for future 
analysis. 
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Cell viability was determined during cell counting by trypan blue exclusion (0.1 % (w/v) 
trypan blue (Sigma), 0.1% acetic acid (v/v) (VWR International)). Dead cells and 
epithelial cells were excluded from the total cell count estimation. 
Differential cell counts in sputum cell preparations were estimated from cytospin 
preparations made using a cytocentrifuge (Shandon, Pittsburg, USA). The sputum cell 
samples were suspended at 1.0 x 106 cells/ml in sterile phosphate buffered saline (1 mM 
KH2P04, 155 mM NaCl, 3 mM Na2HP04, pH 7.4, LPS-free; Invitrogen) and then 
centrifuged at 400 rpm for 6 minutes. Cytopreps were fixed using 50% (v/v) acetone 
(VWR International) in absolute ethanol and then stained for 5 minutes with May-
Grunwald-Giemsa stain (VWR International). Differential cell counts were performed 
by counting 300 cells per slide and expressed as percentages. 
Sputum cell cytospin preparations to be used for immunocytochemistry were made on 
polylysine coated slides (VWR International) and fixed with ice cold dried acetone 
(VWR International), air dried, wrapped in Parafilm M® (SPI Supplies, West Chester, 
USA) to exclude moisture and then stored at -70°C until analysis. 
After an aliquot of cells had been taken for cytospin analysis, as described above, the 
remaining cells were pelleted by centrifugation for future RNA purification. The cell 
pellet was then resuspended in cell lysis buffer (buffer RA1 from the NucleoSpin RNA 
II column system (Macherey-Nagel, Duren, Germany), described in 2.l1.1) then stored 
at -70°C. 
52 
2.5 Murine model of allergic asthma 
Murine models of allergic asthma are widely used (reviewed by Lloyd et aI., 2001). 
Mice are sensitised to protein allergens with adjuvant and subsequently re-challenged 
repeatedly with allergen into the airways. This leads to the development of airway 
eosinophilia and airway hyper-responsiveness. Female BALB/c mice (6 - 8 weeks old, 
Harlan-Olac, Bicester, UK) were used except in studies involving IL-18 gene knockout 
(ko) mice, as detailed below. Mice were quarantined for at least 7 - 10 days before being 
used in experiments. 
BALB/c IL-18 ko mice were produced and bred by Dr. X.Q. Wei, Department of 
Immunology, University of Glasgow as described by Wei et aI., 1999. Both male and 
female mice (age 8 - 16 weeks) were used in experiments. Age and sex matched wild-
type (WT) litter mates were used as controls. 
All animals were housed in the Joint Animal Facility, University of Glasgow, ill 
accordance with UK Home Office animal care guidelines. 
A vertin (Augustin and Sim, 1997) was used as an anaesthetic during all experiments. A 
stock solution was made by dissolving 1,1,1 tri-bromoethanol (Aldrich, Poole, UK) 1: 1 
(w/v) in amyl alcohol (Aldrich). This was stored at 4°C until immediately before use 
when a working solution was made by diluting the stock 1 :40 in LPS-free sterile PBS, 
pH 7.4 (Invitrogen). 
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2.5.1 Induction of airway eosinophilia in mice 
Mice were sensitised to ovalbumin (OVA) (Fraction V; Sigma), as described in Figure 
2.1 by modification of a previously published protocol (Henderson et al., 2000). All 
OV A solutions were filter sterilised prior to use (Millex-GV 0.22 Ilm, Millipore, 
Livingston, UK). An alum suspension (Alhydrogel 2%, Brenntag Biosector, 
Fredriksund, Denmark) was used as an adjuvant. To adsorb the OVA to the alum, a 1 
mg/ml solution of OVA in PBS (Invitrogen) was added to an equal volume of the alum 
suspension and mixed using a vortex mixer. Mice were sensitised by administering 200 
III of the OV Alalum mixture, that is, 100 Ilg alum, by intra-peritoneal (i.p) injection day 
o and day 14. On day 14, at the time ofi.p. injection, mice were anaesthetised with 300 
- 400 III avertin i.p. and 100 Ilg of sterile OVA in 50 III sterile PBS (Invitrogen) was 
given intranasally (i.n.) using a micropipette. Mice were again anaethetised with avertin 
before the administration of three i.n. challenges of 50 Ilg OVA in 50 III PBS 
(Invitrogen) on each of days 25, 26 and 27. Control mice were given PBS in place of 
OV A in both the sensitisation and challenge stages of the protocol. Mice were sacrificed 
on day 28 by giving a fatal dose of avertin. 
Potential anti-inflammatory compounds were administered on days 25, 26 and 27 of the 
above protocol. Thymosin beta 4 sulfoxide (gifted by Dr. John Young, Centre for 
Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow) at a dose of 20 Ilg per mouse 
was given by i.p. injection 30 minutes before each i.n. challenge, as was 3 mg/kg 
dexamethasone (water soluble, Sigma). Simvastatin (gifted by Dr. Anne Crilly, Centre 
for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow), which had been acidified 
to produce the active compound, was given at a dose of 4 mg/kg or 40 mg/kg i.p. 30 
minutes before each i.n. challenge. In separate experiments, simvastatin 40 mg/kg was 
also given by oral gavage 60 minutes before each i.n. challenge. 
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Figure 2.1. Protocol used in the murine model of allergic asthma. 
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Mice were sensitised and challenged with ovalbumin (OVA) as described in the 
protocol above. To sensitise the mice, 100 !-lg of OVA adsorbed to alum was given by 
intraperitoneal (i.p.) injection on day (d)O and d14; 100 !-lg of OVA was also given 
intranasally (i.n.) on d14. Mice were challenged with 50 !-lg of OVA on each of d25, 
d26 and d27. Mice were sacrificed on day 28 and analyses performed. 
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2.5.2 Bronchoalveolar lavage (BAL) 
The thorax was opened carefully and blood was taken by cardiac puncture under direct 
vision for serum immunoglobulin measurements. The trachea was then exposed and a 
small transverse incision made in it immediately below the level of the larynx. 
Polythene tubing (0.58mm ID, 0.78mm OD; VWR International) threaded over a 23 
gauge 'blue' needle was inserted into the trachea and held in place using 12 cm blunt 
forceps (VWR International). The lungs were then lavaged with 2 x 0.5ml of PBS, 
ensuring that both lungs were seen to inflate during the lavage process and that there 
was no leakage of lavage fluid from the trachea. The two lavage samples from each 
mouse were pooled in a 1.5 ml micro centrifuge tube (Thistle Scientific, Uddingston, 
UK) and kept on ice until processing. The BAL fluid was centrifuged at 400 x g for 5 
minutes to pellet the cells and the supernatant removed using a 1 ml syringe attached to 
an 18 gauge needle. This allowed the volume of each lavage sample to be estimated to 
the nearest 0.01 ml. Supernatants were frozen at -20°C until analysis. To remove any 
contaminating red blood cells, the BAL cell pellet was resuspended in 1 ml of F ACS® 
Lysis Buffer (1: 1 0 dilution in sterile distilled water of commercial stock containing 5% 
diethylene glycol, 1.5% formaldehyde; BD Biosciences, Cowley, UK) mixed gently by 
inverting the tube several times, and incubated for 10 minutes at room temperature. The 
cells were then washed twice in PBS before being resuspended in 1ml of PBS. The cell 
number was then counted using a haemocytometer. The absolute cell count per lavage 
was divided by the lavage volume to standardise the cell count per ml of lavage fluid. 
Cytospin preparations were then made using a Shandon Cytospin in a similar way to 
that described for sputum cell cytopreps (Section 2.4.2). Approximately 1 x 105 cells 
were used to make each cytoprep. Cells were centrifuged at 400 rpm for 6 minutes then 
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fixed in methanol for 10 minutes. Cytopreps were stained with Diff-Quik (Triangle 
Biomedical Sciences, Skelmersdale, UK), a staining kit for rapid Romanowsky staining. 
Some slides were also stained specifically for eosinophils using Chromotope 2R (VWR 
International) following the protocol of the Department of Veterinary Pathology, 
University of Bristol, UK (www.bris.ac.uklDeptslPathandMicro/CPLIcarbol.html). 
Differential cell counting was done using standard morphological criteria. Four hundred 
cells were counted per slide. Differential cell counts were expressed as a percentage of 
the number of cells then multiplied by the total cell count per ml to give an absolute cell 
number per ml. 
2.5.3 Lung histology 
2.5.3.1 Preparation of tissue sections 
After BAL sampling had been completed, the lungs were removed from the thoracic 
cavity by careful dissection. Polythene tubing was again inserted into the trachea, as 
described above, and the lungs inflated with Iml of 10% neutral buffered formalin (10% 
(v/v) of 37% aqueous solution of formaldehyde (Aldrich), 30mM NaH2P04.H20, 45 
mM Na2HP04, pH 7). The trachea was tied with 2-0 silk suture (Ethicon, Edinburgh, 
UK) and the lungs immediately immersed in 10% neutral buffered formalin for at least 
72 hours. After fixation, the left lung was then dissected free, embedded in paraffin and 
6 !--tm sections cut (kindly performed by Mr. Roderick Ferrier, Department of Pathology, 
Western Infirmary, Glasgow). Sections were stained with haematoxylin and eosin using 
a standard method. 
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2.5.3.2 Quantification of lung inflammation 
Quantification of lung inflammation on histological sections was determined using a 
semi-quantitative method (Sur et al., 1999). Total lung inflammation was defined as the 
sum of peribronchial and perivascular scores. Inflammation was graded on the scale 0, 
none; 1, mild, 2, moderate; 3, marked and 4, severe. An increment ofO.5 was used when 
severity of inflammation fell between two integers. Sections were scored by a single 
observer blinded to the treatment group of the mice. 
2.6 Isolation of lymphocytes from murine thoracic lymph nodes 
Sensitisation of mice to OVA produced a response in thoracic lymph nodes. To assess 
this further, lymph nodes from the paratracheal and subcarinal areas were obtained by 
careful dissection after the lungs had been removed from the thoracic cavity. Nodes to 
be used for culture or analysis by flow cytometry were stored in complete RPMI on ice 
until processing. Other lymph nodes were placed in RNAlater™ (Ambion, Austin, 
USA), a solution with a high salt concentration which inhibits RNase activity, and used 
later to obtain RNA for RT-PCR analysis of gene expression. 
A single cell suspension was obtained from murine thoracic lymph nodes, obtained as 
described above, by gently pressing the lymph nodes through sterile Nytex using a 2ml 
syringe plunger. The cell suspension was washed three times in complete RPMI, passed 
again through Nytex to remove cellular aggregates and debris and then resuspended in 
an appropriate volume of complete medium. An accurate cell count was then made 
using a haemocytometer. 
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Proliferation assays for thoracic lymph node cells were performed in triplicate in U-
bottom 96 well culture plates (Nunc, Rochester, USA) at 2 x 105 cells/well in 100 fll 
complete RPMI with 10% FCS. Additional cell stimulating agents or medium were 
added in volumes of 100 fll to give a final culture volume of 200 fll per well. Cells were 
stimulated with a final concentration of 500 - 1000 flg/ml OVA or 5 flg/ml Concanavalin A 
(Sigma) in culture medium. Cell culture was allowed to proceed for 96 hours with 1 flCi 
of eH]-thymidine (Amersham, Little Chalfont, UK) in a volume of 25 fll being added 
during the final 8 hours of culture. Plates were harvested onto a glass fibre filter 
(Packard, CT, USA) using a Micromate 196 Harvester (Packard). eH]-thymidine 
incorporation was measured using a Matrix 96 Direct Beta Counter (Packard). Cytokine 
production by thoracic lymph node cells was measured using supernatants derived from 
parallel triplicate cultures in flat-bottom 96 well culture plates (Nunc) in the presence or 
absence of stimuli; these culture supernatants were harvested after 72 hours. 
Supernatants were frozen at -20°C until cytokine assays were perfOlmed in single 
batches (Section 2.8). 
2.7 Flow cytometry 
2.7.1 Analysis of murine lymphocyte phenotype 
The phenotype of murine lymph node lymphocytes was determined by flow cytometric 
analysis using double immunofluorescence staining. The antibodies used are described 
in Table 2.1. Cells suspended 1 x 106 in 100 fll of serum free complete RPMI, were 
placed in a 12 x 75 mm polystyrene tube (Falcon 2052, BD Biosciences). The cells were 
pelleted by centrifugation at 400 x g for 5 minutes and then resuspended in 50 fll of a 
1 :50 (v/v) dilution ofFc Block in FACS buffer (Ix PBS, pH 7.5,5% (w/v) FeS and 
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Antibody specificity Conjugate Host Isotype Source 
CD3 PE Rat IgG2b, K BD Biosciences 
CD4 PE Rat IgG2a, K BD Biosciences 
CD4 FITC Rat IgG2a, K Sigma 
CD8 FITC Rat IgG2a, K BD Biosciences 
CDlla FITC Rat IgG2a Caltag Laboratories 
CD44 FITC Rat IgG2b Caltag Laboratories 
CD45RB FITC Rat IgG2a, K BD Biosciences 
CD62L PE Rat IgG2a, K BD Biosciences 
CD16/32/FcyR Rat IgG2b, K BD Biosciences 
(Fc Block) 
Table 2.1. Antibodies used in FACS analysis of murine lymphocyte phenotype. 
The antibodies used in the F ACS analysis of murine lymphocyte phenotype are listed 
above. 
FITC - fluoroescein isothiocyanate; PE - phycoerythrin 
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Antibody Conjugate Host species Source 
IgG2a FITC Rat Caltag Laboratories 
IgG2a PE Rat BD Biosciences 
IgG2b FITC Rat Caltag Laboratories 
IgG2b PE Rat Caltag Laboratories 
Table 2.2. Negative control antibodies used in flow cytometry. 
The negative control antibodies used in the F ACS analysis of murine lymphocyte 
phenotype are listed above. 
FITC - fluoroescein isothiocyanate; PE - phycoerythrin 
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0.1 % (w/v) sodium azide) and incubated for 10 minutes at room temperature. Antibody 
diluted to an appropriate concentration in 50 III F ACS buffer was then added to each 
tube and the samples incubated at 4°C for 30 minutes. Negative control primary 
antibodies of appropriate isotype and conjugate, as listed in Figure 2.2, were added to 
parallel tubes and similarly processed. Cells were then washed by adding 3 ml of F ACS 
buffer to each tube followed by centrifugation at 400 x g for 5 minutes. Cells were 
washed with 1 ml F ACSFlow (BD Biosciences) followed by centrifugation at 400 x g 
for 5 minutes before being resuspended in 300 III F ACSFlow and analysed by flow 
cytometry (FACScan, BD Biosciences). Gates were set for lymphocytes using forward 
and side light scatter parameters. The percentages of fluoroscein isothiocyanate (FITC) 
or phycoerythrin (PE) positive cells were generated using Cellquest software (BD 
Biosciences ). 
2.8 Enzyme linked immunosorbance assay (ELISA) for cytokines 
2.8.1 Human IL-18 ELISA 
Human IL-18 was measured in sputum cell supernatants using a commercially available 
kit (Diaclone SAS, Besancon, France). The assay was performed using commercial 
reagents following the manufacturer's protocol. The assay recognised both pro-IL-18 
and mature IL-18. The sensitivity of the ELISA was 20 pg/ml. 
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2.8.2 Murine cytokine ELISA protocol. 
Murine IFN-y, IL-4, IL-5 and IL-6 were quantified in BAL fluid or culture supernatants 
using paired capture and biotinylated detection antibodies for each cytokine (BD 
Biosciences). Details of the concentrations of antibodies used and the lower limit of 
detection of each assay are given in Table 2.3. Immulon 4 micro-ELISA plates (Dynex 
Technologies, Ashford, UK) were coated overnight at 4DC with the appropriate 
concentration of capture antibody in 0.1 M NaHC03, pH 8.2. The working volume was 
50 III per well. The plates were washed four times with lxPBS (140 mM NaCl, 4 mM 
NaH2P04, 5 mM KC1, l.5 mM KH2P04, pH 7.4) containing 0.05% Tween 20 (wash 
buffer) and blocked for 2 hours at room temperature with 200 III of 10% (v/v) FCS in 
PBS (ELISA buffer). After four washes with wash buffer, 50 III samples were added in 
duplicate to the plate. Serial twofold dilutions of recombinant cytokine (BD 
Biosciences) in duplicate were also added as standards. The plates were then incubated 
for two hours at room temperature or overnight at 4 DC to allow binding between 
cytokine and antibody. After this, 50 III of biotinylated detection antibody in ELISA 
buffer was added after four washes and samples were again incubated for one hour at 
room temperature. The plates were washed six times before 50 III of 1: 1 000 dilution of 
ExtrAvidin (Sigma) in ELISA buffer was added to each well. After incubation for 30-60 
minutes at room temperature the plates were washed 8 times and then developed using 
100 III per well of TMB Microwell Peroxidase Substrate (KPL, Gaithersburg, USA). 
Plates were incubated at room temperature in the dark until sufficient colour reaction 
product was visible. The plates were then read at 630 nm on a MRX II microplate 
reader (Dynex Technologies), always within 1 hour of the TMB being added. 
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Capture Antibody Detection Antibody Lower Limit of Detection 
Cytokine 
(f!g/ml) (f!g/ml) of Assay (pg/ml) 
IL-4 2 2 10 
IL-5 2 2 10 
IL-6 1 1 10 
IL-18* 5 0.3 40 
IFN-y 1 0.5 40 
Eotaxin# 0.4 0.08 10 
Table 2.3. Antibodies used in murine cytokine ELISAs. 
The antibodies used for the quantification of murine cytokines by ELISA in 
bronchoalveolar lavage fluid and cell culture supernatants are listed above. 
All antibodies were purchased from BD Biosciences, Cowley, UK, except: 
* , purchased from Perprotech, London, UK. 
#, purchased from Rand D Systems, Abingdon, UK. 
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Murine IL-18 was assayed following the above protocol. Paired antibodies for this 
cytokine were purchased Perprotech, see table 2.3, and recombinant murine IL-18 
(R&D Systems, Abingdon, UK) was used as a standard. The range of the standard curve 
was 80 pg/ml - 80 ng/ml. 
Murine eotaxin was assayed using paired capture and biotinylated detection antibodies 
(R&D systems), see table 2.3, using a recombinant murine eotaxin standard (R&D 
Systems). Modifications to the above protocol were as follows: capture antibody coating 
buffer was PBS, pH 7.4; blocking buffer 1 % bovine serum albumin (BSA)(Sigma), 5 % 
sucrose and 0.05% NaN3 (Sigma); assay diluent 0.01 % BSA, 0.05% Tween 20 in Tris-
buffered saline (20 mM Trizma base, 150 mM NaCl), pH 7.3. The range of the standard 
curve was 8 pg/ml - 1000 pg/ml. After incubation with TMB substrate for 30 minutes 
the reaction was stopped at 30 minutes by the addition of 50 !il 1 M H3P04. Plates were 
read at 450 nrn with 570 nrn correction. 
2.9 Murine serum immunoglobulin measurements 
2.9.1 Serum OVA-specific IgG1, IgG2a and IgE levels 
Murine serum OVA-specific IgGl, IgG2a and IgE levels were determined using a 
modification of the ELISA protocol described above, and of a previously published 
method (Garside et aI., 1995). At least five washes with ELISA wash buffer were done 
between each step of the protocol. Immunolon 4 micro-ELISA plates were coated at 4°C 
overnight with 50 !il of a 10 !ig/ml solution of OVA in a coating buffer of 0.05 M 
carbonate/bicarbonate buffer (50mM NaHC03, 50mM Na2C03, pH 9.5). The plates 
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were then blocked with 200 fll of ELISA wash buffer containing 10% (v/v) FCS for 1 
hour. Serum was diluted appropriately in wash buffer, then 50 fll of the diluted serum 
added across the top row of the plate, leaving column 12 with buffer alone. The starting 
dilutions were 1 in 250 for serum IgG 1 assays, 1 in 50 for Ig2a assays and 1 in 20 for 
OVA-specific IgE assays. The samples were then serially diluted with wash buffer 
through rows two to eight of the plate. IgG 1 samples were diluted 1:3 each time and 
IgG2a and IgE samples diluted 1 :2. Samples were then incubated at room temperature 
for 1.5 hours. Biotinylated anti-mouse IgG 1, IgG2a and IgE (BD Biosciences) 
antibodies were added to the appropriate plates at a concentration of 0.5 flg/ml in 50 fll 
wash buffer. The plates were incubated for 1 hour at room temperature. Thereafter, 50 
fll of a 1: 1 000 dilution of ExtrA vadin in wash buffer was added to each well and 
incubated for 30 minutes at room temperature. The plates were developed using 100 fll 
of TMB substrate and then read at 630 nm, as described in section 2.8.2 above. The 
mean optical density for a designated serum dilution for each of OVA-specific IgG 1, 
IgG2a and IgE was recorded to give a comparison of the serum levels of these 
antibodies among different treatment groups. 
2.9.2 Measurement of serum total IgE levels 
Total murine serum IgE levels were measured using the OptiEIA ELISA Mouse IgE Set 
(BD Biosciences) following the manufacturer's guidelines. The working volume was 
100 fll. At least 4 washes were performed between each step. Maxisorp micro-ELISA 
plates (Nunc) were coated with a 1 :250 dilution of capture antibody in 0.1 M 
carbonate/bicarbonate buffer (0.1 M NaHC03, 0.1 M Na2C03, pH 9.5) and incubated at 
4°C overnight. Plates were blocked by incubating with 200 fll of ELISA buffer for 1 
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hour at room temperature. Mouse serum samples diluted 1 :200 in ELISA buffer or the 
supplied IgE standard were then incubated for 2 hours at room temperature. Samples 
were tested in duplicate. The standard curve ranged from 1.6 ng/ml to 100 ng/ml. 
Detection antibody and detection agent, both at a dilution of 1 :250 in ELISA buffer, 
were then added and samples incubated for 1 hour at room temperature. TMB substrate 
was used to develop the ELISA. This reaction was stopped at 30 minutes by the addition 
of 50 ~l 1 M H3P04. Plates were then read at 450 nm with 570 nm correction. 
2.10 Immunocytochemisty 
Sputum cytospin preparations were made using a Shandon cytospin device as described 
in Section 2.4.2. Polylysine coated microscope slides (VWR International) were used to 
help maintain cell adherence to the slides. Cells from some sputum samples were 
cultured for 24 hours in complete DMEM containing 10% FCS in the presence or 
absence of 100 ng/ml LPS from Salmonella enteriditis (Sigma) at a cell concentration of 
2 x 105 cells in 200 ~l. Cells were harvested from the plates by gentle pipetting then 
washed twice in PBS to remove debris before cytospins were prepared as above. 
2.10.1 Human IL-18 immunocytochemistry 
Frozen cytospin slide preparations were allowed to come to room temperature before 
being washed in PBS for 5 minutes. Endogenous peroxidase activity was then blocked 
using 0.5% hydrogen peroxide (Sigma) (v/v) in methanol (VWR international) for 30 
minutes. The slides were washed twice for 10 minutes in PBS at room temperature. A 
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wax rmg was drawn round the tissue section using an ImmEdge ™ pen (Vector 
Laboratories Ltd., Peterborough, U.K.) and lOOfll of blocking serum (20% (v/v) human 
serum (Scottish Antibody Production Unit (SAPU), Lanarkshire, UK) and 20% (v/v) 
horse serum (SAPU) in PBS) placed over each cell preparation and incubated for 30 
minutes at room temperature. The blocking serum was then removed by tapping the 
slides gently on tissue paper and 100 fll of a 1 flg/ml solution of polyclonal mouse anti-
human IL-18 serum (D4/D1, gifted from Dr. Andrew Jackson, CRUK, London) in assay 
diluent (2% (v/v) horse serum and 2% (v/v) human serum in PBS) applied over each 
cytoprep. The samples were incubated at 4°C overnight. Samples were allowed to come 
to room temperature and then washed twice in PBS for 5 minutes each time. The 
secondary antibody solution, 2.5 flg/ml biotinylated horse anti-mouse IgG (DAKO, Ely, 
U.K.) in assay diluent, was applied for 30 minutes at room temperature. The slides were 
then washed twice in PBS at room temperature. After this an alkaline phosphatase 
complex (Vectastain Elite ABC Kit, Vector Laboratories Ltd.) was applied and the 
samples incubated for 30 minutes at room temperature. The samples were again washed 
twice for 5 minutes in PBS before the addition of diaminobenzidine substrate (DAB, 
Vector Laboratories Ltd.) and the slides viewed microscopically until the stain 
developed. The slides were then washed in PBS for 5 minutes and then in tap water for 
5 minutes before counter-staining lightly with Harris haematoxylin (VWR International) 
for 5 minutes. Samples were dehydrated by successive 5 minute washes in 70% ethanol, 
95% ethanol and 100% etahnol and then twice for ten minutes in xylene before being 
mounted using DPX (VWR International). 
Specificity of staining of the primary anti-serum for human IL-18 was demonstrated by 
pre-incubation with recombinant human IL-18 (produced in the Department of 
Immunology, University of Glasgow) which neutralised binding (Mrs. S Kitson, Centre 
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for Rheumatic Diseases, Royal Infirmary, Glasgow) or by the use of 1 ).1g/ml mouse 
IgG 1 (DAKO, Ely, UK) as a negative control. A mouse anti-human CD68 monoclonal 
antibody (DAKO) was used as a positive control. The secondary antibody used did not 
bind to sputum cells in the absence of primary antibodies at the concentrations indicated 
in the above protocol. The alkaline phosphatase conjugate, either alone or in the 
presence of secondary antibody, did not bind sputum cells directly. 
2.11 Reverse transcription - polymerase chain reaction (RT -peR) 
Induced sputum cells were pelleted by centrifugation at 400 x g for 5 minutes and then 
immediately resupended in 350 ).11 of cell lysis buffer (from NucleoSpin RNA II 
purification kit; Macherey-Nagel, Duren, Germany) containing 1% (v/v) 2-
mercaptoethanol, lysed by repetitive mixing with a micropipette and then stored at -
70DC until use. Murine lymph nodes, which had been stored in RNAlater™ at -70DC 
were removed from the RNAlater™, dried on tissue paper and then placed in 350 ).11 of 
lysis buffer 1 % 2-mercaptoethanol in a 1.7ml microcentrifuge tube and homogenised 
using a Kontes Pellet Pestle Cordless Motor (Kontes Glass Company, New Jersey, 
USA). Lysates were again stored at -70DC until required. 
2.11.1 RNA purification 
Total cellular RNA was extracted using NucleoSpin RNA II columns (Macherey-Nagel, 
Duren, Germany) following the manufacturer's protocol. Briefly, cells are lysed in a 
solution containing a large amount of chaotropic ions which inhibit RNase activity and 
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favour the binding of RNA to the silica membrane of the Nucleospin RNA column. 
Contaminating DNA is then removed by a DNase I solution which is applied directly 
onto the silica membrane during the preparation. Washing steps with two different 
buffers remove salts, metabolites and macromolecular cellular components before the 
RNA is eluted under low ionic strength conditions with RNase-free water. RNA from 
sputum cell pellets was eluted in 40 j.ll of RNase-free water while murine lymph node 
RNA was eluted in a volume of 60 j.ll of RNase-free water (Braun, Melsungen, 
Germany). The RNA concentration of each sample was determined using the 260:280 
nrn absorbance ratio of each solution by UV spectrometry. RNA samples were stored at 
-70°C until required. 
2.11.2 DNase treatment of RNA samples 
Some RNA samples purified using the NucleoSpin RNA II columns were found to have 
residual DNA contamination. As this would decrease the efficiency and accuracy of 
subsequent PCR reactions, further treatment with DNase was done using the DNA-
ji-ee™ kit (Ambion, Austin, USA). To 16 j.ll of RNA solution was added 2 j.ll (4 units) of 
DNase I and 2 j.ll of 10 x DNase buffer (lOOmM T!'is-Cl pH 7.5, 25mM MgCh, 1 mM 
CaCh). Samples were incubated at 37°C for 30 minutes. The reaction was stopped by 
the addition 5 j.ll of the supplied DNase Inactivation Reagent to the sample and the 
sample mixed by repetitive pipetting. The tubes were incubated for 2 minutes at room 
temperature, the tube being flicked once during the reaction to re-disperse the DNase 
Inactivation Reagent. Samples were then centrifuged at 10,000 x g for 1 minute to pellet 
the DNase Inactivation Reagent. The RNA-containing supernatant was then removed 
and either used immediately for reverse transcription reactions or placed in a fresh tube 
and stored at -70°C until use. 
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2.11.3 Reverse Transcription 
Cloned (c) DNA was generated using the Superscript II RT system (Invitrogen). 1-2 ug 
of RNA, in a volume of ~ 10 fll was added to 2-3 fll (100 - 150 ng) of random 
hexamers (Invitrogen) and the volume made up to 12 fll by the addition of the 
appropriate volume of RNase-free H20. This mixture was heated at 70°C for 10 minutes 
in a heating block and then placed on ice for at least one minute. During this time a 
mixture of 4 fll 5X First Strand Buffer (250mM Tris-HCI pH 8.3, 375mM KCI, 15mM 
MgCh),2 fll O.1mM and 1 fll of mixed dNTP stock (10mM each ofdATP, dGTP, dCTP 
and dTTP, pH 7) per sample was prepared. This mixture (7 fll) was added to the 
RNA/random hexamer mixture and incubated at 42°C for 2 minutes. Superscript II RT 
(1 ).ll (200 units» and reverse transcription undertaken by successive incubations at 
25°C for 10 minutes, 42°C for 50 minutes and 70°C for 15 minutes. 
2.11.4 Quantitative polymerase chain reaction 
Quantitative 'Taqman™, real-time PCR (Gibson et al. 1996) was performed according to 
the manufacturer's instructions (PE Applied Biosystems, Foster City, USA) and as 
described by Overbergh et al (1999). This is a PCR method that allows rapid and 
accurate quantitation of gene transcription levels from small samples. The principle of 
this method is outlined in Figure 2.2. 
Primers and fluorgenic probes (listed in Table 2.4) were designed by Dr. Carol 
Campbell, Department of Immunology, University of Glasgow, using the Primer 
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Figure 2.2. Taqman real-time RT-PCR. 
The Taqman probe is an oligonucleotide with a 5' reporter dye (R) and a 3' quencher 
(Q). In an intact probe, the proximity of the quencher to the rep011er causes suppression 
of rep011er fluorescence. During PCR, the probe is cleaved by the 5' -) 3' exonuclease 
activity of Taq DNA polymerase separating the reporter from the quencher. Reporter 
fluorescence increases and can be used to determine the quantity of specific product 
generated. The 3' end of the probe is blocked to prevent extension of the probe during PCR. 
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Table 2.4. Taqman Primers and Probes. 
Primers: F = forward; R = reverse 
Probes: 5' F AM (6- carboxy-fluorescein) labelled 
3' TAMRA (6-carboxy-tetramethyl rhodamine; quencher) labelled 
Murine IL-4 F primer: 5' - ACA GGA GAA GGG ACG CCA T - 3' 
R primer: 5' - GAA GCC CT A CAG ACG AGC TCA - 3' 
Probe: 5' F AM -TCC TCA CAG CAA CGA AGA ACA CCA CA - TAMRA 3' 
Murine IL-5 F primer: 5'-AGC ACA GTG GTG AAA GAG ACC TT - 3' 
R primer: 5'- TCC AAT GCA TAG CTG GTG ATT T - 3' 
Probe: 5' FAM - CTG TTG ACA AGC AAT GAG ACG ATG AGG -TAMRA 3' 
Murine IL-13 F primer: 5' - AGA CCA GAC TCC CCT GTG CA - 3' 
R primer: 5' - TGG GTC CTG TAG A TG GCA TTG - 3' 
Probe: 5' FAM - CGGGTTCTGTGT AGCCCTGGA TTCC-TAMRA 3' 
Murine IL-18 F primer: 5' - CAA A TC ACT TCC TCT TGG CCC - 3' 
R primer: 5'- AAC AAA GTC TGG CCT GT A TCC AA - 3' 
Probe: 5' FAM - CTG CCA TGT CAG AAG ACT CTT GCG TCA ACT.-
TAMRA3' 
I 
I 
Murine F primer: 5'- CGC TTC CCG GAA GAG CAT- 3' 
CIITA* R primer: 5'- TCC AAA TAG TTC AGT GAG GTC CTA GA - 3' 
! 
Probe: 5' FAM - CTA TGGACTCAAAGCACAGGAAGCTAGTGCC-
TAMRA-3' 
* MHC-II transactivator 
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Murine HPRT F primer: 5'- GCA GTA CAG CCC CAA AAT GG - 3' 
R primer: 5' - AAC AAA GTC TGG CCT GTA TCC AA 3' 
Probe: 5' FAM - TAA GGT TGC AAG CTT GCT GGT GAA AAG GA -
TAMRA-3' 
Human IL-18 F primer: 5' - GGC CTC TAT TTG AAG ATA TGA CTG ATT - 3' 
R primer: 5' CCT CT A GGC TGG CTA TCT TT A TAC AT A C - 3' 
Probe: 5' F AM - TGA CTG TAG AGA T AA TGC ACC CCG GAC C -
TAMRA3' 
Human HPRT Purchased from PE Applied Biosystems UK (Warrington, UK) 
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Express™vl.O program purchased from PE Biosystems or purchased directly from PE 
Biosystems. PCR reactions were performed in the ABI-prism 7700 Sequence Detector, 
which contains a Gene-Amp PCR system 9600 (PE Biosystems). PCR amplification 
was performed in a total volume of 25 Ill, containing 1 III of sample cDNA, 50 mM 
KCI, 19 mM Tris-HCI (pH 8.3), 10 IlM EDTA, 200 IlM of each of dATP, dCTP and 
dGTP and 400 IlM dUTP, 3.5 mM MgCh, 300 nM each primer, 200 nM fluorgenic 
probe, 0.625 U AmpliTaqGold™ and 0.25 U Amperase Uracil N-Glycosylase (PE 
Biosystems). Each reaction was performed in triplicate using the following conditions: 2 
minutes at 50°C then 10 minutes at 94°C, followed by a total of 45 two temperature 
cycles of 15 seconds at 94°C then Iminute at 60°C. 
Data analysis was performed using the Sequence Detection v1.6.3 software (PE 
Biosystems). The threshold cycle, Ct, was calculated for each sample. This represents 
the PCR cycle at which an increase in fluorescence above a set threshold level can first 
be detected (Figure 2.3). Expression of the gene of interest in a sample was normalised 
by comparison to the expression of a reference reporter gene, HPRT. Firstly, the i1Ct 
was obtained by subtracting the Ct value of HPRT from the Ct value of the gene of 
interest. The formula 2"~Ct was then used to calculate a value for the fold increase in 
gene expression relative to HPRT. Multiplication of this value by 100 gives expression 
of the gene of interest as a percentage of HPRT. The positive error is the standard 
deviation of the difference, s = --J(Sj2 + sl) where Sj and S2 are the standard deviations of 
the Cts of the HPR T and the gene of interest. 
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Figure 2.3. Typical Taqman amplification plots. 
Viewer: ( loRn (Bu. I ~J 
Reporter : ( VI C I U 
The amplification plot shows how the fluorescence emission (normalised Reporter, Rn) 
varies with the PCR cycle number. Initially the fluorescent signal is below the detection 
limit of the Sequence Detector. As the PCR reaction proceeds the signal can be detected 
as it continues to increase in direct proportion to the amount of specific amplified 
product. The Rn reaches a plateau when the ratio of polymerase enzyme to PCR product 
decreases preventing the amount ofPCR product from increasing exponentially. The Ct 
(threshold cycle) is determined during the exponential phase (threshold indicated by the 
black line). Three triplicate samples are shown (A4-A6, BI-B3 and CI-C3). 
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2.12 Photomicrography 
Photographs of microscope slides were taken using a Leica DM RB microscope (Leica 
Microsystems (UK) Ltd., Milton Keynes, UK) connected to a digital camera. Images 
were stored using ImageAxis Software (assisted by Mr. Peter Ken-igan, Department of 
Pathology, Western Infirmary, Glasgow). 
2.13 Statistical analysis 
Data were collated and statistical analyses performed using a statistical software 
package (Minitab Statistical Software, Minitab Inc., State College, P A, USA). Results 
are expressed as median and interquartile range for non-parametric data or mean and 
standard error for normally distributed data. The Student's (-test and analysis of 
variance (ANOVA) were used to compare data sets with normal distribution. Non-
parametric statistics were used (Mann-Whitney U test) for comparison between data 
sets with skewed distribution. Spearman rank con-elation test was used to correlate 
cytokine levels in sputum with cell counts and serum IgE levels. Significance was 
accepted at a level ofp < 0.05. 
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Chapter 3 
The effect of cigarette smoking on interleukin-18 levels 
in induced sputum from asthmatic and normal subjects 
Data from this chapter has been accepted for publication, 
in McKay et aI., (2004) Clin Exp Allergy. 
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3.1 Introduction 
Atopic asthma is a chronic inflammatory condition of the airways associated with 
elevated serum IgE levels. It is characterised pathologically by inflammatory infiltrates 
in the bronchial walls containing eosinophils, T lymphocytes and mast cells (Holt et ai., 
1999). Th2-type T helper lymphocytes and the cytokines they secrete, such as 
interleukin (IL )-4, IL-5 and IL-13, are thought to playa key role in the initiation and 
perpetuation of this airway inflammation (Robinson et ai., 1992, Barnes et ai., 1998). 
An alteration in the balance between a Th2 response and a Thl response, where 
lymphocytes produce interferon gamma (IFN-y), may predispose to the development of 
allergic asthma (Umetsu et ai., 2002). 
IL-18, originally called interferon-gamma inducing factor, is a pro-inflammatory 
cytokine secreted by activated macrophages. In association with IL-12 it plays an 
important role in the development of a Thl response and in the production of IFN-y 
from T cells and NK cells (Okamura et ai., 1995). However, IL-18 can also promote 
Th2 responses, depending on the surrounding cytokine environment (Xu et ai., 2000, 
Nakanishi et ai., 2001) and induce IgE production (Hoshino et ai., 2000, Yoshimoto et 
ai., 2000). It is able to induce IL-4, IL-13 and histamine production in basophils and 
mast cells in association with IL-3 (Yoshimoto et aI., 1999) and, in combination with 
IL-2, induces IL-4 and IL-13 secretion from NK and naive T lymphocytes (Hoshino et 
aI., 199b) and NKT cells (Yoshimoto et ai., 2003). 
IL-18 is expressed in the human airway epithelium (Cameron et ai., 1999) and is also 
produced by human alveolar macrophages (Shigehara et ai., 2001). As yet, there are 
conflicting reports on the actions of IL-18 in both human asthma and animal models of 
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this disease. Serum IL-18 levels have been observed to be elevated in asthmatics with 
stable disease (EI-Mezzein et aI., 2001) and during acute asthma exacerbations (Tanaka 
et aI., 2001a) while, in contrast, IL-18 levels in BAL fluid from asthmatics (Ho et aI., 
2002) and IL-18 mRNA expression in the airway epithelium of asthmatics (Cameron et 
aI., 1999) have been found to be reduced when compared to normal subjects. In animal 
models of asthma, IL-18 promoted allergic airway inflammation when given alone 
(Wild et aI., 2000) but had anti-allergic properties when administered with IL-12 
(Hofstra et aI., 1998). 
In order to assess further the role of IL-18 in airway inflammation in asthma the 
objectives of the present study were to identify and quantify IL-18 levels in sputum 
samples from asthmatic and normal subjects and to assess its cellular distribution. 
Induced sputum is a non-invasive method of sampling airway cells and secretions which 
allows the identification of pro-inflammatory factors ex vivo. Cigarette smoking alters 
airway inflammation in asthma and changes the profile of cytokines secreted in induced 
sputum (Chalmers et aI., 2001, Takanashi et aI., 1999) and so the effect of smoking on 
sputum IL-18 levels was also investigated. 
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3.2 Patient details and pulmonary function 
Sixty six asthmatic (31 smokers, 3 5 non-smokers) and forty normal (20 smokers, 20 
non-smokers) subjects participated in the study. Table 1 presents the age, gender and 
spirometry (forced expiratory volume in 1 second, FEV I, and percentage predicted 
FEV I) in the different study groups. Smoking asthmatics had a significantly lower 
percentage predicted FEV1 than non-smoking asthmatics (p < 0.01). However, smoking 
asthmatics had a higher percentage reversibility after bronchodilators (p < 0.01). The 
daily dose of inhaled steroid taken by smoking asthmatics was not significantly 
different from that of non-smoking asthmatics (median (IQR): smokers 800 (300 -
1300) /-lg vs non-smokers 800 (800 - 1600) /-lg, beclomethasone diproprionate or 
equivalent). There was no difference in the ages of all the groups. 
3.3 Serum total IgE levels 
Atopy was assessed by raised total serum IgE level (> 120 International Units/ml). Forty 
nine percent (17/35) of non-smoking asthmatics and sixty five percent (20/31) of 
smoking asthmatics were atopic. Of the normal subjects, fifteen percent (3120) of non-
smokers and twenty percent (4120) of smokers were atopic. 
Serum total IgE levels (Table 1) were significantly elevated in asthmatics (154 (69 -
434) kU/l, n = 66) when compared to controls (35 (13-88) kU/l, n = 40, p < 0.001). In 
the normal control group smokers had significantly higher levels of serum total IgE 
(smokers 59 (26 - 112) kU/l vs non-smokers 15 (0-54) kU/l,p < 0.01), but in the asthma 
group the smokers did not have significantly higher total IgE levels than the non-
smokers. 
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0
0
 
Sm
okers 
n
 
20 
31 
12 
19 
A
ge (yr) 
42 (35 
-45) 
38 (34 
-42) 
34 (32 
-39) 
40 (37 
-45) 
Sex (M
/F) 
8/12 
22/9 
715 
15/4 
Sm
oking pack years 
28 (15 
-36) 
22 (18 
-30) 
23 (18 
-30) 
20 (18 
-30) 
B
aseline FEV
 1 (1) 
2.8 (2.2 
-3.9) 
2.7 (2.2 
-3.5) 
2.7 (1.8 
-3.5) 
2.7 (2.2 
-3.7) 
B
aseline FEV
 1 (%) 
88 (76 
-
102) 
74 (63 
-89)** 
73 (63 
-83)** 
84 (60 
-92) 
R
eversibility (%) 
17 (8 
-25) *
*
 
16 (7 
-25) *
 
19 (8 
-28) 
Serum
 total IgE (kU/l) 
59 (26 
-
112)** 
234 (78 
-499) 
230 (116 
-431) 
262 (68 
-772) 
3.4 Sputum cell characteristics 
The total cell number and differential cell count in the induced sputum samples of 
asthma patients and controls are shown in Table 2. There was no difference in total cell 
counts between asthmatic and normal subjects in both the smoking and non-smoking 
groups. Asthmatic smokers had a raised percentage of neutrophils (51.3 (35.8 - 58.4) 
%) when compared to non-smoking asthmatics (33.2 (22 - 50.5) %,p < 0.01) and also a 
reduction in sputum eosinophilia (smokers 0 (0 - 0.7) % vs non-smokers 0.5 (0 - 5.9) 
%, p < 0.05). Smokers had lower lymphocyte proportions in both asthmatic subjects 
(smokers 0 (0-0.2) % vs non-smokers 1 (0 - 3) %, p < 0.001) and normal controls 
(smokers 0 (0-0.2) % vs non-smokers 0.6 (0 - 3.3) %,p < 0.01). 
3.5 IL-18 protein levels in induced sputum fluid 
IL-18 levels were significantly reduced in cigarette smokers (smokers 20 (0 - 102) 
pg/ml, n 51, vs non-smokers 358 (50 - 876) pg/ml, n = 55,p < 0.001). This was more 
pronounced in asthmatics (smokers 47 (40 -64) pg/ml vs non-smokers 358 (50 - 876) 
pg/ml, p < 0.001) than in normal subjects (smokers 25 (0 - 78) pg/ml vs non-smokers 
247 (50 - 656) pg/ml, p < 0.01) (Figure 3.1). Within each of the smoking and non-
smoking groups there was no significant difference in IL-18 levels between asthmatic 
and normal subjects, as shown in Figure 3.2. In the asthmatic groups there was no 
difference between IL-18 levels in those treated with P2-agonist alone or with P2-agonist 
and inhaled corticosteroid (non-smokers: P2-agonist 156 (23 - 1522) pg/ml vs inhaled 
corticosteroid 671 (118 - 1137) pg/ml,p = 0.72; smokers: P2-agonist 60 (0 -120) pg/ml 
vs inhaled corticosteroid 0 (0 - 96) pg/ml, p = 0.61). 
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Table 3.2. Sputum differential leukocyte profile. 
Total and differential white cell profiles obtained from induced sputum samples from 
controls and asthmatic patients. Data are presented as median (interquartile range). 
*,p < 0.05, **,p < 0.01, when compared to the corresponding non-smoking group. 
Statistical significance was assessed by Mann-Whitney U test. 
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Figure 3.1. IL-18 levels in induced sputum fluid. 
IL-18 levels in the fluid phase of induced sputum of normal and asthmatic subj ects were 
assessed by ELISA. Asthmatic and normal smokers had significantly reduced sputum 
IL-18 levels when compared to the corresponding group of non-smokers. Horizontal 
bars indicated the median value of each group. Statistical significance was assessed by 
Mann-Whitney U test. 
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Figure 3.2. Comparison ofIL-18 levels in induced sputum fluid between asthmatics 
treated with or without inhaled corticosteroid. 
IL-18 levels in the fluid phase of induced sputum of asthmatic subjects were assessed 
by ELISA. In both the non-smoking and smoking groups there was no difference in IL-
18 levels between asthmatics treated without inhaled corticosteroid (non-steroid-treated; 
n 17 non-smokers, n =12 smokers) and those treated with inhaled corticosteroid 
(steroid-treated; n = 18 non-smokers, n = 19 smokers). For smoking asthmatics treated 
with or without inhaled corticosteroid, there was a significant reduction in sputum IL-18 
levels compared to the corresponding non-smoking group. Horizontal bars indicated the 
median value of each group. Statistical significance was assessed by Mann-Whitney U 
test. 
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There was no correlation between sputum IL-18 levels and any specific cell type in the 
sputum samples or with serum IgE levels in any ofthe groups. 
3.6 IL-18 mRNA expression in induced sputum cells 
Sufficient mRNA was isolated from the sputum cells to allow analysis of IL-18 mRNA 
expression in 22 normal (10 non-smokers, 12 smokers) and 43 asthmatic (21 non-
smokers, 22 smokers) subjects. There was a reduction in the expression of IL-18, 
expressed as a percentage of HPRT mRNA, in asthmatic smokers when compared to 
asthmatic non-smokers (smokers 258 (163 - 317) % vs non-smokers 385 ( 221 - 554) 
%, p < 0.05) In addition, there was no significant difference in IL-18 expression 
between normal subjects and asthmatics in both the smoking and non-smoking groups 
or between normal smokers and normal non-smokers (smokers 214 (111 - 343) % vs 
non-smokers 356 (110 - 548) %, p 0.67) (Figure 3.3). As illustrated in Figure 3.4, 
when comparing the asthmatic therapy groups there was no significant difference in IL-
18 mRNA levels between those treated with ~2-agonist alone and those treated with ~2-
agonist and inhaled corticosteroid (non-smokers: ~2-agonist 364 (157 - 587) % vs 
inhaled corticosteroid 430 (221 - 522) %,p = 0.57; smokers: ~2-agonist 286 (159 - 285) 
% vs inhaled corticosteroid 244 (162 - 306) pg/ml,p = 0.64). 
3.7 IL-18 localisation in sputum cells by immunocytochemistry 
The cellular distribution of IL-18 synthesis was visualised in sputum cytospin 
preparations by immunocytochemistry (Figure 3.5). Positive staining was observed in 
sputum macrophages. There was no positive staining for IL-18 in sputum neutrophils. 
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Figure 3.3. IL-18 mRNA expression in induced sputum cells. 
IL-18 mRNA expression in the cell pellets of induced sputum samples from normal and 
asthmatic subjects, comparing non-smokers and smokers. Smoking asthmatics, but not 
normal smokers, had significantly lower levels of IL-18 expression than the 
corresponding non-smoking group. Horizontal bars indicated the median value of each 
group. n.s. - non-significant. Statistical significance was assessed by Mann-Whitney U 
test. 
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Figure 3.4. Comparison ofIL-18 mRNA levels in induced sputum cells between 
asthmatics treated with or without inhaled corticosteroid. 
IL-18 mRNA in induced sputum cells from asthmatic subjects were assessed by 
quantitative peR. In both the non-smoking and smoking groups there was no difference 
in IL-18 mRNA levels between asthmatics treated without inhaled corticosteroid (non-
steroid treated; n = 11 non-smokers, n = 1 0 smokers) and those treated with inhaled 
corticosteroid (steroid treated; n 10 non-smokers, n 12 smokers). In smoking 
asthmatics treated with or without inhaled corticosteroid, there was no significant 
reduction in sputum cells IL-18 mRNA levels compared to the corresponding non-
smoking group. Horizontal bars indicated the median value of each group. Statistical 
significance was assessed by Mann-Whitney U test. 
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A 
B 
c 
Figure 3.5. Immunocytochemistry of IL-18 in sputum cells. 
Cells from an asthmatic subject were stained with (A) anti-human IL-18, (B) normal 
murine IgG 1 control or (C) anti-human CD68. Positive staining was observed to be 
brown. Staining was observed only in sputum macrophages. Images are shown at 
magnification x 400. 
90 
3.8 Chapter discussion 
In the above study it is demonstrated that IL-18 is detectable in the induced sputum 
fluid of both asthmatic and normal subjects. IL-18 levels do not significantly differ 
between asthmatic and normal subjects, but IL-18 levels were significantly reduced by 
cigarette smoking in both these groups. In asthmatics, but not normal subjects, the 
reduction in IL-18 levels in sputum fluid was associated with reduced IL-18 mRNA 
expreSSIOn m induced sputum cells. IL-18 production was localised to sputum 
macrophages. 
IL-18 is a cytokine which has the ability to promote both Th1 and Th2 responses 
depending on the surrounding cytokine environment (Xu et aI., 2000, Nakanishi et aI., 
2001). There is increasing evidence that IL-18 may have a pro-inflammatory action in 
allergic disease. In murine models of asthma, IL-18 administered alone can promote 
allergen-induced eosinophil influx into the airways (Kumano et aI., 1999, Campbell et 
aI., 2000, Wild et aI., 2000) and increase semm IgE levels (Hoshino et aI., 2000). In 
human studies, semm IL-18 levels were elevated in asthmatic patients during acute 
exacerbations (Tanaka et aI., 2001a) in stable asthmatics (EI-Mezzein et aI., 2001) and 
in those with a related allergic condition, atopic dermatitis (EI-Mezzein et aI., 2001, 
Y oshizawa et aI., 2002). Also, IL-18 levels were found to be raised in nasal secretions 
from patients with allergic seasonal rhinitis (Verhaeghe et aI., 2002). Polymorphisms in 
the IL-18 gene have been associated with asthma (Higa et aI., 2003a). In contrast, IL-18 
had anti-allergic properties when administered with IL-12 in a murine asthma model 
(Hofstra et aI., 1998) and IL-18 deficient mice had increased airway eosinophilia 
(Kodama et aI., 2000). 
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In the current study, the first evidence that IL-18 can be detected in induced sputum 
fluid is presented. There was no significant difference in sputum IL-18 levels between 
asthmatic and normal subjects. However, in non-smokers, IL-18 levels tended to be 
higher in asthmatics than in normal subjects. Previous clinical studies have shown that 
IL-18 levels are reduced in bronchoalveolar lavage (BAL) fluid from asthmatics (Ho et 
aI., 2002) and that IL-18 mRNA expression in the airway epithelium was decreased 
(Cameron et aI., 1999) compared to nOlmal controls and patients with sarcoidosis. Since 
sputum induction provides a sample from the larger airways than BAL (Keatings et aI., 
1997) and samples a different inflammatory compartment to bronchial biopsies (Rutgers 
et aI., 2000), the results presented above may reflect such differences. 
Since cigarette smoking alters airway inflammation in asthma (Chalmers et aI., 2001) it 
was investigated whether smoking altered sputum IL-18 levels. The smoking asthmatics 
who participated in this study satisfied the criteria for the diagnosis of asthma 
(American Thoracic Society, 1987), had a median age of 38 years and been 
symptomatic since their twenties or earlier, and so were felt to be distinct from patients 
with COPD. Cigarette smoking reduced IL-18 levels in both asthmatic and normal 
subjects. This was more pronounced in asthmatic smokers and was associated with a 
decrease in IL-18 mRNA expression. The reason for this is unclear. Smoking is known 
to suppress the ability of alveolar macrophages to secrete pro-inflammatory cytokines, 
such as tumour necrosis factor alpha, in response to inflammatory stimuli (McCrea et 
aI., 1994) and has also been shown to reduce the number of cells spontaneously 
secreting Th1 cytokines in the airways (Hagiwara et aI., 2001). A similar suppressive 
mechanism may be acting on sputum cell IL-18 production. Also, IL-18 is a cytokine 
highly dependent on proteolytic processing for its activity and extracellular secretion. It 
is produced initially as an inactive precursor, pro-IL-18, which is cleaved by IL-1P 
converting enzyme (ICE or caspase-1) into the active protein (Ghayur et aI., 1997). 
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Other proteases, such as neutrophil proteinase-3 (Sugawara et aI., 2001) can also be 
involved in the production of active IL-18 whereas caspase-3 (Akita et aI., 1997) can 
cleave active IL-18 into inactive fragments. Cigarette smoking promotes neutrophil 
influx into the airways (Chalmers et aI., 2001) and increases protease activity in the 
airways (Vignola et aI., 1998). This may contribute to the degradation of sputum IL-18 
in smokers, especially in asthmatics. 
IL-18 mRNA is highly expressed in cells from induced sputum samples. IL-18 mRNA 
levels are significantly lower in asthmatic smokers than in asthmatic non-smokers, and a 
reduction in IL-18 gene expression may therefore contribute to suppression of IL-18 
production in smokers. The control of IL-18 gene expression is less well understood. 
IL-18 mRNA is highly stable and this may explain the high levels detected in sputum 
cells. The gene is constitutively expressed in human peripheral blood mononuclear cells 
(Puren et aI., 1999) but its mRNA expression can be up-regulated by cytokines such as 
IFN-y (Tone et aI., 1997). Cigarette smoke may contain compounds with the ability to 
alter IL-18 gene expression. As there was no significant change in IL-18 mRNA 
expression in normal smokers it is likely that there is some alteration of both IL-18 
mRNA expression and protein processing causing the decrease in sputum IL-18 levels 
observed. 
There was no significant difference in sputum IL-18 levels or sputum IL-18 mRNA 
expression between asthmatics treated with inhaled ~2-agonist alone and those treated 
with inhaled ~2-agonist and inhaled corticosteroid in either the smoking or non-smoking 
groups. In vitro, treatment of PBMC and monocytic cell lines with the steroid 
prednisolone has been shown to increase the levels of IL-18 mRNA expression and 
protein release (Moller et aI., 2002b). Steroid treatment is known to affect the levels of 
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several airway cytokines, including other macrophage-derived cytokines, such as IL-12 
(Naseer et aI., 1997) and IL-15 (Komai-Koma et aI., 2001). Since the present study was 
a cross-sectional study, further longitudinal studies would be necessary to assess fully if 
steroid therapy could alter IL-18 production in the airways. 
Immunocytochemistry localised IL-18 production to sputum macrophages. In 
association with the IL-18 levels found in induced sputum fluid and the high levels of 
IL-18 mRNA expression in sputum cells, this suggests that IL-18 is produced directly 
by the cells in the sputum samples. However, other cells such as the bronchial 
epithelium, may also contribute to the IL-18 detected by ELISA in induced sputum 
fluid. 
In conclusion, IL-18 can be detected in induced sputum fluid and IL-18 gene expression 
is also detectable in cells from induced sputum samples. There is no significant 
difference between sputum IL-18 levels in asthmatic and normal subjects but cigarette 
smoking significantly reduces levels of IL-18 in both these groups. This reduction may 
be mediated by alterations in the post-translational processing of IL-18 but direct 
suppression of IL-18 gene expression could also be involved. IL-18 IS a pro-
inflammatory cytokine which has the ability to induce Th1 and Th2 cytokine secretion, 
and as such, may have a pivotal role in the development of airway inflammation in 
asthma. The reduction in sputum IL-18 levels associated with cigarette smoking may 
alter of the balance of Th1/Th2 cytokines secretion and contribute to increased airway 
inflammation. Further studies are necessary to clarify the mechanisms by which sputum 
IL-18 levels are reduced by cigarette smoking and to determine the precise effect of this 
reduction on ThllTh2 cytokine secretion. 
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Chapter 4 
The effect of IL-18 deficiency in a murine model of allergic asthma 
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4.1 Introduction 
In the previous chapter it was reported that IL-18 levels were reduced in the induced 
sputum fluid of asthmatic and normal smokers. In non-smokers, there was a trend for 
the levels of IL-18 in induced sputum fluid to be higher in asthmatic subjects. To 
investigate further the possible role of IL-18 in allergic airway inflammation, a murine 
model of allergic asthma was used. 
Consistent with the ability of IL-18 to induce either Th1 or Th2 lymphocyte responses 
(Xu et aI., 2000), there have been conflicting reports on the actions of IL-18 in 
experimental asthma models. In association with IL-12, IL-18 reduced antigen-induced 
airway hyper-responsiveness and eosinophilia in a murine model of allergic asthma 
(Hofstra et aI., 1998). A similar reduction in the airway inflammatory response was 
observed when IL-18 gene was expressed in the airways using an adenoviral vector 
(Walter et aI., 2001) or when exogeneous IL-18 was administered with sensitisation in 
an RSV -induced murine asthma model (Zhang et aI., 2003). An anti-inflammatory role 
for IL-18 in these animal models of asthma was supported by the observation that IL-18 
deficient C57BLl6 mice had more severe airway inflammation after antigen 
sensitisation and challenge than wild-type mice (Kodama et aI., 2000). In addition, the 
use of a neutralising antibody to IL-18, resulted in an increase in airway inflammation 
in a murine model of fungal-induced asthma (Blease et aI., 2001). However, IL-18 can 
increase IL-4 and IL-5 production and airway eosinophilia if given at the time of 
allergic sensitisation (Wild et aI., 2000), and can enhance eosinophil influx to the 
airways (Kumano et aI., 1999, Campbell et aI., 2000). When co-administered with 
antigen challenge, IL-18 has also been demonstrated to induce airway inflammation and 
AHR in naIve mice which have previously received antigen-specific memory Th1 cells 
(Sugimoto et aI., 2004). 
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C57BLl6 mice deficient in IL-18 have been shown to have increased airway 
inflammation in response to antigen (Kodama et aI., 2000). Such C57BLl6 mice have a 
genetic bias to produce Th 1 responses. The absence of IL-18 produced a decrease in 
IFN-y production, and subsequent failure to suppress the Th2 response. In vitro, IL-18 
can stimulate the development of Th2 cells and production of IgE (Yoshimoto et aI., 
2000), and IL-4 and IL-13 secretion from basophils (Yoshimoto et aI., 1999), NK cells 
and naIve T lymphocytes (Hoshino et aI., 1999) and NKT cells (Yoshimoto et aI., 
2003). IL-18 has also been shown enhance antigen-induced production of IL-9, IL-13 
and GM-CSF from Th1 cells in vitro (Sugimoto et aI., 2004). 
It was postulated that the ability of IL-18 to promote Th2 responses would be more 
apparent in a strain of mice in which had a tendency to produce Th2 cytokines. In 
murine models of Leishmania major infection, disease-susceptible BALB/c mice have 
been shown to have an intrinsic predisposition to produce higher levels of IL-4 and 
predominant Th2 responses when compared to resistant C57BLl6 mice (Fowell et aI., 
1998). Therefore, IL-18 gene knockout (ko) mice on a BALB/c background were used 
in a murine model of asthma in the following studies to assess further the role of IL-18 
in allergic airway inflammation. 
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4.2 Bronchoalveolar lavage cellularity in IL-18 knockout mice 
To assess the role of IL-18 in the pathogenesis and development of the inflammatory 
response in a murine asthma model, BALB/c wild type (WT) mice and BALB/c IL-18 
gene knockout (ko) mice were sensitised and then challenged with ovalbumin (OVA). 
The protocol for OV A sensitisation and challenge is shown in Figure 2.1. This asthma 
model induced a significant increase in cell numbers and altered the cell profile in 
bronchoalveolar lavage fluid after antigen challenge. Eosinophils were the predominant 
cell type observed, but there was also an increase in the influx of other inflammatory 
cells, such as macrophages, lymphocytes and neutrophils. Histologically, perivascular 
and peribronchial inflammatory infiltrates, containing eosinophils, with associated 
mucosal hyperplasia in the bronchial walls were observed in lung tissue sections from 
mice previously sensitised and challenged with OV A. 
4.2.1 Total bronchoalveolar lavage cellularity. 
Mice sensitised and challenged with OVA had increased total BAL cellularity when 
compared to PBS sensitised and treated controls (Figure 4.1). However, total BAL 
cellularity was significantly reduced in OVA-treated IL-18 ko mice when compared to 
OV A-treated WT mice (p < 0.05). 
4.2.2 Bronchoalveolar lavage differential cell count. 
Differential cell counts were performed on the BAL fluid samples to determine which 
cell types in lavage fluid were reduced in OVA-treated IL-18 ko mice. In OVA-treated 
IL-18 ko mice there was a significant reduction in the numbers of eosinophils present 
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when compared to OVA-treated WT mice (p < 0.05). There was no significant 
difference in the numbers of macrophages, lymphocytes and neutrophils between these 
two groups, as shown in Figure 4.2. 
4.3 Histological analysis of lung inflammatory infiltrates 
Histological analysis of lung tissue was done to assess if the reduction in BAL 
cellularity and eosinophilia was accompanied by a decrease in total lung inflammation. 
Representative tissue sections from each of the groups are shown in Figure 4.3. Sections 
from PBS treated control WT mice (Figure 4.3A) and IL-18 ko mice (Figure 4.3B) show 
no evidence of airway inflammation. Both OV A-sensitised and challenged WT mice 
(Figure 4.3C) and IL-18 ko mice (Figure 4.3D) have peribronchial and perivascular 
inflammatory infiltrates containing eosinophils with associated mucosal hyperplasia in 
the bronchial walls. However, on semi-quantitative scoring of the histological slides 
(Figure 4.4) there was no significant difference in the severity of the inflammatory 
infiltrates between WT and IL-18 ko mice. 
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Figure 4.1. Total bronchoalveolar lavage cellularity. 
Wild type (WT) and IL-18 knockout (KO) BALB/c mice were sensitised with OV A and 
then challenged with OV A i.n. on three consecutive days from day 25-27. Control 
(CON) mice were sensitised and challenged with PBS. BAL cell counts were performed 
on day 28. In OVA treated mice, total BAL cellularity was significantly reduced in the 
IL-18 KO group when compared to WT mice. Data are expressed as mean ± SEM. (n = 
11 - 16 mice per group). * p < 0.05. Statistical significance was assessed by ANOV A. 
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Figure 4.2. Bronchoalveolar lavage differential cell count. 
Differential cell counts were determined on the BAL cell counts performed on day 28. 
In OVA-treated mice, BAL (A) eosinophils were significantly reduced in IL-18 
knockout (KO) mice when compared to wild-type (WT) mice. (B) Macrophage, (C) 
lymphocyte and (D) neutrophil numbers were not significantly different between OVA-
treated IL-18 knockout and WT mice. Data are expressed as mean ± SEM. (n = 11 - 16 
mice per group). * p < 0.05. Statistical significance was assessed by ANOV A. 
101 
A B 
c o 
4.3. Histological evidence of lung inflammation in OVA-treated mice. 
A representative section is shown from each group of mice. (A) Control wild type (WT) 
and (B) control IL-18 knockout mouse given PBS challenges. (C) OVA-challenged WT 
mouse and (D) OVA-challenged IL-18 knockout mouse; peribronchial and perivascular 
infiltrates are seen, with eosinophils present, and mucosal hyperplasia. There was no 
difference in inflammatory cell infiltrates between OVA challenged WT and IL-18 ko 
mice. H&E staining, magnification x200. 
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Figure 4.4. Histological score of lung inflammation. 
Total lung inflammation on histological sections was determined as the sum of 
peribronchial and perivascular scores. Inflammation was graded on the scale 0, none; 1, 
mild, 2, moderate; 3, marked and 4, severe. An increment of 0.5 was used when severity 
of inflammation fell between two integers. OVA-treated wild-type (WT) and IL-18 
knockout (ko) mice had significantly increased perivascular and total lung inflammation 
compared to the corresponding PBS-treated controls. OVA-treated WT mice also had 
significantly increased peribronchial inflammation, compared to PBS-treated mice. 
There was no significant difference in inflammatory scores between OVA-treated WT 
and IL-18 ko mice. (n = 3-10 mice per group). t,p < 0.05, tt,p < 0.01 (when compared 
to corresponding PBS-treated controls). Significance was assessed by Student's ttest. 
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4.4 Bronchoalveolar lavage cytokines 
Since prior OV A sensitisation and challenge produced an eosinophilia in the BAL fluid, 
we wished to assess if this was associated with an increase in the levels of cytokines in 
the lavage fluid, and whether the levels of these cytokines differed between IL-18 ko 
mice and WT mice. In OVA-treated WT mice the levels of IL-4 in BAL fluid were 
significantly elevated when compared to PBS-treated WT controls (p < O.OS) (Figure 
4.S). This was not seen in IL-18 ko mice. When comparing OVA-treated mice, although 
there was a trend for IL-4 levels in BAL fluid to be lower in IL-18 ko mice, but this did 
not reach statistical significance (p = 0.08). There was no difference in IL-S levels in 
BAL fluid between the OVA-treated groups or between the OVA-treated groups and the 
PBS control groups, Figure 4.SB. 
Since IL-18 is lmown to induce eotaxin production in the airways (Campbell et aI, 
2000), levels of this chemokine were measured in BAL fluid. Only low levels of eotaxin 
were detected in BAL fluid but WT mice sensitised and challenged with OV A had a 
small but significant rise in eotaxin levels in BAL fluid when compared to the PBS-
treated WT mice (Figure 4.SC). There was no significant difference between eotaxin 
levels in OVA-treated WT and ko mice. 
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Figure 4.5. Bronchoavelolar lavage cytokine levels. 
Bronchoalveolar lavage IL-4, IL-5 and eotaxin levels were determined by ELISA. (A) 
IL-4 levels and (C) eotaxin levels were significantly higher in OVA-treated wild type 
(WT) mice when compared to PBS-treated WT controls but there was no difference in 
(B) IL-5 levels. There was no significant difference in the levels of all cytokines 
between OVA-treated WT mice and OVA-treated IL-18 knockout (KO) mice. Data is 
expressed as mean ± SEM. (n = 11 - 16 mice per group). t J P < 0.05 (when compared to 
corresponding PBS treated control). Statistical significance was assessed by ANOV A. 
105 
4.5 Serum immunoglobulins 
Figure 4.6 shows the serum immunoglobulin levels from control and OVA-treated WT 
and IL-18 ko mice. OVA sensitisation and challenge increased total serum IgE and 
OVA-specific IgE levels in both WT and IL-18 ko mice, with no significant difference 
in the amount of these immunoglobulins found between WT and IL-18 ko mice. 
Similarly, levels of OV A-specific IgG 1 and IgG2a did not differ between these two 
groups. 
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Figure 4.6. Serum immunoglobulin levels. 
Serum immunoglobulin levels were assessed by ELISA. (A) Serum total IgE levels, (B) 
serum OVA-specific IgE (serum dilution 1/160), (C) serum OVA-specific IgGl (serum 
dilution 1/60,000) and (D) serum OVA-specific IgG2a (serum dilution 11800) levels 
were not significantly different between OVA-treated wild type (WT) mice and OVA-
treated IL-18 knockout (KO) mice, (n = 7 - 16 mice per group), Data are expressed as 
mean ± SEM, Statistical significance was assessed by Student's t test. 
107 
4.6 Flow cytometric analysis of thoracic lymph node cells 
To determine if there was any difference in lymphocyte populations during the 
inflammatory response in IL-18 ko mice, cells from thoracic lymph nodes were isolated 
from OVA treated WT and IL-18 ko mice on day 28 of the experimental protocol for 
analysis by flow cytometry (Figure 4.7). 
The lymph node cells from IL-18 ko mice had similar proportions of CD 19+ B cells and 
CD3+ T lymphocytes to lymph node cells from WT mice (Figure 4.7C and D). Of the 
total lymph node cells, although the IL-18 ko group had a higher proportion of CD4+ 
lymphocytes than WT mice (Figure 4.7E and F), the ratio of CD4+:CD8+ cells was 
similar between the IL-18 ko and WT mice (CD4+:CD8+ ratio - WT 2.5; IL-18 ko 2.7). 
In addition, the CD4+ from both WT and IL-18 ko mice did not appear to differ in their 
activation status since levels of CD44, CD 11 a, CD45RB and CD62L were comparable 
between the two groups, as illustrated in Figure 4.8. 
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Figure 4.7. Analysis by FACS of purified thoracic lymph node cells. 
Cells were isolated from pooled thoracic lymph nodes (n = 5 mice per group) obtained 
from WT and IL-18 knockout (ko) mice sensitised and challenged with OV A on day 28 
of the experimental protocol. Flow cytometric analysis for lymphocyte cell surface 
markers was performed. The percentage of cells in each quadrant is displayed at the top 
right of each plot. (A) and (B) show the isotype controls WT and IL-18 ko groups, 
respectively. (C) Cells from WT mice have a marginally higher proportion of CD19+ 
cells, but similar proportions of CD3+ cells compared to (D) IL-18 ko mice. (E) A 
marginally lower proportion of CD4+ lymphocytes are present in the lymph nodes of 
WT mice than (F) IL-18 ko mice, but CD8+ levels are similar. Results are shown from 
single experiment. 
C
04
 
C
03
 
PE
 Is
ot
yp
e 
Co
nt
ro
l 
~ 
~ 
~ 
m
 
0 
»
 
FL
2f
 
FL
2f
 
10
4 
FL
2t 
10
0 
10
1 
10
 
10
3 
10
4 
10
0 
10
1
10
 
10
3 
10
° 
10
1 
10
 
10
3 
1(1
4 
.
.
.
 
0
"
 
•
•
 
~ 
.
 
' 
r C 
±
 
±
 
1:: 
-
of
 
.
I'-
co
 
1\
 
-
< 
.
I'-
-
-
.
J 
.
"
 
-
-
.
J 
.
.
.
.
.
 
"
"
0 
.
I'-
1\
 
-
I 
N
 
1\
 
m
 
.
.
.
.
.
 
(X
) 
.
.
.
.
.
 
.
.
.
.
.
 
w
 
0 
(')
 
0
0
 
-
.
I>
. 
~
 
0 
.
.
.
.
.
.
 
.
I>
. 
f/)
 
0 
0 
0 
\0
 
0 
-
C 
'
<
 
C 
'T1
 
.
.
.
:It
. 
C 
"
C 
to
 
co
 
FL
21
 
CD
 
FL
21
 
CD
 
FL
2f
 
1]1
 
10
0 
10
1 
10
 
10
3 
10
4 
10
0 
10
1 
10
 
10
3 
10
4 
(')
 
10
0 
10
1
10
 
10
3 
10
4 
0 :::::I
 
-
.
:.
:-
: 
"
"
'I 0 
r I ...:I
t. 
-
co
 
±
 
±
 
±
 
~
 
-
* 
c.n
 
w
 
.
.
.
.
.
 
-
-
.
J 
N
 
co
 
0 
(X
) 
.
.
.
.
.
 
1\
 
.
I'-
1\
 
c.n
 
.
.
.
.
.
 
0 
.
.
.
.
.
 
1\
 
.
.
.
.
.
 
0 
0 
.
I>
. 
.
I>
. 
0 
.
I>
. 
A. CD44 B. CD11a 
0 c:> :] ~ <::> 
<X> 
-
C 
::a.:j ::::I c:> <D 
0 
0 ~.:j In 0 v 
Q; 
~.:j 1 \ 0 <=> N 
c \cr,.hiii I 1' i.illl"2' Liiiiill L 111111'4 
- , """"1' ''''''r; , """', . · .. ···'4 
100 10 10 103 10 10
0 10 102 103 10 
• 
Mean fluorescent intensity 
C. CD45RB D. CD62L 
0 0 :] ~ 0 
0:> 
-
0> 
C 
::::I ::a.:l 0 0 "" 
0 ~.:I J'l 0 v 
Q) 
0 ~j or , 0 N 
o ~ I I jIIiTft'l l' I I 1I1IIi2' I I 111111 I I 11111. 4 
-
100 10 10 103 10 
1~0' ' .. ';~ l' '''';~2' , "';'03 ' .. ";'04 
• 
Mean fluorescent intensity 
Figure 4.8. Cytometric analysis of cell surface activation markers on CD4+ cells. 
Cells were isolated from pooled thoracic lymph nodes (n = 5 mice per group) obtained 
from WT and IL-18 knockout (ko) mice sensitised and challenged with OVA on day 28 
of the experimental protocol. Flow cytometric analysis for lymphocyte cell surface 
activation markers was performed. The analyses of cells from WT mice are shown by 
the grey shaded areas, and those from IL-18 ko mice by the thick black line. No 
difference in the cell surface levels of (A) CD44, (B) CDlla, (C) CD45RB and (D) 
CD62L was seen between the two groups of mice. Results are shown from a single 
experiment. 
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4.7 In vitro thoracic lymph node cell responses in wild-type and IL-18 
knockout mice 
The reduction observed in IL-4 levels in BAL fluid suggested that there might be 
suppression of Th2 responses in IL-18 knockout mice. To investigate this further, cells 
isolated from thoracic lymph nodes of both WT mice and IL-18 ko mice were cultured 
and in vitro OVA-induced cell proliferation and cytokine production assessed. 
4.7.1 In vitro OVA-induced cell proliferation in thoracic lymph node cells 
The OVA-induced cell proliferation responses in thoracic lymph node cultures are 
illustrated in Figure 4.9A. There was no significant difference in OVA-induced cell 
proliferation between WT mice and IL-18 ko mice which had previously been sensitised 
and challenged with OVA. In the experiment shown, spontaneous cell proliferation was 
significantly higher in IL-18 ko mice (p < 0.05). The proliferative response to 
Concanavalin (Con) A was not significantly different between these groups of mice 
(Figure 4.1 OA). 
4.7.2 In vitro OVA-induced cytokine production in thoracic lymph node cells 
The OVA-induced cytokine responses, from parallel cultures to those described in 
Section 4.4.1, are shown in Figures 4.9B to D. The levels of IL-4 (Figure 4.9B), and 
IFN-y (Figure 4.9D) detected in culture supernatants of lymph node cells from OVA-
sensitised and challenged IL-18 ko mice were reduced when compared cells from 
similarly treated WT mice (IL-4 p < 0.01; IFN-y (p < 0.05). The levels of IL-5 (Figure 
4.9D) were not significantly different between these two groups. The reduction in IL-4 
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Figure 4.9. Proliferative and cytokine responses in thoracic lymph node cells in vitro. 
Thoracic lymph node cells (n = 3 mice per group) were harvested from mice on day 28 
and cultured with medium alone (D) or OVA (.; 1 mg/ml). (A) T cell proliferation was 
assessed by uptake of eH]-thymidine after 96 hours of culture; there was no significant 
difference in cell proliferation between IL-18 knockout (KO) and wild-type (WT) mice. 
Cytokine levels in cell culture supernatants were assessed by ELISA after 72 hours of 
culture. (B) IL-4 and (D) IFN-y levels were significantly reduced in lymph node cells 
from IL-18 KO mice compared to WT mice. (C) IL-5 levels were not significantly 
different. Data are expressed as mean ± SEM. * p < 0.05, ** p < 0.01. Statistical 
significance was assessed by Student's t test. 
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Figure 4.10. Proliferative and cytokine responses in thoracic lymph node cells in vitro. 
In parallel cultures to those in 4.6 (a), thoracic lymph node cells from (n = 3 mice per 
group) cultured with 5 Ilg/ml Concanavalin (Con) A. (A) T cell proliferation was 
assessed by uptake of eH]-thymidine after 96 hours of culture; there was no significant 
difference in cell proliferation between IL-18 knockout (KO) and wild-type (WT) mice. 
Cytokine levels in cell culture supernatants were assessed by ELISA after 72 hours of 
culture. (D) IFN-y production in response to Con A was significantly reduced in lymph 
node cells from IL-18 KO mice. There was no significant difference in (B) IL-4 and (C) 
IL-5 production. Data are expressed as mean ± SEM. * p < 0.05. Statistical significance 
was assessed by Student's t test. 
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production was antigen-specific, since the amount of IL-4 induced by Con A (Figure 
4.10B) was not lower in lymph node cells from IL-18 ko mice. This was not the case for 
IFN-y, since the levels of this cytokine in cultures with Con A were also decreased (p < 
0.05). There was no difference in IL-5 production induced by Con A between these two 
groups of mice. 
4.8 Cytokine mRNA expression in thoracic lymph nodes. 
IL-4 mRNA expression in thoracic lymph nodes was determined using quantitative R T-
PCR to assess if alterations in its gene expression accompanied the decreased levels of 
this cytokine detected by ELISA in cell culture supernatants in IL-18 deficient mice. 
IL-5 mRNA levels were also measured. These results are shown in Figure 4.11. 
The level of IL-4 mRNA were increased in OV A-treated WT and IL-18 ko mice when 
compared to the PBS-treated controls. IL-4 expression was reduced in IL-18 ko mice 
when compared to the WT group. There was also a reduction in IL-5 mRNA levels in 
OVA-treated IL-18 ko mice. 
The above experiments on thoracic lymph node cells are from pooled lymph nodes from 
single groups of mice and so statistical analysis could not be performed. Insufficient 
mice were available to repeat the LN studies to confirm these results and therefore 
further work would focus on these studies. 
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Figure 4.11. Cytokine expression in thoracic lymph node cells. 
The levels of IL-4 and IL-5 mRNA expression were determined by the use of RT-
quantitative peR from lymph nodes harvested on day 28. Levels of (A) IL-4 and (B) 
IL-5 mRNA were reduced in OVA-treated IL-18 KO mice when compared to WT 
controls. (Pooled lymph nodes, n = 3-5 mice per group). Data are expressed as mean ± 
adjusted error. 
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4.9 Chapter discussion 
The above investigations have demonstrated that, in this murine model of allergic 
asthma, BALB/c IL-18 gene deficient mice have decreased BAL total cell numbers and 
eosinophilia after antigen sensitisation and challenge when compared to WT mice. The 
reduction in BAL eosinophilia was not associated with a reduction in inflammatory 
infiltrates in lung histology. There was a non-significant decrease in IL-4 levels in the 
BAL fluid of antigen-sensitised and challenged IL-18 ko mice when compared to WT 
mice. Serum OVA-specific or total IgE levels, or OVA-specific IgG 1 and IgG2a levels 
were not altered in IL-18 gene deficient mice. However, in vitro thoracic lymph node 
cells from IL-18 ko mice produced less IL-4 in response to OV A than cells from WT 
mice. Also, lower levels of IL-4 mRNA were expressed in thoracic lymph nodes from 
IL-18 ko mice. These observations suggest that IL-18 has a pro-inflammatory action in 
this murine model of asthma which is, at least in part, mediated by its ability to 
stimulate IL-4 secretion. 
In murine models of inflammatory arthritis (Wei et al., 2001) and infectious disease 
(Wei et al., 1999), mice genetically deficient in IL-18 have a decreased ability to mount 
a Th1 lymphocyte responses with an associated decrease in IFN-y production. 
Consistent with these properties, in a murine model of asthma, C57BLl6 IL-18 gene 
knockout mice had increased airway inflammation after antigen sensitisation and 
challenge which was proposed to be related to decreased IFN-y production (Kodama et 
al., 2000). However, it is now thought that IL-18 can stimulate the development of both 
Th1 and Th2 responses depending on the surrounding cytokine environment (Xu et al., 
2000). This theory has been supported in studies in transgenic mice over-expressing IL-
18, where higher serum levels of both IFN-y and IL-4, and also increased IgE, were 
observed (Hoshino et al., 2001). 
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In the present study, BALB/c IL-18 ko mice sensitised and challenged with OVA had 
reduced total BAL cellularity mainly due to reduced numbers of eosinophils when 
compared to identically treated WT controls, although there was no associated reduction 
in inflammatory infiltrates seen on lung histology. This is in contrast to the previous 
study where C57BLl6 mice lacking IL-18 were used (Kodama et aI., 2000); in this 
study an increase in eosinophil numbers was observed but again, there was no alteration 
in the influx of other cell types into the airways during this inflammatory response. 
The reduction in BAL eosinophilia, but not histological inflammation, seen after antigen 
challenge in IL-18 ko mice in the current study may reflect alterations in the production 
of cytokines, chemokines and adhesion molecules which are involved in eosinophil 
trafficking to the lung and into the bronchial lumen during allergic responses. The 
numbers of eosinophils within the inflammatory infiltrates was not quantified, and it is 
possible that these differ between IL-18 deficient and WT mice while the amounts of 
other inflammatory cells remain unchanged, or are relatively higher. IL-18 given intra-
tracheally at the time of antigen challenge promotes eosinophil chemotaxis into the 
airways by stimulating the production of eotaxin but does not directly stimulate 
eosinophil migration (Campbell et aI., 2000). IL-18 can inhibit airway eosinophilia 
when given intraperitoneally in relatively low doses at the time of antigen challenge, an 
effect dependent on the production of systemic IFN-y (Hofstra et aI., 1998, Walter et aI., 
2001). However, when high doses of IL-18 are given systemically, eosinophil influx 
into the airways is induced through the production of TNF-a (Kumano et aI., 1999), 
which negates the suppressive effect of IFN -yon airway inflammation. In vitro, IL-18 
has been shown to induce the production of the cytokine IL-9, IL-13, GM-CSF, TNF-a 
and the chemokines RANTES and macrophage inflammatory protein (MIP) 1 alpha, 
which may all contribute to the recruitment of eosinophils into the lung. Eosinophils 
express the IL-18Ra chain and are able to produce IL-8 in response to IL-18 (Wang et 
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al., 2001), and so may respond directly to IL-18 stimulation in other ways, for example 
by alterations in the expression of adhesion molecules involved in eosinophil migration 
such as very late activation antigen (VLA)-4 (Sagara et al., 1997). The absence of IL-18 
in BALB/c IL-18 ko mice is therefore likely to cause complex alterations in the balance 
of cytokine and chemokine secretion which may inhibit eosinophil migration into the 
airways. 
Although the absence of IL-18 in the lung in IL-18 ko mice may alter pulmonary 
cytokine and chemokine production leading to altered BAL and tissue eosinophilia, it is 
likely that there are also reduced T helper lymphocyte responses in IL-18 gene deficient 
mice. In the above study, there was a non-significant decrease in IL-4 levels in BAL 
fluid. However, the reduction in OVA-stimulated IL-4 production from thoracic lymph 
node cells in vitro was significant and was associated with decreased IL-4 mRNA 
expression in thoracic lymph node cells. The reduction in IL-4 production was antigen-
specific, since production of this cytokine by the T -lymphocyte mitogen Concanavalin 
A was not reduced. These results are consistent with IL-18 having a role in the 
production of Th2 responses by enhancing the production of IL-4. The ability of IL-18 
to stimulate IL-4 production may be important in the development of allergic 
sensitisation to antigen. NaIve T lymphocytes (ThO) express low levels of IL-18 
receptor alpha (IL-18Ra) and, in the presence ofIL-2, IL-18 stimulates IL-4 production 
and Th2 development in these cells (Hoshino et al., 1999). NKT cells express higher 
levels of IL-18Ra, and also produce IL-4 and IL-13 in response to IL-18 (Yoshimoto et 
al., 2003), and these NKT cells, and also basophils and mast cells (Yoshimoto et al., 
1999) may provide the initial amounts of IL-4 needed to enhance Th2 development. It 
has previously been shown that the exogenous administration of IL-18 at the time of 
allergic sensitisation increased the inflammatory airways response (Wild et al., 2000); it 
may be that the exogenous IL-18 potentiates the production of IL-4 from antigen-
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stimulated T lymphocytes to further augment Th2 cell development. Since BALB/c 
mice have greater propensity to produce IL-4 in response to stimulation with uCD3 than 
C57BLl6 mice (Xu et al., 2000, Habu et al., 2001), if IL-18 enhances the induction of 
IL-4 secretion through T cell receptor stimulation in vivo, its absence in BALB/c IL-18 
ko mice could have a more profound effect on Th2 development than in the C57BLl6 
IL-18 gene deficient mice which were used in the study of Kodama et ai. (2000). 
Th1 cells may contribute the inflammatory response in murine asthma models (Hansen 
et al., 1999, Randolph et al., 1999a, Randolph et al., 1999b). IL-18 has been shown to 
induce eosinophilic airway inflammation and AHR in mice which have previously 
received Th1 memory cells, and to enhance the secretion of cytokines and chemokines, 
including IL-13 and RANTES, from IFN-y-producing Th1 cells in vitro (Sugimoto et 
al., 2004). In the lymph node cultures described above, the production of IFN-y in 
response to OVA was also reduced. This may indicate that there is also some 
suppression of Th1 responses in these IL-18 ko mice and that this may contribute to the 
decrease in airway inflammation observed. 
Atopic asthmatic responses are associated with increased levels of serum IgE. In vitro, 
IL-18 can induce IgE production, which is dependent on the presence of CD4+ T cells 
and IL-4 (Yoshimoto et al., 2000). In mice, NKT cells are also thought to be essential 
for this response in vivo (Yoshimoto et aI., 2003). Increased levels of IgE are also seen 
in mice treated with exogenous IL-18 (Wild et al., 2000) and in transgenic mice 
overexpressing IL-18 (Hoshino et al., 2001). In contrast, when IL-12 is present, IL-18 
inhibits the production ofIgE by inducing IFN-y production (Yoshimoto et al., 1997). In 
the above experiments there was no significant difference in the levels of total serum 
IgE or OVA-specific IgE, IgG 1 and IgG2a in the IL-18 ko mice which had been treated 
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with OV A compared to the WT mice. This is comparable to previous studies where no 
difference in serum IgE levels was observed in C57BLl6 IL-18 ko mice (Kodama et aI., 
2000) nor serum IgE or IgG 1 levels in wild-type BALB/c mice treated with IL-18 and 
OVA adsorbed to alum (Pollock et aI., 2003). 
Wei et aI. (1999) have previously noted that antigen naive IL-18 deficient mice, on a 
CD1 background, had similar levels of CD4+ and CD8+ T lymphocytes, B cells and NK 
cells as WT mice on flow cytometric analysis. In this current study, flow cytometric 
analysis of thoracic lymph nodes cells revealed marginally decreased proportion of B 
lymphocytes in OVA-treated IL-18 ko mice when compared to OVA-treated WT mice. 
Since immunoglobulin levels are unaffected, the relevance of this is unclear. Also, as 
there was a relatively larger proportion of CD4+ cells in the thoracic lymph nodes of IL-
18 ko mice, it would imply that a decrease in the amount of T helper lymphocytes 
present does not contribute to the decrease in IL-4 and IFN-y production observed in 
lymph node cell cultures. IL-18 is known to up-regulate the cell surface expression of 
the intracellular adhesion molecules ICAM-1 in monocytes (Stuyt et aI., 2003) and 
VCAM-1 on endothelial cells (Morel et aI., 2002), so promoting the influx of 
leukocytes to sites of inflammation. Although IL-18 may influence the expression of the 
molecules, the results above suggest that it does not induce alterations in the levels of 
the lymphocyte adhesion molecules CD44, CD 11 a and CD62L on murine T helper 
lymphocytes; this is consistent with the observation that IL-18 does not alter the levels 
of these molecules on human peripheral blood T cells (Yoshida et aI., 2001). 
In conclusion, in this murine model of asthma, IL-18 knockout mice had decreased 
airway eosinophilia, but not tissue inflammation, when compared to wild-type mice 
after OVA-sensitisation and challenge. There was a tendency for IL-4 levels in BAL 
fluid to be lower in IL-18 ko mice. OVA-induced IL-4 production was significantly 
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decreased in cultures of thoracic lymph node cells from OVA-sensitised and challenged 
IL-18 ko mice when compared to cells from similarly treated WT mice. The above 
results suggest that IL-18 may have a pro-inflammatory action in allergic airway 
inflammation which may in part be mediated by decreased IL-4 production. Further 
work is required to confirm that IL-18 is important in augmenting the secretion of IL-4 
during the development of allergic airway inflammation, and to identify the cell types 
on which IL-18 acts to enhance the secretion of this cytokine. In addition, investigations 
are needed to elucidate the actions of IL-18 on eosinophil activity and migration, 
including a comparison of quantification of tissue eosinophilia between OVA-sensitised 
and challenged IL-18 gene knockout mice and wild-type mice. IL-18 is likely to affect 
the secretion of several cytokines and chemokines which promote allergic responses, 
and these should also be studied to clarify the pro-inflammatory role of IL-18 in allergic 
airway inflammation in order to assess more fully its potential as a therapeutic target in 
the treatment of human asthma. 
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Chapter 5 
The anti-inflammatory actions of simvastatin 
in a murine model of allergic asthma 
Data from this chapter has been published in 
McKay et al., (2004) J Immunol. 172, 2903-8. 
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5.1 Introduction 
Statins are inhibitors of the rate-limiting enzyme, 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, in cholesterol biosynthesis. As such, they have 
been widely used in clinical practice as cholesterol lowering agents to reduce morbidity 
and mortality from coronary artery disease (Scandinavian Simvastatin Survival Study, 
1994, Shepherd et al., 1995). There is evidence from clinical studies (Albert et al., 2001, 
10ukhadar et al., 2001) and in vitro experiments (Crisby et al., 2001, SPalTOW et al., 
2001) that statins have additional anti-inflammatory propeliies in atherosclerotic disease 
which are unrelated to their lipid lowering activity. There are likely to be several 
molecular mechanisms through which statins exert their immunomodulatory effects 
(Takemoto and Liao, 2001) but these have not yet been fully elucidated. Statin 
treatment has the potential to modify T lymphocyte-driven disease through the ability to 
allosterically inhibit the interaction between the cellular adhesion molecules lymphocyte 
function-associated antigen (LF A)-l and intercellular adhesion molecule (ICAM)-l 
(Weitz-Schmidt et al., 2001) and decrease IFN-y-induced expression of major 
histocompatibility complex (MHC)-II on antigen presenting cells (Kwak et al., 2000). 
Also, by inhibiting the production of L-mevalonic acid and its metabolites, statins 
prevent the isoprenylation of signalling molecules such as Ras and Rho which are 
involved in lymphocyte activation (Czyzyk et al., 2003, Greenwood et al., 2003). 
Statins may therefore have beneficial effects in a broad range of inflammatory 
conditions. 
Atherosclerotic plaques contain large numbers of lymphocytes which are mainly of T 
helper (Th)-l type (Frostegard et al., 1999) which characteristically secrete IFN-y. Since 
statins inhibit inflammation in plaques, recent studies have focussed on the potential 
ability of statins to modulate Th1-predominant disease, such as rheumatoid arthritis 
123 
(Dolhain et aI., 1996) and multiple sclerosis (Lassmann et aI., 2001). In animal models 
of both these conditions statins have had an immunosuppressive action (Leung et aI., 
2003, Youssef et aI., 2002, Aktas et aI., 2003). In contrast, evidence is lacking as to 
whether statins might modulate inflammation in which Th2 lymphocytes, secreting 
interleukin (IL)-4, IL-5 and IL-13, are important. 
Treatments targeted at inhibiting the function of LF A-I have been effective in reducing 
airway eosinophilia in a murine model of allergic asthma (Winn et aI., 2001) and 
sputum eosinophilia after allergen challenge in asthmatic patients (Gauvreau et aI., 
2003). Since simvastatin can inhibit LF A-lIICAM-l interaction, we sought to establish 
whether this drug could modulate inflammatory responses in a murine model of allergic 
asthma, a Th2-driven condition. In this study it is shown for the first time that 
simvastatin can effectively suppress acute eosinophilic airway inflammation and Th2 
cytokine secretion. 
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5.2 The effect of simvastatin on bronchoalveolar lavage cellularity 
In order to determine if simvastatin treatment could influence the development of 
allergic airway inflammation, the murine model of allergic asthma used in Chapter 4 
was used. BALB/c mice were sensitised and challenged with OVA, following the 
protocol outlined in Figure 2.1. Simvastatin was given by either intraperitoneal injection 
30 minutes before each antigen challenge, or oral gavage 60 minutes before each 
allergen challenge, on days 25 - 27 of the experimental protocol. Control mice were 
treated with PBS. Experiments were terminated on day 28. 
5.2.1 The effect of intraperitoneal simvastatin treatment on total 
bronchoalveolar lavage cellularity 
In initial experiments, simvastatin was given by intrperitoneal injection before each 
intranasal challenge with OV A. Simvastatin at 40 mg/kg i.p., but not at 4 mg/kg, 
produced a significant reduction in BAL total cell count (Figure 5.1). 
5.2.2 The effect of intraperitoneal simvastatin on bronchoalveolar lavage 
differential cell count 
Simvastatin at 40 mg/kg i.p. but not at 4 mg/kg produced a reduction in BAL 
eosinophilia and macrophage count, as shown in Figure 5.2 A and B. At either dose, 
simvastatin did not alter BAL lymphocyte or neutrophil numbers (Figure 5.2 C and D). 
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Figure 5.1. Total bronchoalveolar lavage cellularity after intraperitoneal 
simvastatin treatment. 
BALB/C mice were sensitised with OV A and then challenged with OVA i.n. on three 
consecutive days from day 25-27. Simvastatin 40 mg/kg or 4 mg/kg i.p. was given 30 
minutes before each antigen challenge. Control mice were given PBS. Bronchoalveolar 
lavage (BAL) cell counts were performed on day 28. Treatment with simvastatin 40 
mg/kg resulted in a significant reduction in BAL total cell count. Data are expressed as 
mean ± SEM. (n = 7-14 mice per group). **p < 0.01. Statistical significance was 
determined by ANOV A. 
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Fig. 5.2. Bronchoalveolar lavage differential cell count after treatment with 
simvastatin intra peritoneally . 
BALB/c mice were sensitised with OV A and then challenged with OV A i.n. on three 
consecutive days from day 25-27. Simvastatin 40 mg/kg or 4 mg/kg i.p. was given 30 
minutes before each antigen challenge. Control mice were given PBS. Bronchoalveolar 
lavage (BAL) cell counts were performed on day 28. Treatment with simvastatin 40 
mg/kg resulted in a significant reduction in BAL (A) eosinophil and (B) macrophage 
numbers. There was no significant difference in BAL (C) lymphocyte or (D) neutrophil 
levels. Data are expressed as mean ± SEM. (n = 7-14 mice per group). **p < 0.01. 
Statistical significance was determined by ANOV A. 
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5.2.3 The effect of oral simvastatin on bronchoalveolar lavage total cellularity 
As simvastatin is orally administered in clinical use, it was important to determine if a 
similar anti-inflammatory effect could be obtained by giving the drug enterally. When 
simvastatin 40 mg/kg was given by oral gavage (o.g) before the allergen challenges on 
days 25 to 27, a significant decrease in BAL total cellularity was again observed (Figure 
5.3). 
5.2.4 The effect of oral simvastatin on bronchoalveolar lavage differential cell 
count 
These results are shown in Figure 5.4. Treatment with simvastatin 40 mg/kg orally 
produced a reduction in BAL eosinophilia (Figure 5A). but no reduction was seen in the 
amounts of macro phages, lymphocytes or neutrophils in the lavage fluid (Figure 5.4B-D). 
5.3 Histological analysis of lung inflammatory infiltrates 
Histological analysis demonstrated that there was a reduction in inflammatory infiltrates 
in the lungs of mice treated with i.p. simvastatin 40 mg/kg. Representative 
photomicrographs of this are shown in Figure 5.5. This reduction in inflammatory 
infiltration in these mice, but not mice treated with simvastatin 4mg/kg 
intraperitoneally, was confirmed by histological scoring (Figure 5.6A). Similarly in 
mice treated with simvastatin 40 mg/kg orally, although there was a reduction in 
perivascular inflammation on histological scoring, there was no significant decrease in 
total lung inflammatory scores (Figure 5.6B). 
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Figure 5.3. Bronchoalveolar lavage total cell count after treatment with 
simvastatin orally. 
BALB/c mice were sensitised with OV A and then challenged with OVA i.n. on three 
consecutive days from day 25-27. Simvastatin 40 mg/kg. was given by oral gavage 60 
minutes before each antigen challenge. Control mice were given PBS. Broncholaveolar 
lavage (BAL) cell counts were performed on day 28. Treatment with simvastatin 40 
mg/kg by oral gavage resulted in a significant reduction in BAL total cell count. Data 
are expressed as mean ± SEM. (n = 8 - 16 mice per group). **p < 0.01. Statistical 
significance was determined by ANOV A. 
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Fig. 5.4. Bronchoalveolar lavage differential cell count after treatment with 
simvastatin orally. 
BALB/c mice were sensitised with OVA and then challenged with OVA i.n. on three 
consecutive days from day 25-27. Simvastatin 40 mg/kg was given by oral gavage 60 
minutes before each antigen challenge. Control mice were given PBS. Broncholaveolar 
(BAL) cell counts were performed on day 28. Treatment with simvastatin resulted in a 
significant reduction in BAL (A) eosinophil numbers. There was no significant 
difference in BAL (B) macrophage, (C) lymphocyte or (D) neutrophil levels. Data are 
expressed as mean ± SEM. (n 8 - 16 mice per group). **p < 0.01. Statistical 
significance was determined by ANOV A. 
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c 
Fig. 5.5. Histological evidence of decreased lung inflammation in mice treated with 
simvastatin 40 mg/kg intraperitoneally. 
A representative section is shown from each group of mice (n = 3-5 per group). (A) 
Naive mouse, given PBS challenge. (B) OVA challenged mouse; peri-bronchial and 
peri-vascular inflammatory infiltrates are seen, with eosinophils present, and mucosal 
hyperplasia. (C) OVA challenged plus treatment with simvastatin 40 mg/kg i.p; a 
reduction in inflammatory infiltrates is seen compared with (B). H&E staining, 
magnification x200. 
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Figure 5.6. Histological score of lung inflammation in mice treated with simvastatin. 
Total lung inflammation on histological sections was determined as the sum of 
peribronchial and perivascular scores. Inflammation was graded on the scale 0, none; 1, 
mild, 2, moderate; 3, marked and 4, severe. An increment of 0.5 was used when severity 
of inflammation fell between two integers. (A) Intraperitoneal treatment with 
simvastatin 40 mg/kg, but not 4 mg/kg, produced a significant reduction in perivascular 
and total lung inflammation when compared to PBS-treated mice. (B) Mice treated with 
simvastatin 40 mg/kg by oral gavage had a significant reduction in perivascular 
inflammation, but total lung inflammatory scores were not significantly different from 
control mice given PBS. Data are expressed as mean ± SEM. * P < 0.05. (n = 3 -7 mice 
per group). Statistical significance was assessed by Student's ttest. 
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5.4 Bronchoalveolar lavage cytokines 
In order to establish if the reduction in BAL total cellularity and eosinophilia produced 
by simvastatin treatment was accompanied by decreased Th2 cytokine production, the 
levels of IL-4 and IL-5 in BAL fluid were measured. Since statin treatment has 
previously been shown to increase IL-18 secretion from human peripheral blood 
monocytes (Montero et al., 2000), IL-18 levels in BAL fluid were also determined, as 
were the levels of the chemokine eotaxin, a chemoattractant for eosinophils. 
Intraperitoneal administration of simvastatin produced a dose-related reduction in the 
levels of IL-4 and IL-5 in BAL fluid (Fig. 5.7A and B) when compared to PBS-treated 
control mice (IL-4 - simvastatin 4 mg/kgp < 0.05, simvastatin 40 mg/kgp < 0.01; IL-5 
- simvastatin 4 mg/kgp < 0.01, simvastatin 40 mg/kgp < 0.01). However, the levels of 
IL-18 (Figure 5.7C) were not significantly different between PBS-treated mice and 
simvastatin treated mice, nor between naive mice and OV A-sensitised mice. Levels of 
the chemokine eotaxin (Figure 5.7D) tended to be higher in OVA-sensitised and 
challenged mice but again, intraperitoneal simvastatin treatment did not significantly 
alter its levels in BAL fluid. IFN-y was not detectable (data not shown). 
Oral simvastatin treatment did not significantly alter the levels of IL-4, IL-5, IL-18 or 
eotaxin in bronchoalveolar lavage fluid, as shown in Figure 5.8. 
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Figure 5.7. Bronchoalveolar lavage cytokines in mice treated with simvastatin 
intraperitoneally. 
Levels of IL-4, IL-5 and IL-18 and the chemokine eotaxin in bronchoalveolar lavage 
(BAL) fluid were determined by ELISA. (A) IL-4 levels and (B) IL-5 levels were 
significantly reduced by treatment with simvastatin 4 mg/g and 40 mg/kg i.p. compared 
to PBS-treated controls. Levels of (C) IL-18 and (D) the chemokine eotaxin were not 
significantly different in simvastatin-treated mice compared to control mice treated with 
PBS. Data are expressed as mean ± SEM. (n = 6 -11 mice per group). * p < 0.05, ** P < 
0.01. Statistical significance was assessed by ANOV A. 
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Figure S.S. Bronchoalveolar lavage cytokines in mice treated with simvastatin 
orally. 
Levels of the cytokines IL-4, IL-5 and IL-18 and the chemokine eotaxin in 
bronchoalveolar (BAL) fluid were determined by ELISA. (A) IL-4 levels, (B) IL-5, (C) 
IL-18 and (D) eotaxin levels were not significantly altered by treatment with 
simvastatin 40 mg/kg by oral gavage. Data are expressed as mean ± SEM. (n = 8 -14 
mice per group). Statistical significance was assessed by ANOV A. 
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5.5 Serum immunoglobulin levels 
Figure 5.9 shows the serum total IgE and IgG subclass profiles. Treatment with 
simvastatin intraperitoneally at the time of antigen challenge did not significantly affect 
serum levels of total IgE or OV A-specific IgG 1 or IgG2a. Levels of these 
immunoglobulins were elevated in all OVA-treated groups compared to naIve mice. 
Similarly, oral simvastatin treatment did not significantly alter the amount of these 
immunoglobulins compared to PBS-treated mice (data not shown). 
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Figure 5.9. Serum immunoglobulin levels in mice treated with simvastatin 
intra peritoneally . 
Serum immunoglobulin levels were assessed by ELISA. Treatment with simvastatin 4 
mg/kg or 40 mg/kg intraperitoneally did not alter (A) serum total IgE levels (n = 6 mice 
per group) when compared to PBS-treated controls. In addition, (B) Serum OVA-
specific IgG 1 (serum dilution 11180,000) and (C) serum OVA-specific IgG2a levels 
(serum dilution 1/800) were also unaffected by treatment with simvastatin compared to 
mice treated with PBS alone (OVA) (n=6 mice per group). Data are expressed as mean 
± SEM. Statistical significance was assessed by Student's t test. 
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5.6 In vitro thoracic lymph node cell responses following the in vivo 
administration of simvastatin 
Since there was a reduction in IL-4 and IL-5 levels in BAL fluid, this suggested that 
there was suppression of Th2 lymphocyte responses. To investigate this further, cells 
isolated from the lymph nodes of mice previously treated with simvastatin, both 
intraperitoneally and orally were cultured in vitro and OVA-induced cell proliferation 
and cytokine production assessed. 
5.6.1 In vitro OV A-induced cell proliferation in thoracic lymph node cells 
Figure 5.10 demonstrates the proliferative responses of thoracic lymph node cells to 
OVA and Concanavalin (Con) A. Neither intraperitoneal simvastatin, at both the higher 
and lower doses, nor oral simvastatin treatment altered cell proliferation in response to 
OVA or Con A. 
5.5.1 In vitro OVA-induced cytokine responses in thoracic lymph node cells 
Treatment with both simvastatin 4 mg/kg and 40 mg/kg intraperitoneally resulted in a 
significant decrease in OVA-induced IL-4 and IL-5 production from thoracic lymph 
node cells compared to cells from PBS-treated controls (IL-4 - s imvastatin 4 mg/kgp < 
0.05, simvastatin 40 mg/kg p < 0.01; IL-5 - simvastatin 4 mg/kg p < 0.01, simvastatin 
40 mg/kg p < 0.01) (Figure 5.11A and B, respectively). Treatment with oral simvstatin 
did not affect the levels of these cytokines (Figure 5.11 C and D). 
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Figure 5.10. Proliferative responses in thoracic lymph node cells ill vitro. 
Thoracic lymph node cells Cn = 3 mice per group) were harvested from mice on day 28 
and cultured for 96 hours with (A) and (C) medium alone CD) or OVA C.; 500 Ilg/ml) 
or (B) and (D) 5 Ilg/ml Concanavalin A. T cell proliferation was assessed by uptake of 
eH]-thymidine. (A) Mice treated with simvastatin 4 mg/kg or 40 mg/kg 
intraperitoneally or (C) simvastatin 40 mg/kg orally had no significant reduction in 
OVA-induced cell proliferation and spontaneous cell proliferation when compared to 
mice treated with PBS alone. Similarly neither (B) intraperitoneal nor (D) oral 
simvastatin treatment reduced the proliferative response to Concanavalin A. Data are 
expressed as mean ± SEM. Statistical significance was assessed by ANOV A. 
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Con A-induced production of IL-4 and IL-S from thoracic lymph node cells is 
illustrated in Figure S.12. For the experiment shown, IL-4 production significantly 
decreased from thoracic lymph node cells from mice treated with simvastatin 4 mg/kg 
intraperitoneally. Treatment with simvasatatin 40 mg/kg i.p. or orally did not alter 
ConA-induced IL-4 production. IL-S production was not affected by simvastatin 
treatment intraperitoneally or orally (Figure S.12B and D). 
As shown in Figure S.13A and C, OVA-induced IFN-y production was significantly 
reduced by all conditions of simvastatin treatment (simvastatin i.p. 4 mg/kg and 40 
mg/kg,p < 0.01; simvastatin orally 40 mg/kgp < O.OS). Similarly, thoracic lymph node 
cells from mice treated with simvastatin 40 mg/kg i.p or orally produced less IL-6 in 
response to OVA (both p < O.OS), than cells from PBS treated mice, Figure S.13B and 
D. IFN-y and IL-6 production may therefore be differentially regulated by the 
pharmacological actions of simvastatin, compared to that ofIL-4 and IL-S. 
Previous in vivo simvastatin treatment, either intraperitoneally or orally, did not 
significantly affect the production of IFN-y or IL-6 in response to ConA in thoracic 
lymph node cells in vitro (Figure S .14). 
For the above data, in the majority of cases, prior simvastatin treatment appears to 
specifically suppress antigen-induced cytokine production from thoracic lymph node 
cells. 
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Figure 5.11. OVA-induced IL-4 and IL-5 responses in thoracic lymph node cells 
in vitro. 
In parallel cultures to those in Figure 5.10, thoracic lymph node cells (n = 3 mice per 
group) were harvested from mice on day 28 and cultured for 72 hours with medium 
alone (D) or OVA (.; 500 Ilg/ml). Cytokine levels in cell culture supernatants were 
assessed by ELISA. (A) IL-4 and (B) IL-5 production in response to OV A were 
significantly reduced in lymph node cells from mice treated with simvastatin 4 mg/kg 
and 40 mg/kg intraperitoneally when compared to cells from mice treated with PBS 
alone. (C) IL-4 and (D) IL-5 production were not reduced in cells from mice treated 
with simvastatin 40 mg/kg orally. Data are expressed as mean ± SEM. ** p < 0.01. 
Statistical significance was assessed by ANOV A. 
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Figure 5.12. Concanavalin A-induced IL-4 and IL-5 responses in thoracic lymph 
node cells in vitro. 
In parallel cultures to those in Figure S.10, thoracic lymph node cells (n = 3 mice per 
group) were harvested from mice on day 28 and cultured for 72 hours with Concanavalin 
(Con) A S /lg/ml. Cytokine levels in cell culture supernatants were assessed by ELISA. 
(A) IL-4 production in response to Con A was significantly reduced in mice treated 
intraperitoneally with simvastatin 4 mg/kg, but not 40 mg/kg, compared to cells from 
PBS-treated controls. (B) IL-S production was not affected by intraperitioneal simvastatin 
treatment. (C) IL-4 and (D) IL-S production were not significantly reduced in cells from 
mice treated with simvastatin 40 mg/kg orally. Data are expressed as mean ± SEM. 
** p < 0.01. Statistical significance was assessed by ANOV A. 
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Figure 5.13. OVA-induced IFN-y and IL-6 responses in thoracic lymph node cells 
in vitro. 
In parallel cultures to those in Figure 5.10, thoracic lymph node cells (n = 3 mice per 
group) were harvested from mice on day 28 and cultured for 72 hours with medium alone 
(D) or OVA (.; 500 Ilg/ml). Cytokine levels in cell culture supematants were assessed by 
ELISA. IFN-y production in response to OVA was reduced in thoracic lymph node cells 
from mice treated with (A) simvastatin 4 mg/kg and 40 mg/kg intraperitoneally and (C) 
simvastatin 40 mglkg orally, when compared to cells from PBS treated mice. OV A-
induced IL-6 production was reduced in cells from mice treated with (B) simvastatin 40 
mg/kg intraperitoneally and (D) 40 mg/kg orally. Data are expressed as mean ± SEM. 
* p < 0.05, ** p < 0.01. Statistical significance was assessed by ANOV A. 
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Figure 5.14. Concanavalin A -induced IFN-y and IL-6 responses in thoracic lymph 
node cells in vitro. 
In parallel cultures to those in Figure 5.13, thoracic lymph node cells (n = 3 mice per 
group) were harvested from mice on day 28 and cultured for 72 hours with Concanavalin 
(Con) A 5 /-tg/ml. Cytokine levels in cell culture supernatants were assessed by ELISA. 
(A) IFN-y and (B) IL-6 production in response to Con A was not significantly different in 
mice treated intraperitoneally with simvastatin 4 mg/kg,or 40 mg/kg compared to cells 
from PBS-treated controls. Similarly, (C) IFN-y and (D) IL-6 production were not 
significantly different in cells from mice treated with simvastatin 40 mg/kg orally 
compared to cells from control mice. Statistical significance was assessed by ANOV A. 
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5.7. Gene expression in mice treated with simvastatin intraperitoneally 
5.7.1 Gene expression in thoracic lymph nodes 
Since previous treatment with simvastatin intraperitoneally influenced OVA-induced 
production of IL-4 and IL-5 in cultures of thoracic lymph node cells, the gene 
expression of these cytokines was assessed in thoracic lymph nodes taken from mice on 
day 28 of the experimental protocol. As shown in Figure 5.15A, the expression ofIL-4 
mRNA tended to be higher in OVA-sensitised and challenged mice when compared to 
naIve mice but simvastatin treatment did not significantly alter its levels. There was no 
significant difference in IL-5 amongst any of the groups (Figure 5.15B). Similarly, the 
expression of IL-18 did not differ significantly between naIve nor OV A-sensitised and 
challenged mice, or with simvastatin treatment (Figure 5.15C). 
Statins have previously been shown to suppress IFN-y-induced MHC-II expression on 
antigen presenting cells through suppression of the transcription factor MHC-II 
transactivator (CIIT A) (K wak et al., 2000), and so levels of CIIT A mRNA expression in 
thoracic lymph nodes were also determined. There was no significant difference in the 
levels of CIIT A expression between simvastatin-treated and PBS treated mice (Figure 
5.15D). 
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Figure 5.15. Gene expression in thoracic lymph nodes from mice treated with 
simvastatin intra peritoneally . 
The mRNA expression of the cytokines IL-4, IL-5 and IL-18 and the MHC class II 
transactivator (CIITA) in pooled thoracic lymph nodes (n = 3-5 mice per group) was 
determined by the use of RT-quantitative PCR on day 28. There was no significant 
difference in the levels of (A) IL-4, (B) IL-5, (C) IL-18 or (D) CIITA mRNA 
expression in thoracic lymph nodes from naive mice, OVA-sensitised mice treated with 
PBS and OVA-senstised mice treated with simvastatin 4 mg/kg or 40 mg/kg 
intraperitoneally. Data are expressed as mean ± adjusted error. 
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5.7.2 IL-18 expression in the lungs of mice treated with simvastatin 
intra peritoneally 
As shown above in Section 5.4, IL-18 protein levels in BAL fluid did not significantly 
differ between naIve mice and OV A-sensitised and challenged mice, or with simvastatin 
treatment. To assess if this correlated with constant levels of pulmonary IL-18 gene 
expression, quantitative PCR was used to determine IL-18 mRNA levels in lung tissue. 
There was a trend for IL-18 mRNA expression to be far higher in antigen-naIve mice, 
which had been treated with alum and PBS, than in OVA-sensitised mice. Although 
simvastatin treatment appeared to increase the levels of IL-18 expression, this was not 
significant when compared to PBS-treated, OVA-challenged mice (shown in Figure 
5.16, below). 
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Figure 5.16. IL-18 expression in the lungs of mice treated with simvastatin 
intra peritoneally . 
IL-18 mRNA expression was determined by the use ofRT-quantitative PCR on day 28. 
There was a trend for the levels of IL-18 mRNA expression was significantly reduced in 
OVA-sensitised and challenged mice compared to naIve controls. Data are expressed as 
mean ± SEM. (n = 3-6 mice per group). Statistical significance was assessed by ANOV A. 
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5.8 Chapter discussion 
The prevalence of asthma is rising (Umetsu et aI., 2002). Consequently, there is an 
increased need for the development of new agents for its treatment, especially for 
patients who respond poorly to conventional therapy. In this study we have shown that 
simvastatin has an effective anti-inflammatory action in a murine model of allergic 
airway inflammation. In mice previously sensitised to OVA, simvastatin treatment, 
either orally or intraperitoneally, reduced the total inflammatory cell infiltrate and 
eosinophilia in bronchoalveolar lavage (BAL) fluid in response to inhaled OVA 
challenge. Simvastatin therapy i.p. was also associated with a reduction in IL-4 and IL-5 
levels in BAL fluid and, at higher doses, a histological reduction in inflammatory 
infiltrates in the lungs. OVA-induced IL-4 and IL-5 secretion was reduced in thoracic 
lymph node cultures from simvastatin-treated mice. Simvastatin treatment did not alter 
serum total IgE or OVA-specific IgG 1 and IgG2a levels. Therefore, statins, or similar 
agents may have potential as therapeutic agents in human asthma. 
Simvastatin has previously been shown to have an acute anti-inflammatory action in 
carrageenan-induced footpad swelling in mice (Sparrow et aI., 2001) and in 
thioglycolate-induced peritoneal inflammation (Weitz-Schmidt et aI., 2001). In both of 
these models the inflammatory infiltrate is predominantly neutrophils. Statins have not 
previously been shown to have an inhibitory action on eosinophilic infiltration. In this 
current study, the anti-inflammatory effect of simvastatin is, at least in part, mediated 
through a suppressive action on T lymphocytes since OVA-specific IL-4, IL-5, IL-6 and 
IFN-y secretion were reduced in thoracic lymph node cultures from mice treated with 
simvastatin intraperitoneally. A reduction in BAL fluid IL-4 and IL-5 levels was also 
observed in these mice. Similarly, IL-4 and IL-5 secretion in thoracic lymph node cell 
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cultures in response to OVA was reduced in simvastatin-treated mice; this was not 
associated with a reduction in IL-4 and IL-5 mRNA expression in thoracic lymph 
nodes. The reduction in Th2 cytokine production in thoracic lymph node cultures was 
not accompanied by an increase in the secretion ofIFN-y, a Thl cytokine. Indeed, IFN-y 
production was also reduced in lymph node cultures. There is now evidence that Thl 
cells (Hansen et aI., 1999, Randolph et aI., 1999a, Randolph et aI., 1999b) and IFN-y 
secretion (Ford et aI., 2001) may exacerbate airway inflammation in asthma. Therefore, 
there may also be suppression of Thl cells, and hence IFN-y levels, contributing to the 
decrease in inflammation seen. This result corresponds with the previous observation in 
murine collagen-induced arthritis (CIA), where a decrease in Thl cytokines was not 
associated with an increase in Th2 cytokine secretion (Leung et aI., 2003). This is in 
contrast to that seen in murine experimental allergic encephalitis (EAE), where statin 
treatment increased the Th2 bias in antigen-stimulated lymph node cultures (Youssef et 
aI., 2002, Aktas et aI., 2003) while reducing a Thl response. In these studies, 
atorvastatin was used, and the immunomodulatory effects of this drug may differ from 
those of simvastatin. 
In contrast to the CIA and EAE inflammatory models, a reduction in antigen-induced 
cell proliferation in lymph node cells was not observed in the present study. These other 
models were of chronic inflammatory conditions and statin treatment was continued for 
at least 15 days after the last dose of antigen. In this current study, simvastatin was only 
given for three days and was not given after the last challenge with OV A. This shorter 
exposure to statin therapy may explain the failure to suppress cell proliferation. This 
result suggests there may be divergent mechanisms by which statins inhibit cytokine 
secretion and cell proliferation. 
149 
Simvastatin treatment at a dose of 40 mg/kg i.p. reduced BAL eosinophil and 
macrophage numbers. This might reflect the reduction in Th2 lymphocytes responses, 
but a direct suppressive effect of the simvastatin on eosinophils and macrophages 
cannot be excluded. Eosinophils and macrophages both express LF A-I and so 
simvstatin may have a direct effect on trafficking of these cells into the auways 
(Watkins et aI., 1996, Watanabe and Fan, 1998). IL-5-mediated Ras activation is 
important in eosinophil survival (Hall et aI., 2001) and simvastatin may inhibit the 
activity of this signalling molecule in this model. Statins have also been shown to 
modify the secretion pro-inflammatory cytokines, such as macrophage chemotactic 
protein (MCP)-1 and IL-8, in macrophages (Kothe et aI., 2000). 
Simvastatin has previously been shown to suppress IFN-y-induced MHC II expression 
on antigen presenting cells through suppression of the transcription factor CIIT A (K wak 
et aI., 2000). However, CIITA expression in thoracic lymph nodes was not significantly 
different between simvastatin-treated and PBS-treated mice, suggesting that general 
suppression of inducible class II MHC expression was not an important contributing 
factor in the production of these immunosuppressive actions of simvastatin in this 
inflammatory model. 
It was important to establish that simvastatin could have an anti-inflammatory effect 
when administered orally, since this is the route of administration of the drug in clinical 
practice. Although oral therapy produced an anti-inflammatory effect, this was less 
pronounced than with i. p. administration of the same dose. This is likely to be due to 
first-pass hepatic metabolism of the drug after absorption from the gastrointestinal tract, 
where several metabolites may be produced (Prueksaritanont et aI., 1997) so reducing 
the effective dose of simvastatin available. 
150 
The doses of simvastatin used in this study are higher than those used in man. Statin 
doses comparable to those used here are commonly used in rat/murine studies (Sparrow 
et aI., 2001, Dimmeler et aI., 2001, Ni et aI., 2001, Youssef et aI., 2002, Aktas et aI., 
2003) since there is rapid up-regulation of of HMG-CoA reductase with statin treatment 
in rodents (Kita et aI., 1980). In a previous study in murine CIA, a dose of simvastatin 
40 mg/kg i.p. did not produce a reduction in cholesterol levels, and liver function tests 
were similar between placebo and simvastatin-treated mice (Leung et aI., 2003). 
In conclusion, the current investigations demonstrate that simvastatin treatment is 
effective in reducing BAL total cellularity and eosinophilia in a murine model of 
allergic asthma. Treatment with simvastatin also decreases IL-4 andIL-5 levels in BAL 
fluid when given intraperitoneally and, at higher doses, is associated with a histological 
reduction in pulmonary inflammatory infiltrates. OVA-induced IL-4 and IL-5 secretion 
was reduced in thoracic lymph node cultures from simvastatin-treated mice. The 
immunomodulatory effects of simvastatin are likely to occur through several different 
anti-inflammatory pathways and these mechanisms require further elucidation. In 
particular, the effects of simvastatin on sensitisation to antigen and on airway 
inflammation after prolonged administration will be of interest. Clinical studies are also 
necessary to assess if simvastatin has therapeutic potential in allergic asthma. 
151 
Chapter 6 
The anti-inflammatory actions of thymosin beta 4 sulfoxide 
in a murine model of allergic asthma 
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6.1 Introduction 
The beta thymosins are a group of 5 kDa peptides which have the principal intracellular 
activity of binding monomeric G-actin to inhibit its polymerisation into F -actin 
(Nachmias, 1993). Thymosin ~4, the most abundant of this group, is released from cells 
at sites of inflammation and cell damage. Extracellularly, thymosin ~4 has anti-
inflammatory properties supplementary to its actin-binding ability. Thymosin beta 4 has 
been shown to promote keratinocyte migration in vitro and accelerate skin wound 
healing in animal models (Malinda et al., 1999, Philp et al., 2003). Similarly, thymosin 
~4 stimulated conjunctival cell migration and corneal wound healing (Sosne et al., 
2001, Sosne et al., 2002a, Sosne et al., 2002b). Oxidation of the methionine residue at 
position 6 of thymosin ~4 forms thymosin ~4 sulfoxide (T~4S0), which has been 
identified as the factor reducing fMLP-induced neutrophil chemotaxis in supernatants 
derived from steroid-treated monocytes in vitro (Chettibi et al., 1994, Young et al., 
1999). The oxidation of thymosin ~4 to T~4S0 greatly enhances its wound-healing 
ability in an in vitro assay, and also its anti-inflammatory actions in carrageenen-
induced footpad inflammation in mice, a neutrophil-predominant inflammatory model 
(Young et al., 1999). L T~4, a splice variant of thymosin ~4 derived from lymphocytes, 
which contains two oxidised methionine residues, had anti-inflammatory activity in 
murine models of the T lymphocyte mediated-conditions, irritant contact dermatitis and 
allergic contact dermatitis (Girardi et al., 2003). 
Glucocorticoids are widely used as anti-inflammatory agents in the treatment of human 
asthma. They suppress the production of pro-inflammatory cytokines such as IL-4, IL-5 
(Robinson et al., 1993) and IL-13 (Naseer et al., 1997) by down-regulating their gene 
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expression and decrease the numbers of inflammatory cells present in the auways 
(Barnes and Adcock, 2003). 
Neutrophils are the predominant inflammatory cell observed in carrageenin-induced 
footpad inflammation and in models of wound healing. Since eosinophils are also of 
granulocytic lineage, it was postulated that TP4S0 may have an anti-inflammatory 
action in a murine model of allergic asthma, an eosinophil-predominant inflammatory 
model. The ability of glucocorticoids to induce the release of TP4S0 from monocytes 
may contribute to their anti-inflammatory properties, and so the effect of TP4S0 on 
airway inflammation was compared to that of the glucocorticoid dexamethasone. 
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6.2 The effect of thymosin beta 4 sulfoxide on bronchoalveolar lavage 
cellularity 
The anti-inflammatory effects of TP4S0 were assessed using the same murine asthma 
model as in the previous chapters. The protocol for OV A-sensitisation and challenge is 
detailed in Figure 2.1. Mice were treated with either TP4S0 20 Ilg (an approximate 
dose of 1 Ilg/g) or dexamethasone 3 mg/kg by i.p. injection thirty minutes before the 
intra-nasal challenge with OVA on days 25 to 27. Control mice were treated with PBS. 
Experiments were telminated on day 28. 
6.2.1. Total bronchoalveolar lavage cellularity 
Treatment with TP4S0 resulted in a significant reduction in the total number of cells 
present in BAL fluid when compared to control mice which had been treated with PBS 
alone (Figure 6.1, p < 0.01). Dexamethasone treatment also significantly reduced BAL 
total cellularity (p < 0.05). 
6.2.2 Bronchoalveolar lavage differential cell count 
Differential cell counts were performed on the BAL fluid samples to determine which 
cell types in lavage fluid were being inhibited by TP4S0 and dexamethasone. Both 
these compounds significantly suppressed eosinophil numbers (Figure 6.2A, p < 0.01 
for TP4S0 and dexamethasone). TP4S0 also significantly reduced macrophage (Figure 
2B, p < 0.05) and neutrophils (Figure 6.2D, p < 0.05), but dexamethasone did not. In 
contrast, the amount of lymphocytes present in lavage fluid was reduced by 
dexamethasone (Figure 6.2C, p < 0.05) but not Tp4S0. 
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Figure 6.1. Total bronchoalveolar lavage cellularity after treatment with 
dexamethasone and thymosin P4 sulfoxide. 
BALB/C mice were sensitised with OV A and then challenged with OV A intranasally on 
three consecutive days from day 25 - 27. Dexamethasone (DEX) 3 mg/kg or thymosin 
P4 sulfoxide (TP4S0) 20 Ilg were given 30 minutes before each antigen challenge. 
Control mice were given PBS (OV A). Bronchoalveolar (BAL) cell counts were 
performed on day 28. Total BAL cellularity was significantly reduced by 
dexamethasone and TP4S0 treatment. Data are expressed as mean ± SEM. (n = 6 - 11 
mice per group). * p < 0.05, ** P < 0.01. Statistical significance was assessed by 
ANOVA. 
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Figure 6.2. Bronchoalveolar lavage differential cell count after treatment with 
dexamethasone and thymosin P4 sulfoxide. 
Differential cell counts were determined on the bronchoalveolar (BAL) cell counts 
performed on day 28. BAL (A) eosinophils were significantly reduced by both 
dexamethasone (DEX) 3 mg/kg and thymosin P4 sulfoxide (TP4S0) 20 /-Lg treatment 
when compared to PBS-treated controls (OVA). (B) Macrophage and (D) neutrophil 
numbers were reduced by thymosin P4 sulfoxide whereas (C) BAL lymphocytes were 
suppressed by dexamethasone treatment. Data are expressed as mean ± SEM. (n = 6 -
11 mice per group). * p < 0.05, ** P < 0.01. Statistical significance was assessed by 
ANOVA. 
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6.3 Histological analysis of lung inflammatory infiltrates 
Histological analysis of lung tissue was done to assess if the reduction in BAL 
cellularity and eosinophilia was representative of a decrease in total lung inflammation. 
Representative tissue sections from each of the groups are shown in Figure 6.3. OV A-
sensitised and challenged mice which received PBS as control treatment (Figure 6.3B) 
had peribronchial and perivascular inflammatory infiltrates containing eosinophils, and 
associated mucosal hyperplasia in the bronchial walls. Mice treated with dexamethasone 
(Figure 6.3C) or T~4S0 (Figure 6.3D) had a reduction in lung inflammatory infiltrates. 
However, on histological scoring, although there was a significant decrease in 
perivascular inflammation with dexamethasone treatment (p < O.OS), the reduction 
observed in peribronchial and total lung inflammatory scores following treatment with 
either dexamethasone or T~4S0 did not reach statistical significance (Figure 6.4). 
6.4 Bronchoalveolar lavage cytokines 
Treatment with thymosin ~4 intraperitoneally in a murine model of endotoxic shock 
reduced serum concentrations ofIL-la and TNFa levels (Badamchian et aI., 2003). To 
determine if the anti-inflammatory effects of T~4S0 were mediated by alterations in 
cytokine production, BAL IL-4, IL-S, IL-6 and IFN-y levels were measured. Treatment 
with T~4S0 and dexamethasone significantly reduced IL-4 and IL-S concentrations in 
BAL fluid (Figure 6.SA and B, p< 0.01 for both T~4S0 and dexamethasone). Although 
a reduction in IL-6 was observed (Figure 6.SC), this was not statistically significant. 
IFN-y was not detected in the lavage fluid (data not shown). 
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Figure 6.3. Histological evidence of decreased lung inflammation in mice treated 
with dexamethasone and thymosin (34 sulfoxide. 
A representative section is shown from each group of mice (n = 3 mice per group). (A) 
Naive mouse given a PBS challenge, (B) OVA-challenged mouse; peribronchial and 
perivascular infiltrates are seen, with eosinophils present, and mucosal hyperplasia. (C) 
OVA-challenged mouse plus treatment with dexamethasone 3 mg/kg and (D) OVA-
challenged mouse plus treatment with thymosin (34 sulfoxide 20 /-tg; both these groups 
show a reduction in inflammatory infiltrates compared with (B). H&E staining, 
magnification x200. 
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Figure 6.4. Histological score of lung inflammation in mice treated with 
dexamethasone and thymosin beta 4 sulfoxide. 
Total lung inflammation on histological sections was determined as the sum of 
peribronchial and perivascular scores. Inflammation was graded on the scale 0, none; 1, 
mild, 2, moderate; 3, marked and 4, severe. An increment of 0.5 was used when severity 
of inflammation fell between two integers. Intraperitoneal treatment with 
dexamethasone (DEX) 3 mg/kg, but not thymosin beta 4 sulfoxide (TI34S0) 20 f!g 
produced a significant reduction in perivascular when compared to PBS-treated mice 
(OV A). Peribronchial and total lung inflammatory scores were not significantly 
different in mice treated with dexamethasone or thymosin 134 sulfoxide from control 
mice given PBS. Data are expressed as mean ± SEM. * p < 0.05. (n = 3 mice per group). 
Statistical significance was assessed by Student's t test. 
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Figure 6.5. Broncholavelolar lavage cytokine levels in mice treated with 
dexamethasone and thymosin ~4 sulfoxide. 
Bronchalveolar lavage (BAL) IL-4, IL-5 and IL-6 levels were detelmined by ELISA. 
(A) IL-4 levels and (B) IL-5 levels were significantly reduced by treatment with 
dexamethasone (DEX) 3mg/kg and thymosin ~4 sulfoxide (T~4S0) 20 Ilg compared to 
PBS-treated controls (OVA). The reduction seen in (C) IL-6 levels was not significant. 
Data are expressed as mean ± SEM. en = 6 -11 mice per group). ** p < 0.01. Statistical 
significance was assessed by ANOV A. 
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6.4 Cytokine mRNA expression in lung tissue 
Since IL-4 and IL-5 levels were reduced in BAL fluid, the levels of the mRNA were 
assessed by quantitative RT-PCR to assess if alterations in gene expression 
accompanied the changes the levels of the cytokines detected by ELISA. Since IL-13 is 
an important cytokine in Th2 responses in asthma, the levels of its mRNA were also 
assessed. In in vitro models of corneal wound healing, T~4 treatment produced a rise in 
IL-18 mRNA levels 6 hours after treatment, but down-regulated its expression after 24 
hours (Sosne et aI, 2001); IL-18 mRNA levels were therefore measured to determine if 
T~4S0 treatment altered its expression. The levels of IL-4 and IL-5 mRNA did not 
reflect the cytokine levels measured in BAL fluid (Figure 6.6A and B). There was a 
trend for the levels of levels of IL-4, IL-5 and IL-13 (Figure 6.6C) to be higher in mice 
which had been OVA-sensitised and OVA-challenged but T~4S0 and dexamethasone 
treatment did not alter their levels of expression. IL-18 mRNA (Figure 6.6D) was 
relatively highly expressed in lung tissue and was greatly reduced in OVA-sensitised 
and OVA-challenged mice when compared to naIve controls (PBS-treated controls, p < 
0.05, dexamethasone p < 0.05 and T~4S0 p < 0.01). Although the expression of IL-18 
was increased in the T~4S0-treated group, this was not significant when compared to 
the PBS-treated controls or dexamethasone-treated group. 
6.5 Serum immunoglobulins 
Figure 6.7 shows the serum total IgE levels and IgG subclass profiles. Treatment with 
T~4S0 or dexamethasone did not significantly alter serum total IgE levels, or those of 
OV A-specific IgG 1 or IgG2a. All OVA treated groups had elevated levels of these 
immunoglobulins when compared to the naIve mice. 
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Figure 6.6. Lung cytokine expression in mice treated with dexamethasone and 
thymosin P4 sulfoxide. 
Lung IL-4, IL-5, IL-13 and IL-18 mRNA expression was determined by the use ofRT-
quantitative peR on day 28. There was a trend for the levels of (A) IL-4, (B) IL-5 and 
(C) IL-13 mRNA levels to be increased the groups which had been sensitised and 
challenged with OVA compared to naIve mice; dexamethasone (DEX) 3 mg/kg or 
thymosin P4 sulfoxide (TP4S0) 20 flg treatment did not alter the mRNA levels for 
these cytokines compared to mice treated with PBS alone (OVA). (D) IL-18 mRNA 
expression was significantly reduced in OV A-sensistised and challenged mice 
compared to naIve controls. Data are expressed as mean ± SEM. (n = 3-5 mice per 
group). t p < 0.05, tt p < 0.01. Statistical significance was assessed by ANOV A. 
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Figure 6.7. Serum immunoglobulin levels in mice treated with dexamethasone and 
thymosin P4 sulfoxide. 
Serum immunoglobulin levels were assessed by ELISA. Treatment with dexamethasone 
(DEX) 3 mg/kg or thymosin P4 sulfoxide (TP4S0) 20 /-ig did not alter (A) serum total 
IgE levels (n = 6 - 11 mice per group) when compared to PBS-treated controls. (B) 
Serum OVA-specific IgG 1 (serum dilution 1160,000) and (C) serum OVA-specific 
IgG2a (serum dilution 11400) levels were also unaffected by treatment with 
dexamethasone or thymosin P4 sulfoxide compared to mice treated with PBS alone 
(OVA) (n = 6 mice per group). Data are expressed as mean ± SEM. Statistical 
significance was assessed by Student's t test. 
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6.7 In vitro thoracic lymph node cell responses following the in vivo 
administration of thymosin beta 4 sulfoxide and dexamethasone 
The reduction IL-4 and IL-5 levels in BAL fluid suggested that Th2 lymphocyte 
responses were being suppressed. To investigate this further, cells isolated from thoracic 
lymph nodes of mice previously treated with T~4S0 or dexamethasone were cultured 
and in vitro OVA-induced cell proliferation and cytokine production assessed. 
6.7.1 In vitro OVA-induced cell proliferation in thoracic lymph node cells 
The OVA-induced cell proliferation responses in thoracic lymph node cultures are 
illustrated in Figure 6.8A. Cell proliferation in response to OVA was reduced in lymph 
node cells taken from mice treated with T~4S0 (p < 0.01) and dexamethasone (p < 
0.01) when compared to PBS-treated controls. Prior treatment with T~4S0 and 
dexamethasone also reduced spontaneous cell proliferation when compared to that of 
PBS treated controls (T~4S0 p < 0.05, dexamethasone p < 0.05). This response is 
antigen-specific, since cell proliferation to Concanavalin (Con) A was the same in all 
groups (Figure 6.8B). 
6.7.2 In vitro OVA-induced cytokine production in thoracic lymph node cells 
The OVA-induced cytokine responses, from parallel cultures to the one described in 
Section 6.7.2, are shown in Figures 6.9. Both T~4S0 and dexamethasone treatment 
significantly reduced the production of OVA-induced IL-4 (Figure 6.9A: T~4S0 p < 
0.01, dexamethasone p < 0.01), IL-5 (Figure 6.8B: T~4S0 p < 0.01, dexamethasone p < 
0.01), IFN-y (Figure 6.8C: T~4S0 p < 0.05, dexamethasone p < 0.01) and IL-6 (Figure 
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6.8D: TP4S0 P < 0.01, dexamethasone p < 0.01) when compared to the response in 
lymph node cells from OVA-sensitised and challenged mice treated with PBS alone. 
The reductions in cytokine responses were not OVA-specific since cytokine production 
induced by Con A (Figure 6.10) was also reduced, although to a proportionately lesser 
extent than that seen in the OVA-induced cytokine responses. 
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Figure 6.8. Proliferative responses in thoracic lymph nodes cells in vitro. 
Thoracic lymph node cells (n = 5 mice per group) were harvested from mice on day 28 
and cultured for 96 hours with (A) medium alone (D) or OVA (.; 500 f!g/ml) or (B) 5 
f!g/ml Concanavalin (Con) A. T cell proliferation was assessed by uptake of eH]-
thymidine. (A) Mice treated with dexamethasone (DEX) 3 mg/kg or thymosin ~4 
sulfoxide (T~4S0) 20 f!g had a significant reduction in OV A-induced cell proliferation 
and spontaneous cell proliferation when compared to mice treated with PBS alone 
(OVA). (B) The proliferative response to Con A was the same in all groups. Data are 
expressed as mean ± SEM. * p < 0.05, ** p < 0.01. Statistical significance was assessed by 
ANOVA. 
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Figure 6.9. OVA-induced cytokine responses in thoracic lymph node cells in vitro. 
In parallel cultures to those in Figure 6.8, thoracic lymph node cells (n = 5 mice per 
group) were harvested from mice on day 28 and cultured for 72 hours with medium 
alone (D) or OVA (.; 500 /-Lg/ml). Cytokine levels in cell culture supernatants were 
assessed by ELISA. (A) IL-4, (B) IL-5, (C) IFN-y and (D) IL-6 production in response 
to OV A were all significantly reduced in lymph node cells from mice treated with 
dexamethasone (DEX) 3 mg/kg and thymosin ~4 sulfoxide (T~4S0) 20 /-Lg, when 
compared to cells from mice treated with PBS alone (OVA). Data are expressed as 
mean ± SEM.* p < 0.05, ** P < 0.01. Statistical significance was assessed by ANOV A. 
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Figure 6.10. Concanavalin A-induced cytokine responses in thoracic lymph node 
cells in vitro. 
In parallel cultures to those in Figure 6.9, thoracic lymph node cells (n = 5 mice per 
group) cultured for 72 hours with Concanavalin (Con) A 5 Ilg/ml. Cytokine levels in 
cell culture supernatants were assessed by ELISA. (A) IL-4, (B) IL-5, (C) IFN-y and 
(D) IL-6 production in responses to Con A were all significantly reduced in lymph node 
cells from mice treated with dexamethasone (DEX) 3 mg/kg and thymosin 134 sulfoxide 
(T~4S0) 20 Ilg, when compared to cells from mice treated with PBS alone (OVA). 
Data are expressed as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. Statistical 
significance was assessed by ANOV A. 
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6.8 Comparison of the anti-inflammatory activities of thymosin beta 4 and 
thymosin ~4 sulfoxide 
In the study of Young et al. (1999) it was proposed that T~4S0 was the active anti-
inflammatory component of thymosin ~4 and that any anti-inflammatory action of the 
non-oxidised thymosin ~4 was due to contamination of the preparation with T~4S0, 
either during preparation of the compound or spontaneous oxidation during storage. A 
provisional experiment was done to assess if T~4S0 reduced inflammation in 
comparison to T~4. 
These results are presented in Figure 6.11. Total absolute BAL cell count numbers were 
reduced in mice treated with T~4S0 (p < 0.05). The percentage of eosinophils was also 
significantly lower in T~4S0 treated mice (p < 0.01). There was a reciprocal rise in the 
percentage of BAL macrophages in the group of mice which received T~4S0. There 
was no difference in percentages of neutrophils or lymphocytes between the two groups 
(data not shown). Although not strictly comparable, the total cell count in the T~4-
treated group (mean ± SEM: 30.6 ± 3.1 x 104) was similar to that of the PBS-treated 
control group in the initial experiment in section 6.2 (30.1 ± 4 x 104 cells per lavage) 
while that of T~4S0 mice was lower (22.5 ± 2 x 104 cells per lavage). The percentage 
eosinophils was also comparable (T~4-treated 43.1 ± 4.29 % vs PBS-treated controls 48 
± 3.1 %) with the T~4S0-treated group in this experiment having a lower percentage 
eosinophil count (33.5 ± 3.9%). This would suggest that T~4S0 has anti-inflammatory 
activity while T~4 does not. 
170 
A 
35 
-
"'" 30 0 
~ 
>< I 
* 
- 25 .... 
t: 
::l 20 0 
U 
Q) 15 
U 
S 
10 
0 5 I-
0 
TJ34 TJ34S0 
8 C 
60 
-
70l 
* 
- S S 50 
.s 60 
.s 
** 
?ft. 50 ~ 40 
-
Q 
-
I/) 40 I/) Q) 30 C> 
J:: cu 30 c. J:: 
0 20 c. 20 t: 0 
'Ci) '-10 0 0 cu 10 w ~ 0 0 
TJ34 TJ34S0 TJ34 TJ34S0 
Figure 6.11. Bronchoalveolar lavage total cellularity, and eosinophil and macrophage 
proportions in mice treated with thymosin 134 or thymosin 134 sulfoxide. 
BALB/c mice were sensitised with OVA and then challenged with OVA i.n. on three 
consecutive days from day 25-27. Thymosin 134 (TI34) 20 flg (n = 10) or thymosin 134 
sulfoxide (TI34S0) 20 flg (n = 11) were given 30 minutes before each antigen challenge. 
BAL total cell counts and differential counts were performed on day 28. (A) Total BAL 
cellularity and (B) percentage eosinophilia were significantly reduced in mice treated 
with thymosin 134 sulfoxide (C) The percentage of BAL macrophages is higher in mice 
treated with thymosin 134 sulfoxide. Data is expressed as mean ± SEM. * p < 0.05, ** p < 
0.01. Statistical significance was assessed by ANOV A. 
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6.9 Chapter discussion 
The above data confirm that thymosin ~4 sulfoxide (T~4S0) has anti-inflammatory 
properties. In this murine model of asthma, T~4S0 and dexamethasone reduced BAL 
total cell count and eosinophil numbers to a similar extent. This was not associated with 
a significant reduction in inflammatory infiltrates in tissue histology. Prior treatment 
with both T~4S0 and dexamethasone significantly reduced levels of IL-4 and IL-5 in 
the bronchoalveolar lavage fluid of treated mice and also reduced OVA-induced 
production of these cytokines in cultures of thoracic lymph node cells. T~4S0 treatment 
reduced BAL total cellularity and eosinophilia when compared to thymosin ~4. 
In the above experiments, treatment with both T~4S0 and dexamethasone suppressed 
BAL eosinophil numbers in this mouse asthma model. This was not associated with a 
significant reduction in inflammatory infiltrates in lung histology. This may reflect the 
fact that only low numbers of tissue sections (n = 3 mice per group) were taken from 
each group of mice; to detect a difference in histological scoring between T~4S0-
treated mice and mice treated with PBS alone would require 7 - 14 mice per group, for a 
level 0.05 and a ~ level of 0.8, for the standard deviations observed for these groups in 
this study. Higher doses of T~4S0 and dexamethasone, or a longer duration of 
treatment, may be required to suppress tissue inflammatory infiltrates. 
In addition to decreased eosinophilia in the BAL fluid, a reduction in BAL macrophage 
and neutrophil numbers was observed in T~4S0-treated mice but not those treated with 
dexamethasone. In human asthma, neutrophilic airway inflammation is relatively 
steroid-resistant and corticosteroids have been demonstrated to be ineffective in 
reducing airway neutrophilia in severe asthmatics (Wenzel et aI., 1997). Corticosteroids 
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prevent neutrophil apoptosis while enhancing that of eosinophils (Meagher et aI., 1996). 
This may explain why neutrophil levels are not reduced by dexamethasone treatment in 
the murine model of asthma used above. Infection may also produce a neutrophilia 
which would be unresponsive to steroids, but infection seldom developed in 
experiments with this murine asthma model. Treatment with TP4S0, but not 
dexamethasone, also led to a significant decrease in BAL macrophage numbers. In 
contrast, lymphocyte numbers were decreased by dexamethasone, but not by Tp4S0. 
Corticosteroids have several suppressive actions on lymphocytes, including the 
inhibition of cell migration (Pitzalis et aI., 1997), down-regulation of activation markers 
(Almawi et aI., 1996) and the enhancement of apoptosis (Zacharchuk et aI., 1990). All 
the mechanisms may contribute to the decreased level of lymphocytes seen in 
dexamethasone treated mice. 
Although TP4S0 treatment did not significantly reduce lymphocyte numbers in BAL 
fluid, the reduction in BAL IL-4 and IL-5 levels observed in the above study suggested 
that TP4S0 may be having an effect on T lymphocyte function in this murine asthma 
model. This is consistent with the observation that L TP4, a compound related to 
TP4S0, has been shown to reduce inflammatory responses in animal models of the T 
cell-mediated conditions of irritant contact dermatitis and allergic contact dermatitis 
(Girardi et aI., 2003). A suppressive action for TP4S0 on lymphocyte activity was 
confirmed by the in vitro studies on thoracic lymph node cells. TP4S0 and 
dexamethasone both reduced OVA-induced cell proliferation in thoracic lymph node 
cultures. Their anti-proliferative response was antigen-specific since it did not alter the 
proliferative response to the T cell mitogen Concanavalin (Con) A. Both Tp4S0 and 
dexamethasone also suppressed spontaneous lymph node cell proliferation, indicating 
that this suppressive action on lymphocytes is also occurring in vivo. Thymosin beta 4 
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sulfoxide and dexamethasone were also able to suppress OVA-induced IL-4, IL-5, IFN-
Y and IL-6 cytokine production. This was part of a more general immunosuppressive 
action on cytokine production since cytokine secretion in response to Con A was also 
reduced, but to a proportionately lesser extent. For dexamethasone, this is consistent 
with the fact that glucocorticoid-mediated down-regulation of cytokine production does 
not involve signalling via T-cell receptor activated pathways, but requires direct binding 
to promoter regions of cytokine genes (Almawi et al., 1996). Since T~4S0 reduces 
cytokine production and cell proliferation in a similar pattern to that of dexamethasone, 
it may activate similar signalling mechanisms. The ability of T~4S0 to reduce OV A-
induced cell proliferation indicates that it is able to influence antigen specific-responses 
in lymphocytes, but whether this is a direct action or a consequence of alteration of 
down-stream signalling processes remains to be elucidated. 
The above results indicate that divergent pathways are involved in the effects of 
dexamethasone and T~4S0 on lymphocyte proliferation and cytokine production, since 
Con A can overcome the suppressive action of these agents on cell proliferation but not 
cytokine secretion. Since treatment with T~4S0 reduces IL-4 and IL-5 levels in BAL 
fluid and OV A-induced production of these cytokines in thoracic lymph node cultures, 
it is likely that a reduction in Th2 lymphocyte activity and cytokine secretion 
contributes to the reduction in eosinophil levels observed in BAL fluid. The reduction in 
OVA-induced IFN-y secretion in thoracic lymph node cultures also suggests that 
T~4S0 may also suppress Th1 lymphocyte activity. 
Serum total IgE levels or OVA-specific IgG 1 or IgG2a levels were not altered by the 
administration of either T~4S0 or dexamethasone. As serum was collected 96 hours 
after the first antigen challenge, the same time as the initial administration of 
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dexamethasone or TP4S0, and this is likely to be too short a period to observe any 
changes in serum antibody levels. 
The current studies also demonstrated that TP4S0 was able to reduce BAL total cell 
count and eosinophilia in comparison to Tp4. The rise in macrophage proportions in this 
experiment is most likely to reflect a compensatory rise for the decline in relative 
proportions of eosinophils present. Young et al. (1999) reported that Tp4 preparations 
can be contaminated with approximately 5% TP4S0, and can oxidise spontaneously in 
air. Therefore, the TP4 used may have some anti-inflammatory activity due to 
contaminating TP4S0 and this could explain why the reduction in eosinophilia was not 
as pronounced as that observed in the first experiment. 
Thymsosin P4 sulfoxide has been observed to have definite anti-inflammatory 
properties, both in the murine model of allergic airway inflammation used in these 
present studies, and previously in other inflammatory models. The exact mechanisms by 
which TP4S0 exerts its extracellular actions are unknown. Most studies concerning the 
extracellular actions of thymosins have used thymosin P4, the immunomodulatory 
activity of which might be due to the presence of contaminating Tp4S0. It is unclear 
how thymosin P4 is released from cells, since it lacks a signal peptide. It is likely that 
thymosin beta 4 is oxidised to TP4S0 locally at sites of inflammation by free oxygen 
species, such as H20 2, which are produced by neutrophils and other inflammatory cells. 
It is possible that TP4S0 may have an anti-oxidant role, since this peptide can be 
subsequently reduced by the activity of methionine sulfoxide reductase (Moskovitz et 
aI., 1998). By inhibiting further influx of neutrophils, Tp4S0 acts in a negative 
feedback loop to prevent further oxidative damage (Young et aI., 1999). Thymosin P4 
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can be bound to collagen and fibrin by the activity of Factor XIII a, a transglutaminase 
released from activated platelets (Huff et ai., 2002), which may help maintain high 
concentrations of TP4S0 in inflamed areas. In addition to promoting the release of 
TP4S0 from monocytes (Chettibi et ai., 1994), corticosteroids may further augment the 
activity of TP4S0 by promoting the secretion of anti-proteases such as leukocyte 
protease inhibitor 2 (Abbinante-Nissen et ai., 1995). In a wound healing model, a 
synthetic peptide analogue of part of the actin-binding region also had anti-
inflammatory activity (Philp et aI, 2003), indicating that other regions of TP4S0 in 
addition to the methionine sulfoxide residue at position 6, might also contribute to the 
immunomodulatory actions of Tp4S0. Thymosin P4 has been shown to inhibit the 
production of granulo-monocytic bone-marrow progenitor cells which would then 
differentiate to form eosinophils or neutrophils (Bonnet et ai., 1996). As yet, it is 
unknown whether TP4S0 binds to cell surface receptors to alter intracellular signalling 
pathways. Although thymosins have been localised to the nucleus (Watts et ai., 1990), 
there is no evidence that they act as transcription factors, or bind to them in a similar 
manner to the action of glucocorticoids. 
In conclusion, the above data confirm that TP4S0 has anti-inflammatory activity in this 
murine model of allergic asthma. At the doses given, it reduced BAL total cellularity 
and eosinophilia to a similar extent as dexamethasone. In this study, TP4S0 was more 
effective than dexamethasone in reducing BAL macrophage and neutrophil numbers, 
but less effective in suppressing lymphocyte levels. The decrease in BAL cellularity 
was not accompanied by a reduction in inflammatory infiltrates in lung histology, but 
was associated with a reduction in IL-4 and IL-5 levels in BAL fluid. In thoracic lymph 
node cell cultures, TP4S0 reduced OVA-induced proliferation of lymph node cell 
cultures and OVA-induced cytokine secretion, indicating that at least part of its anti-
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inflammatory activity in this experimental model is mediated by its actions on 
lymphocytes. T~4S0 was effective in reducing BAL total cell count and cellularity 
when compared to the non-oxidised T~4. Further investigations are needed to determine 
if T~4S0 has direct inhibitory effects on eosinophils and other cell types, and to 
elucidate its mechanisms of action. Thymosin beta 4 sulfoxide may have therapeutic 
potential in allergic asthma. 
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7.1 The role ofIL-18 in allergic airway inflammation 
The inflammatory response in asthma involves the complex interaction of many cell 
types, cytokines, chemokines, intercellular adhesion molecules, enzymes and other 
small pro-inflammatory molecules. Th2 lymphocytes, secreting the cytokines IL-4, IL-5 
and IL-13, are thought to have an important central role in the modulation of the 
asthmatic response. In contrast, Thl lymphocytes which secrete IFN-y may have anti-
inflammatory activity, since Thl and Th2 cells were initially shown to mutually 
antagonise the development of each other in animal models of parasitic infection 
(Mosmann and Coffman, 1989). Since the prevalence of asthma is increasing, it was 
proposed, in the "Hygiene Hypothesis", that a "cleaner" modern lifestyle alongside 
decreased viral and bacterial infections in childhood, reduced development of Thl 
responses leading to a predisposition to Th2-driven conditions (Umetsu et aI., 2002). 
However, Thl cells have been shown to enhance airway inflammation in animal models 
of asthma (Hansen et aI., 1999, Randolph et aI., 1999a, Randolph et aI., 1999b), and 
alternative cell types, such as regulatory T cells, may be required for effective down-
regulation of the asthmatic response (Ling et aI., 2004). 
IL-18 was initially identified as interferon gamma inducing factor, with the ability to 
promote Thl responses in association with IL-12 (Okamura et aI., 1995). However, it is 
now known to promote Th2 responses and, as summarised in Figure 7.1, it can also act 
directly on other cell types, including eosinophils, mast cells and NKT cells, to promote 
allergic responses (reviewed by Nakanishi et aI., 2001). IL-18 has recently been shown 
to stimulate the production of IL-9, IL-13, GM-CSF and chemokines, which are also 
able to enhance allergic responses, from IFN-y-positive Thl cells in vitro and Thl 
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Figure 7.1. The actions ofIL-18 on cell types involved in allergic responses. 
This figure illustrates the cells which may produce IL-18 in the lung, and the cell types 
on which IL-18 may act to influence the development of allergic airway inflammation. 
IL-18 has been shown to promote Th2 development and act on several other cell types 
to augment allergic responses. In the presence ofIL-12, IL-18 will assist the maturation 
of Thl lymphocytes and have potential anti-allergic actions by stimulating IFN-y 
production. 
"Others": IL-18 enhances histamine release from human PBMC cultures in vitro and 
eotaxin production in murine lung in vivo. 
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memory cells augmented airway inflammation in a murine model of asthma (Sugimoto 
et aI., 2004). In contrast, IL-18-induced production of IFN-y from Thl cells, and 
potentially from pulmonary macrophages and dendritic cells, may down-regulate 
allergic reactions in the lung. Although the exact circumstances in which IL-18 will 
promote Th 1 or Th2 responses remain to be defined, it is thought that the surrounding 
cytokine environment is important in influencing this. In particular, the presence of IL-
12 clearly causes IL-18 to have a predominant Thl-promoting effect. Conversely, when 
IL-12 is absent, IL-18 will enhance Th2 responses. Consistent with the ability of IL-18 
to promote both Th1 and Th2 development, there is conflicting evidence for its role in 
both clinical asthma and animal models of allergic airway inflammation. 
IL-18 has previously been shown to be expressed in the bronchial epithelium (Cameron 
et aI., 1999) and present in alveolar macrophages (Shigehara et aI., 2001). IL-18 
therefore has the potential to modulate lung immunity, including the asthmatic response. 
In the clinical study described in Chapter 3, IL-18 was detected in induced sputum fluid 
from asthmatic and normal subjects, and was expressed at relatively high levels in 
induced sputum cells. Its production was localised to sputum macrophages. There was 
no significant difference in IL-18 levels in induced sputum fluid between asthmatic and 
normal subjects, in contrast to previous studies where IL-18 was reduced in BAL fluid 
from asthmatics compared to normal controls (Ro et aI., 2002). Cigarette smoking 
significantly reduced IL-18 levels in induced sputum fluid in both asthmatic and nOlmal 
smokers. This effect was most pronounced in asthmatic smokers when compared to 
asthmatic non-smokers where decreased levels of IL-18 protein in induced sputum fluid 
were associated with reduced IL-18 mRNA expression in induced sputum cells. The 
reduction in mRN A levels was proportionately less than that in IL-18 protein 
production, which is consistent with the understanding that the activity of IL-18 is 
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mainly regulated at a post-translational level by enzymatic cleavage of pro-IL-18 into 
mature IL-18 by caspase-1, and subsequent proteolytic processing by other enzymes to 
inactive peptides (Akita et ai., 1997). All smokers had higher proportions of neutrophils 
in their induced sputum samples. The significance of the reduction of IL-18 levels in 
cigarette smokers is unclear. It may contribute to the increased susceptibility to 
respiratory tract infections seen in smokers (Aronson et ai., 1982) and may also lead to 
an alteration of the nature of airway inflammation in asthmatic subjects by influencing 
the balance of Th1 and Th2 cytokine secretion. 
The studies performed in a murine model of allergic asthma in BALB/c IL-18 gene 
knockout mice sensitised and challenged with ovalbumin (OVA), supported the 
hypothesis that IL-18 may have a pro-inflammatory role in allergic airway inflammation 
(Chapter 4). The observed effects of IL-18 gene deficiency on allergic airway 
inflammation are summarised in Table 7.1. Airway eosinophilia was decreased in IL-18 
deficient mice when compared to wild-type controls, but this was not associated with a 
significant reduction in tissue inflammatory infiltrates lung histology. There was a trend 
for IL-4 levels to be lower in the BAL fluid of IL-18 deficient mice, associated with 
decreased OVA-induced IL-4 production in thoracic lymph node cultures and IL-4 
mRNA expression in thoracic lymph nodes. Serum total and OVA-specific IgE levels 
did not differ significantly between IL-18 deficient and wild-type mice. In the 
subsequent studies using the murine model of allergic asthma in wild-type mice 
(Chapter 5 and Chapter 6), levels of IL-18 levels in BAL fluid were not significantly 
different between wild-type naIve mice and those sensitised and challenged with OVA 
(Figure 5.7C). Surprisingly, the expression of IL-18 mRNA in total lung tissue was 
much lower OVA-treated mice in than in naIve mice (Figure 5.16 and Figure 6.6D); it is 
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In vivo 
BAL total cellularity 
BAL eosinophilia 
Inflammatory infiltrates in 
lung histology 
IL-4 in BAL fluid 
IL-5 in BAL fluid 
Serum total IgE 
Serum OVA-specific IgE 
Thoracic lymph node cultures 
IL-4 (OVA-induced) 
IL-5 (OVA-induced) 
IFN-y (OVA-induced) 
IL-4 (Con A-induced) 
IL-5 (Con A-induced) 
IFN-y (Con A-induced) 
Spontaneous cell proliferation 
Cell proliferation (OVA-induced) 
Cell proliferation (Con A-induced) 
The effect of IL-18 deficiency in a 
murine model of allergic asthma 
-J, 
-J, 
~ 
~ 
~ 
~ 
~ 
-J, 
~ 
-J, 
~ 
~ 
-J, 
~ 
~ 
~ 
Table 7.1. The effect of IL-18 deficiency in a murine model of allergic asthma. 
The responses observed in IL-18 gene knockout mice in comparison to wild-type mice, 
sensitised and challenged with ovalbumin, are summarised in the table above. 
183 
not evident from these studies whether IL-18 mRNA expression in the lung is down-
regulated at the time of sensitisation with OVA or after antigen challenge. 
Although the above murine studies suggest that the pro-inflammatory role of IL-18 in 
allergic airway inflammation is, at least in part, related to its ability to augment IL-4 
production, it is not clear if this effect is most important at the time of sensitisation to 
antigen or at the time of antigen challenge. In murine models of allergic asthma, it has 
previously been demonstrated that exogenous IL-18 administered at the time of antigen 
sensitisation increased the allergic response (Wild et aI., 2000) while levels of IL-18 in 
whole lung tissue increased after antigen challenge and intra-tracheal administration of 
IL-18 enhanced eosinophil accumulation in the lungs (Campbell et aI., 2000). Therefore 
IL-18 is likely to have pro-inflammatory actions at both these stages through the intra-
pulmonary induction of cytokines and chemokines, including IL-4 and eotaxin, which 
enhance the allergic response. 
As stated above, the magnitude of the pro-allergic actions of IL-18 will be influenced by 
the presence or absence of IL-12. A higher relative amount of IFN-y to IL-4 will 
predispose to down-regulation of airway inflammation. Systemic administration of IL-
18, especially in association with IL-12, tends to have an anti-inflammatory action in 
murine models of asthma most probably though the induction of high levels of systemic 
IFN-y which suppresses pulmonary eosinophilia (Hofstra et aI., 1998). In murine 
models of asthma where Aspergillus Jumigatus (Blease et aI., 2001) or respiratory 
syncitial virus (Zhang et aI., 2003) were used to induce eosinophilic airway 
inflammation, the actions of IL-18 were thought to be anti-inflammatory but this again 
may related to the IL-12 secretion induced by the fungus and virus enhancing the IFN-y-
inducing properties of IL-18. 
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Genetic factors are likely to be important in determining the ability of IL-18 to enhance 
or suppress allergic responses. BALB/c mice are genetically predisposed to develop 
Th2 responses. They have been shown to produce lower serum levels of IL-18 in 
response to LPS when compared to the more Thl-biased C57BLl6 mice (Habu et ai., 
2001). However, spleen cells from BALB/c mice produce higher levels of IL-4, and 
lower levels of IFN-y, in response to IL-18 and uCD3 stimulation than those from 
C57BLl6 mice (Xu et ai., 2000). Such inherent differences in the propensity to secrete 
differing relative amounts of IL-4 and IFN-y could explain the results of Kodama et al. 
(2000) where a lack of IFN-y and its suppressive action was thought to a key factor in 
causing increased airway inflammation after antigen sensitisation and challenge in 
C57BLl6 IL-18 gene knockout mice. In the BALB/C mice used in Chapter 4, although 
IFN-y was also reduced in IL-18 deficient mice, the effect of this may be outweighed by 
the lack of IL-4, leading to decreased total inflammatory cell numbers and eosinophils 
in BAL fluid. 
Several genetic polymorphisms have been linked to the development of human asthma 
(Cookson, 2002). Genetic polymorphisms also exist in the human IL-18 gene and these 
have been associated with allergic disease (Higa et ai., 2003a, Kruse et ai., 2003). It is 
therefore possible that IL-18 may also have differing actions in human asthma 
depending on the genetic influences of each asthmatic subject. 
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7.2 The anti-inflammatory actions of simvastatin and thymosin beta 4 
sulfoxide 
Through its ability to induce IFN -y, IL-18 was initially postulated as a possible anti-
inflammatory therapy for asthma. However, the studies in IL-18 gene knockout mice 
demonstrated that it has probable pro-inflammatory actions in a murine model of 
allergic airway inflammation. In contrast, both simvastatin and thymosin beta 4 
sulfoxide had definite anti-inflammatory properties in this animal model. These are 
summarised in Table 7.2, together with the effects of dexamethasone. 
Simvastatin is a commonly used cholesterol lowering agent in clinical practice. It has 
been shown to have anti-inflammatory properties independent of its lipid lowering 
properties in clinical atherosclerotic disease (Albert et aI., 2001) and in experimental 
models of multiple sclerosis (Youssef et aI., 2002, Aktas et aI., 2003) and rheumatoid 
arthritis (Leung et aI., 2003). The lymphocytes involved in the inflammatory infiltrate in 
these conditions are thought to be of a predominantly Th1 phenotype. In the murine 
model of allergic asthma used in this study, it shown for the first time that simvastatin 
can also have anti-inflammatory actions in Th2-mediated inflammation. The 
suppressive action of simvastatin on IL-4 and IL-5 levels in BAL fluid and in OVA-
stimulated thoracic lymph node cultures implies that that there is a direct suppressive 
action on Th2 lymphocytes. IFN-y levels were also reduced suggesting there may be an 
accompanied suppression ofTh1 responses. 
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Simvastatin T~4S0 Dexamethasone 
In vivo 
BAL total cellularity -!.- -!.- -!.-
BAL eosinophilia -!.- -!.- -!.-
Inflammatory infiltrates in 
-!.- ~ ~ 
lung histology 
IL-4 in BAL fluid -!.- -!.- -!.-
IL-5 in BAL fluid -!.- -!.- -!.-
Serum total IgE levels ~ ~ ~ 
Thoracic lymph node cultures 
IL-4 COV A-induced) -!.- -!.- -!.-
IL-5 (OVA-induced) 
-!.- -!.- -!.-
IL-4 (Con A-induced) ~ -!.- -!.-
IL-5 (Con A-induced) ~ -!.- -!.-
Spontaneous cell proliferation ~ -!.- -!.-
Cell proliferation COV A-induced) ~ -!.- -!.-
Cell proliferation (Con A-induced) ~ ~ ~ 
Table 7.2. The anti-inflammatory actions of simvastatin, thymosin beta 4 sulfoxide 
and dexamethasone in a murine model of allergic asthma. 
The effects of treatment with simvastatin, thymosin beta 4 sulfoxide and 
dexamethasone, when compared to PBS-treated controls, in ovalbumin-sensitised and 
challenged mice. 
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Thymosin beta 4 sulfoxide (T~4S0) had previously been shown to have anti-
inflammatory activity in carrageenan-induced footpad inflammation in mice, in which 
neutrophils are the predominant inflammatory cell type observed (Young et al., 1999). 
Peptides related to T~4S0 have been shown to have immunosuppressive activity in 
models of irritant and allergic contact dermatitis, where lymphocytes have a regulatory 
role (Girardi et al., 2003). The data presented in Chapter 6, demonstrate that T~4S0 can 
also suppress eosinophilic inflammation in a murine model of allergic asthma. 
Comparable to simvastatin, the inhibition of airway inflammation is at least partly 
dependent on the suppression of Th2 lymphocyte activity, since IL-4 and IL-5 levels 
were again reduced in BAL fluid and thoracic lymph node cultures. Also, IFN-y levels 
were reduced by T~4S0 in thoracic lymph node cultures, suggesting that Thl 
lymphocyte responses may also be reduced. 
Although both simvastatin and T~4S0 both appear to inhibit lymphocyte activity, there 
are likely to be divergent mechanisms through which this occurs. Simvastatin treatment 
decreased antigen-induced cytokine production from lymph node cells and did not 
affect cell proliferation, whereas T~4S0 appears to have a more general 
immunosuppressive action, inhibiting both OVA-induced cytokine production and 
OV A-induced cell proliferation. The immunosuppressive action of T~4S0 more closely 
resembles that of dexamethasone than simvastatin; since steroids promote the release of 
T~4S0 from monocytes (Chettibi et al., 1994), it is possible that T~4S0 may mediate 
some of the anti-inflammatory actions of cOliicosteroids. Only treatment with high dose 
simvastatin (40 mg/kg) resulted in a significant reduction in inflammatory infiltrates in 
lung histology, but it maybe that a higher dose of T~4S0 is required to produce a 
similar effect on histological inflammation. Neither compound altered the serum total 
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IgE or OVA-specific IgG 1 and IgG2a levels, most probably as they were given at the 
time of antigen challenge and not with sensitisation. 
7.3 Future work 
The clinical study using induced sputum from asthmatic and normal subjects did not 
show any significant difference in IL-18 levels in induced sputum fluid between 
asthmatics and normal subjects, nor between asthmatics treated with salbutamol alone 
or those treated with inhaled corticosteroid. The study performed was a cross-sectional 
study and a longitudinal study would be necessary to assess fully if IL-18 production 
could be altered by steroid treatment. The ELISA used to determine IL-18 
concentrations only detected total IL-18, and so a comparison of the relative proportions 
of pro-IL-18 and mature IL-18 between asthmatics and normal individuals may reveal 
differences. This would require Western blotting which would be technically difficult 
with induced sputum samples because of the small volume of sample obtained. A study 
using BAL samples may therefore be needed. Such a study could involve a comparison 
with total IL-18 levels in induced sputum to attempt to explain the difference in the 
results in this study from previous reports, and permit a more detailed study on the 
effect of cigarette smoking on cytokine production in the airways and from pulmonary 
inflammatory cells such as alveolar macrophages. An assessment of changes in IL-18 
levels after antigen challenge would also be of interest. 
In the studies in the murine model of allergic asthma, the levels of IL-18 in BAL fluid 
were not altered by OVA-sensitisation and challenge when compared to naIve mice. 
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Also, the levels of IL-18 mRNA expression in murine lung did not reflect BAL IL-18 
levels 24 hours after the last antigen challenge. More detailed investigation of the 
alterations in IL-18 mRNA expression and protein levels, around the periods of 
sensitisation and challenge are required, including quantification of the relative amounts 
of pro-IL-18 and active IL-18 present in the lungs and BAL fluid. The experiments in 
IL-18 gene knockout mice suggest that IL-18 contributes to the inflammatory response 
in the murine model of asthma used by augmenting the production of IL-4. Further 
experiments are needed to confirm these findings and to establish whether levels of 
other Th2 cytokines, including IL-9, IL-13 and GM-CSF, are also reduced. There was 
no difference in the ratio of CD4:CD8 lymphocytes between OVA-treated IL-18 ko 
mice and WT mice. However, since IL-18 can enhance both Th1 and Th2 development, 
the relative ratios of Th1 :Th2 lymphocytes in thoracic lymph nodes and infiltrating into 
the lung could be assessed. IL-18 has been shown to stimulate IL-4 production from 
Th2 lymphocytes, NKT cells, mast cells and basophils in vitro, and it would be of 
interest to study how IL-4 production differs in these cells in vivo in IL-18 ko mice 
during antigen sensitisation and challenge. The importance of the activity of IL-18 
during sensitisation and challenge could be further assessed by replacing IL-18 at each 
of these times in IL-18 knockout mice. 
Both simvastatin and TP4S0 have been shown to have anti-inflammatory propeliies in a 
murine model of allergic asthma. These effects are at least in part T cell mediated, as 
demonstrated by the ability of both simvastatin and TP4S0 to suppress antigen-induced 
IL-4 and IL-5 production from lymphocytes in culture. Further in vitro studies to 
determine if either of these compounds have a direct suppressive action on eosinophil 
migration, activation and survival are needed. Also, the specific ability of both 
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simvastatin and T/34S0 to inhibit Thl or Th2 lymphocyte activity could be more fully 
assessed. It would also be important to investigate if these agents have anti-
inflammatory actions if administered before antigen sensitisation. This is particularly 
relevant for simvastatin, since related statins have been shown to inhibit IFN-y-induced 
MHC-II up-regulation on macrophages and subsequent T cell activation (Kwak et aI., 
2000). 
The molecular mechanisms by which both simvastatin and T/34S0 inhibit airway 
inflammation require elucidation. It is thought that the anti-inflammatory effects of 
simvastatin are likely to be independent of reductions in cholesterol lowering, but this 
could be confirmed by assessing serum cholesterol levels and comparing the effect of 
simvastatin with that of a different class of cholesterol-lowering agent, such as a fibrate. 
If the administration of mevalonate, the product of uninhibited HMG-CoA reductase, 
reversed the anti-inflammatory activity of simvastatin this would indicate that inhibition 
of signal transduction proteins which require mevalonate-dependent isoprenylation was 
an important process for the anti-inflammatory action of statins in this animal model. 
Statins also allosterically inhibit the interaction of the adhesion molecule LF A-I with 
ICAM-l (Weitz-Schmidt et aI., 2001) and the expression and binding activity ofLFA-l 
could be studied ex vivo on lymphocytes from mice previously treated with simvastatin. 
The intracellular mechanisms of action of T/34S0 are as yet unknown. It is unclear if 
T/34S0 binds to a cell surface receptor and this needs to be established, as does the 
action of T/34S0 on intracellular signalling pathways, including those which result in 
the activation of pro-inflammatory transcription factors such as NF-KB. 
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Since aitway hyper-responsiveness is a feature of clinical asthma, future studies in the 
murine model of allergic asthma, whether it be to determine the effect of IL-18 
deficiency or the outcome of treatment with simvastain or T~4S0, should include an 
assessment of this. 
7.4 Concluding remarks 
The increasing prevelance of asthma, and the failure of some patients to respond to 
corticosteroid treatment, means that there is a continual search for new therapeutic 
agents. IL-18 was initially proposed as cytokine which could have anti-inflammatory 
activity in asthma, but is now thought to have pro-inflammatory actions in this 
condition. Its role in allergic airway inflammation is therefore complex and a more 
complete understanding of its actions still required before any treatment can be targeted 
at alteIing its activity. In contrast, both simvastatin and thymosin beta 4 sulfoxide have 
shown definite anti-inflammatory properties in as murine model of allergic asthma, and 
these, or related compounds, may therefore have therapeutic potential in clinical asthma. 
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